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ABSTRACT 
 
Rectal cancers are thought to contribute approximately one third of all colorectal cancers 
worldwide, and are associated with considerable morbidity and mortality. Worryingly, the 
incidence of rectal cancer is increasing in developed economies, as genetics and environment 
converge to cause pathology in increasingly older populations.  
Despite current detailed knowledge of various molecular mechanisms responsible for 
oncogenesis, in general, the precise sequence of events causing disease, or influencing 
prognosis, in a particular patient is not completely understood. This is unsurprising given the 
multifactorial nature of disease and treatment responses in human populations with highly 
variable clinical histories.  
To overcome this knowledge gap, this thesis sought to further refine the understanding of the 
molecular mechanisms at work during rectal cancer development, and their effect on treatment 
responses and patient outcomes. Furthermore, by defining the molecular mechanisms of 
disease, biomarkers (single or multiple molecules whose expression levels serve to identify 
disease processes common to many patients with the same disease) can be developed and 
applied to clinical situations – helping to diagnose, prognosticate and determine treatment 
modalities, depending on the application in question.  
To this end, and given the large heritage literature concerning DNA damage response proteins 
and cancer pathophysiology, the expression of four central DNA repair proteins (ATM, 
MRE11, NBS1 and RAD50) in rectal cancers has been quantified by immunohistochemistry. 
This will enable correlation of expression levels in different regions of the tumour with 
available clinicohistopathological variables, such as overall and disease-free survival. 
Furthermore, although radiotherapy represents a first-line treatment for rectal cancer, highly 
variable treatment responses have been documented amongst patients. As not all patients stand 
to benefit from such treatments, the expression of the candidate proteins – central to repairing 
damaged DNA generated by radiotherapy – and the association with radiotherapy responses 
are investigated in rectal tumours. 
 
Firstly, in the case of ATM, it was found that reduced expression in the growing edge of the 
tumour (tumour periphery) was associated with better responses to radiotherapy and improved 
disease-free survival. ATM expression in the tumour centre was also associated with disease-
free survival by uni- and multi-variate analyses. Secondly, MRE11 expression was found to be 
predictive of patient outcomes, when patients were also scored positive for high-grade disease, 
metastasis positive, and showed perineural invasion. In contrast, NBS1 expression levels in 
rectal tumours were only found to have a marginal association with patient overall survival, 
necessitating additional studies of NBS1 in rectal cancer. Low RAD50 expression was 
associated with worse disease-free survival. RAD50 levels also proved to be useful to delineate 
low- and high-grade disease subgroups. Together, the analysis of these four markers 
individually, led to several novel associations with regards to rectal cancer – highlighting their 
‘biomarker’ potential in this clinical context. 
Furthermore, by combining expression of these proteins into combinatorial panels – made up 
of either ATM and MRE11, or MRE11, NBS1 and RAD50 – a greater predictive power of 
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their expression levels with respect to patient outcomes was demonstrated, and support the use 
of multiple markers to better understand disease in different patient groups.  
Therefore, the utility of examining DDR proteins in the context of rectal cancer is demonstrated 
in this thesis, and the results provide evidence to support future studies investigating the roles 
of these proteins in larger rectal cancer patient cohorts and other cancers. Further studies and 
validation of the results of this thesis will help determine whether such proteins can serve as 
clinically-useful biomarkers for disease intervention. 
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1.1 The basis of biological systems and human health in modernity 
 
Without a grounding in the workings of our environment, cells, proteins, genes, and evolution, 
understanding cancer is difficult (Berg et al., 2013). Therefore, before considering the 
molecular mechanisms of rectal cancer, the DNA damage response, biomarkers, and how the 
pathology can be diagnosed and treated, it is useful to consider how biological systems first 
came into existence, and how, in general, we understand them.  
 
1.1.1 Chemical beginnings 
 
Life on Earth is believed to have originated from basic chemical reactions between atoms and 
molecules interacting in the complex soup of the early atmosphere – abiogenesis (Maher and 
Stevenson, 1988). On Earth, such reactions may have paved the way for the development of 
more complex molecules and networks of reactions (perhaps put in place by chemical catalysis 
already existing in the present matter) – like adenosine triphosphate (ATP), carbohydrates and 
lipids – which allowed for energy-dependent cellular processes to evolve and biological 
information to be stored. The triggers for such chemical activity are not known, although 
lightning and radiation are often primary candidate environmental cues (Martin et al., 2014).  
 
The precise sequence of molecular events leading to complex organic life remain a matter of 
intense research and debate, although various studies have demonstrated that essential 
biological molecules, such as amino acids, can be formed from their constituent parts under 
conditions that resemble those of the young Earth (Hörst et al., 2012). As complex organic 
molecules have been found in space, it is difficult to rule out that they were the precursors to 
life; the Panspermia hypothesis (Gribbin, 1999). 
 
Regardless where in the universe life may have started, science has shown us that fundamental 
elements exhibit properties allowing for life. For example, carbon and water - both of which 
are readily abundant. Carbon is unique in its ability to provide a stable scaffold for other 
elements, such as oxygen, allowing complex molecules to stably exist (i.e. CO2). Water, on the 
other hand, is nature’s great solvent, and by having both electrically negative and positive 
domains, it allows a wide range of molecules to dissolve in it (Clayden et al., 2001). 
Furthermore, as water is less dense when frozen compared to its liquid state, ice floats and 
cellular life can exist below it.  
 
Based upon carbon and water, diverse lipids, carbohydrates, and nitrogenous bases can be 
generated. Nucleic acids, for example, are built from monosaccharides, nitrogenous bases and 
phosphate groups, and together encode deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA) recipes. A considerable portion of the biological community considers that life first 
emerged in an RNA world, in which proteins could be made from the RNA messages 
replicating themselves in the environment (Robertson and Joyce, 2012). From such collections 
of proteins, networks of interactions are predicted to have joined together to generate new 
molecules and carry out tasks that would presumably have benefitted that present in the 
environment. Nucleic acids, DNA and RNA store the information for these complex networks 
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to exist. DNA is as a linear molecule consisting of different bases – adenine, cytosine, guanine, 
thymine – joined together by a phosphate backbone.  
 
In respect to living organisms, it’s useful to remember that we (and all our cells) are all built 
from DNA-encoded messages, many of which are shared amongst ourselves, plants and 
microorganisms; systems are natural, related and dynamically adapt to their environment; 
cancer included. DNA is responsible for cancer, a disease in which a cell in a multi-cellular 
organism becomes rogue to its autologous neighbours and attempts clonal expansion and 
invasive tissue formation (neoplasia).  
 
Zircon-preserved carbon suggests that biogenic life is at least 4.1 billion years old; whereas 
Earth formed circa 4.5 billion years ago (Bell et al., 2015). Putative fossilised organisms – 
dated to be circa 4.2 billion years old – have also been discovered in hydrothermal vents in the 
deep ocean, meaning that they would have come into existence shortly after the oceans 
themselves were formed, 4.4 billion years ago. These time scales provide ample time for the 
evolution of the systems that we are discussing. At present, scientific theory predicts that early 
life on Earth first consisted mainly of bacterial and archaeal biofilms which replicated 
asexually (Donlan, 2002). The later development of photosynthesis, approximately 3.5 billion 
years ago, led to a build-up of oxygen in the atmosphere, causing the great oxygenation event 
of approximately 2.4 billion years ago. Around 1.8 billion years ago, eukaryotic cells 
containing mitochondria (allowing for oxygen to be more efficiently used metabolically) 
emerged. Endosymbiotic theory holds that mitochondria and other free-living prokaryotes, 
such as chloroplasts, were joined to form more complex cells (Archibald, 2015). This ability 
to metabolise oxygen efficiently via the mitochondrion (to generate energy stored as ATP) is 
thought to have spurred the development of multi-cellular life – which is currently dated to 
have occurred approximately 1.7 billion ago – allowing individual cells within the same 
organism to become specialised and carry out unique functions; endowing organisms with 
increased functional capacities, and thus, abilities to exploit diverse ecological niches. Given 
the time at which all these early evolutionary events took place, it is perhaps unsurprising that 
the origins of sexual reproduction are also shrouded in mystery.  
 
The remarkable similarity between different species (now known to be due to shared genetic 
mechanisms) was the defining feature of nature leading to Charles Darwin’s Theory of 
Evolution, published in 1859. In it, Darwin suggests that natural selection of inherited genomic 
variants allows populations to better adapt to their environment; those variants ill-suited to the 
present are more likely to not be passed on to subsequent generations given that they encode a 
reduced fitness (Shanks and Pyles, 2007). When thinking about cancer, one can view the loss 
of regulatory genomic control in tumour cells as leading to a survival of the fittest scenario, in 
which the cancer outcompetes the normal cells to benefit its own survival and replication; that 
generated by the variants present in its genes, and as has been shown in cancer stem cell 
resistance to therapeutics (Eyler and Rich, 2008).  
 
These evolutionary systems have led to an explosion of life, with life forms as diverse in 
appearance and function as imaginable. This diversity is genetically encoded in DNA. Yet, life 
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is also short-lived and dynamic, with new genes replacing new ones every generation and every 
cell division (Stratton et al., 2009). Sadly, we are also living through a mass extinction event 
driven by human population expansion, urbanisation, pollution and illegal activities, and it is 
estimated that natural causes have led to more than 99% of all species to have inhabited the 
Earth to be now extinct (Ceballos et al., 2015). Presently, approximately 14 million species are 
hypothesised to be free-living.  
 
Most biologists now consider life to have a single common ancestor, as it is highly improbable 
that unique lineages evolved the same complex biochemical mechanisms common to all of 
them. With that in mind, much can be learnt about diseases, such as cancer, from studies in 
related animals that share the same proto-oncogenes, such as mice and dogs, and indeed we 
owe a great deal of debt to the discoveries made in animal models that have benefitted human 
health (MacEwen, 1990).  
Remarkably, certain types of cancer have also been reported to be infectious and transmissible 
between members of the same species; such as canine transmissible venereal tumours and 
Tasmanian devil facial tumour disease (Murchison, 2008). Transmissible tumours are not 
thought to occur in humans. The use of animals in research has also recently shown RNA-
lipoplexes are able to deliver neo-antigens to dendritic cells in murine lymph nodes, which then 
prime T cells to attack tumour cells around the body. These studies demonstrated a reduction 
an IFN-α-dependent T cell rejection of progressive tumours (Kranz et al., 2016).  
 
The importance of our relatedness to other organisms cannot be overstated when it comes to 
defining molecular mechanism and understanding the evolution of life (Moulder, 1985).  
 
 
1.1.2 Genomics, health and disease in the 21st century 
 
Since the Human Genome Project completed its primary aim in 2003, our understanding of 
human biology and disease has been transformed (Siva, 2008). In this tractable system (and 
map) we can refine biological knowledge at the molecular level in various ways. In fact, it 
guides many of the hypotheses used to enquire about the natural world.  
 
Principally, we use genetics in the same way (albeit at higher resolution) that Mendel learnt of 
segregating entities in the 1860s; we increasingly define the genes and genomic marks (such 
as methylation) associated with various phenotypes and conditions (Westra et al., 2013; Xu 
and Li, 2012). Understanding such relationships greatly refine our understanding of 
pathophysiological mechanisms, as we can correlate genetic activity to function and clinical 
pathology.  
 
In many ways, the increased genomic resolution available to human genetics - largely discussed 
in terms of the advent of massively parallel DNA sequencing (Shendure and Ji, 2008) - coupled 
to our increasing mechanistic understanding of the genome, proteome and metabolome, allows 
us to see a sub-cellular world afflicting our health; much in the way that the microscopes of 
Van Leeuwenhoektransformed our understanding of the equally important microbial world. A 
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future in which a person’s genome is known and professionally consulted upon by public 
healthcare services is only a matter of time (Kaye et al., 2010). Indeed, the National Health 
Service in England was reported to be considering plans to have whole genome sequences 
produced from all children born in NHS hospitals (Gray, 2013).  
 
To date, the genomic architecture of a multitude of human traits have been defined, such as 
diverse cancers, height, intelligence, neurodegeneration, immune responses and obesity. In 
prostate cancer, nine loci have been shown to be associated with disease development (Thomas 
et al., 2008). This was facilitated by genome-wide association studies, which analysed single 
nucleotide polymorphisms segregated between cohorts of interest and controls. In this way, the 
common-variant, common-disease mechanism hypothesis came about, which states that 
common variants present in populations (some with very low minor allele frequencies) together 
account for the genetic component of the majority of common, complex human diseases 
(Frayling et al., 2007); non-communicable diseases have been particularly well defined. In 
essence, we are defining the genetic features constituting our functioning and how these 
contribute to diseases, such as cancer. 
 
This mechanism for disease, however, sits alongside the examples of monogenic conditions 
(and cancer mutations) where variants are highly penetrant and drive a clear phenotype 
individually; a topic reviewed well elsewhere (Duncan et al., 2014). It suffices to say that not 
all mutations are equal, and genetic complexity in disease seems endless, with each patient and 
lesion unique.  
 
As we will discuss, the environment is thought to provide the additional risk for disease 
development, but determining the factors remains a challenge logistically in the clinic (i.e. 
recruitment of sufficient samples sizes and co-variable reduction between outbred humans) and 
in the laboratory (i.e. difficult to experiment in human subjects) (Emanuel et al., 2003). 
 
Cancer, in many ways, is a prototypical genomic disease – single base-pair changes amongst 
3.3 billion can lead to oncogenesis, and somatic mutation accumulation is a cancer hallmark. 
How and why these mutations arise remains a highly active area of research. Yet, in this day, 
it is safe to say that cancer cells have a different genome to their neighbours – with this 
uniqueness targeted diagnostically and therapeutically (Schumacher and Schreiber, 2015). 
 
Given the nature of cancer, it stands to benefit tremendously from the technological 
advancement currently underway of relevance to biological and medical sciences – the so-
called –omic age - where multi-dimensional, high-throughput phenotyping technologies 
(genomic, proteomic, and metabolomic read-outs) are combined with microfluidics, nano-scale 
engineering, and advanced programming and machine learning, to generate vast archives of 
biological data, and characterise and intervene in biological systems (Becher et al., 2014; 
Bendall et al., 2011; Brodin et al., 2015; Price et al., 2012).  
 
In the next 30 years, one will likely have access to one’s whole genome sequence (and, 
therefore, knowledge about cancer predisposition). This will allow for genetic counselling, 
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screening, and crucially, prior knowledge before seeing a doctor with an acute ailment. During 
the consultation, the doctor will have a wider array of precise and multi-dimensional bed-side 
assays available to generate a more complete picture of your health (Ginsburg and Willard, 
2009). Indeed, recent breakthroughs in liquid biopsy technology - based on cell-free cancer 
DNA present in the patient’s plasma - are testament to the fact that ever smaller sample 
volumes and less invasive procedures can diagnose cancer more quickly than was previously 
possible (Diaz and Bardelli, 2014). Couple this to tumour-specific pharmacogenomics 
(Wheeler et al., 2012), and more patients can be saved.  
 
Through such ambitious approaches, not only will more diverse types of cancer be identified 
more quickly and accurately, and treatments targeted, but we will have a better idea of organ 
function through time, helping us care for our bodies and further improve human life 
expectancy. What’s more, in the future, artificial intelligence will be able to examine billions 
of data points from an individual to more accurately determine the nature and potential cause 
of disease. Indeed, IBM has recently rolled out the computer, Watson, to do that just in 
hospitals around the world (Chen et al., 2016). Watson’s answers are compared to human 
decisions and sometimes used to guide treatment. As computers can perceive data in more 
dimensions than we can, it may be only a matter of time before cognitive computing is 
diagnosing disease. 
 
Already, the application of genomic techniques has been hugely beneficial to the fight against 
cancer. For several years, it has now been possible across many countries to have your genome 
sequence checked for highly-penetrant risk variants for cancer; with the examples of BRCA1 
and BRCA2 in breast cancer standing out as great success stories. Here, crucially, genetics 
enables prevention, as prophylactic mastectomy proves Such advancements would not have 
been possible without basic research studies in genetics and cell biology, allowing the defective 
genes to be identified, and robust tests developed.  
 
Applications such as these clearly illustrate the power of genetics and molecular biology in 
cancer medicine, and defining and characterising the molecules involved in disease 
development, maintenance and progression (such as DNA damage response proteins), remains 
our best hope to prevent, treat and cure disease. As we learn more about the different molecular 
compositions of different tumours(Shipitsin et al., 2007), we will be better placed to understand 
the defective cellular mechanisms involved and identify individuals susceptible to, or suffering 
from, disease.  
 
1.2 The aetiology and epidemiology of cancer 
 
Given the exciting developments underway in biomedical research and clinical medicine, we 
stand poised to make breakthroughs in cancer medicine. Cancer refers to a group of diseases 
characterised by rapid, un-regulated cellular division and growth in which the abnormal cells 
acquire aggressive, functions and invade and occupy different tissues than those of origin 
(Cooper and Hausman, 2007). In all cases, cancer evades the cellular regulatory mechanisms 
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in place to maintain normal tissue homeostasis, remodelling and repair; discussed in section 
1.3. 
 
1.2.1 The history of cancer 
 
The acknowledgement of cancer as a disease entity is as old as human history, with several 
sources from ancient civilisations describing in detail the phenotypes and consequences 
associated with the disease. For example, the Edwin Smith Papyrus, a medical text from ancient 
Egypt written in 1600 BC (considered to be amongst the first attempts to distinguish medicine 
from magic) describes cases of breast cancer, amongst 48 other common ailments (Atta, 1999). 
Later, at around 400 BC, Hippocrates used the Greek term karkinos (meaning crab) to describe 
cancer morphology based on the highly-vascularised nature of sectioned tumours; providing 
valuable insight into the angiogenic nature of abnormal tissue formation (Sudhakar, 2009).  
 
Subsequently, in 40 AD, the encyclopaedist Celsus translated karkinos to Latin, giving us the 
contemporary name, cancer. The Roman also suggested for the first time that surgical resection 
may be a means to halt the deleterious effect of the condition, something which we still rely 
upon in the present day (Karamanou et al., 2009). Unfortunately, however, another prominent 
scientist of the second century AD, Galen, disagreed with the notion of surgical resection, and 
given his sphere of influence, meant that cancer was treated mostly with purgatives for the next 
1,000 years. These observations illustrate the pervasive and common nature of the disease 
throughout evolutionary history, suggesting that if environmental triggers are required for 
cancer formation, they may have been present in ancient times also; indeed, excessive exposure 
to UV radiation is a well-known risk factor for melanoma (Berwick et al., 2005).  
 
Despite our historical appreciation of the clinical problems associated with cancer, it was not 
until the era of the European renaissance and the scientific method – in the 15th, 16th and 17th 
centuries – that our understanding of cancer was furthered in considerable detail. During this 
time, clinicians began to attempt to explain the causes of cancer through post-mortem 
dissections and modern pathological techniques. These studies led to the hypotheses that acidic 
lymph fluid and milk clots were responsible for tumour formation in different anatomical areas. 
An important insight into the disease at the time came from Nicolaes Tulp, who posited that 
cancer is like a poison able to spread from one location to another (Blumenthal, 1996). Indeed, 
Campbell De Morgan, building on the observations of John Hilland Percivall Pott (who found 
associations between cancer and tobacco and chimney sweeping, respectively), later exploited 
advances in microscopy at the time (between 1871-1874) to describe metastases (or cancer 
spreading) of the primary tumour to secondary lymphodensities, helping cement our 
fundamental understanding of the disease (Sudhakar, 2009). 
 
1.2.2 An introduction to cancer biology 
 
Wherever cancer cells are located, they are able to disrupt normal tissue organisation and 
function; often with fatal consequences. Figure 1.1 illustrates the nature of oncogenic lesions 
histologically, and in terms of their gross morphology. Such abnormal growths of cancerous 
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cells are referred to as tumours (and may be solid or diffuse), although it is important to 
remember that not all tumours are malignant (cancerous); with some being benign and lacking 
the ability to spread.  
 
All cancers are a form of neoplasm (a new and abnormal growth of tissue), and according to 
present day clinical guidelines must adhere to the following to be considered malignant: 
 
• Exhibit un-restrained cell growth and division in the absence of normal physiological 
stimuli. 
• Exhibit continuous growth even in the presence of inhibitory signals. 
• Exhibit a lack of programmed cell death pathway functions. 
• Exhibit promotion of angiogenesis (for tumour nutrient supply). 
• Exhibit limitless replication potential.  
• Exhibit tissue invasion capacity, leading to the establishment of secondary tumours 
(metastases).  
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A.  
B. 
 
 
Figure 1-1 Gross and histological pathology examples of cancer.  
(A) Gross pathology specimen of a colectomy specimen showing an invasive colorectal carcinoma with its 
irregular disrupted form (B) Histological image of colonic carcinoid stained by haemotoxylin and eosin, with 
prominent mitotic figures seen  
From: https://en.wikipedia.org/wiki/Adenocarcinoma 
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If we couple the destructive power of un-restrained cancer growth to a cancer’s ability to spread 
and set-up secondary tumour sites, scenarios in which normal biological function is severely 
compromised are easy to appreciate. Early detection is key to catch the cancer before secondary 
metastases are formed. Depending on the nature of any particular tumour, its anatomical 
location, and metastatic potential, cancers can be more or less problematic clinically, and 
within different time frames; with some developing quickly and very deleteriously, and others 
taking years to progress to relevant phenotype. In the most extreme cases, the tumour burden 
of a tissue can lead to organ failure, and other life-threatening complications, such as peritonitis 
and sepsis arising from a loss of epithelial barrier integrity in the colon or rectum. 
 
However, it is worth remembering that cancer cells do not only affect cells near to them. In 
many instances, paraneoplastic syndromes arise due to the systemic effects of tumour cells. 
Many paraneoplastic syndromes affect endocrine functions, due to cancer cell 
production/consumption of hormones, whilst other cancers are associated with neurological 
inflammation (Delellis and Xia, 2003). Overall, these changes lead to global dysregulation that 
further undermine health. Indeed, cancer always has a consequence on the body.  
 
1.2.3 The biology of rectal and colorectal cancer  
 
The focus of our investigations here presented is, specifically, rectal cancer – that is, malignant 
tumours affecting the most distal portion (bar the anus) of the human gastrointestinal tract. This 
point is emphasised as rectal cancer is often considered alongside (and the term is used 
synonymously with) colorectal or colon cancer when diagnosing and treating malignant disease 
in the distal intestine. This makes quantifying incidence and refining biological mechanism 
more challenging; as clinical heterogeneity abounds (Li and Lai, 2009). That said, current 
estimates suggest that approximately one third of colorectal cancer cases are comprised of 
tumours originating in the rectum.  
 
Until the recent advent of advanced live surgical imaging and molecular genomic techniques 
(such as genome-wide mRNA transcription and DNA methylation profiling), which allow the 
tissue origin of biopsied tumours to be more clearly defined, the origin of the primary tumour 
– be it rectal, colonic or other segments of the distal bowel – was largely unknown, with 
clinicians relying upon exploratory surgery to determine the nature of the disease and treatment 
modalities.  
 
Unfortunately, this lack of clinical stratification has hampered efforts to better understand 
disease aetiology and deliver targeted, effective treatments. For example, if we consider that a 
considerable portion of the rectum lies beyond the peritoneum and is associated with its own 
specialised lymphoid tissue to counter environmental challenge (Standring, 2008), the triggers 
required for malignancy in this location are likely often different to those driving oncogenesis 
in more proximal bowel segments, where dietary antigens may more strongly predispose to 
cellular transformation (Yu et al., 2001). In general, mechanistic differences between cancers 
originating in different anatomical locations impact not only how the cancer functions and 
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metastasises, but also how disease can be treated; as different cell lineages and tissues have 
specialised functions, the tissue of origin may endow important mechanistic properties to the 
malignancy. In future, with improved diagnostic procedures, cancers affecting different parts 
of the large bowel will be increasingly considered as separate diseases, removing some of the 
ambiguity arising from the clinical heterogeneity present between patients with various forms 
of large bowel cancer, thereby refining the molecular mechanisms at play. Such efforts will 
also be increasingly helped by the collection of human tissue biobanks (such as the Cambridge 
BioResource of the University of Cambridge; 
https://www.cambridgebioresource.group.cam.ac.uk), where clinically well-defined tissue 
samples from patients are deposited, processed and made available to basic researchers for 
discovery and drug development work. 
 
Most tumours in these anatomical regions of the GI tract start off as polyps which protrude 
from the epithelial (inner) surface before becoming malignant (see Figure 1.2) (Subramaniam 
et al, 2016). Polyps may be pedunculated or sessile. Furthermore, although polyps are present 
at diverse locations in the GI tract, especially in older age, not all of them are cancerous, making 
delineating rectal and colon cancer difficult in many cases. Adenomas are more likely to 
become malignant (Brenner et al., 2007). Despite the difficulties associated with cancer 
location determination, research has shown that the clinical and biological features of 
gastrointestinal tumours, drug responses and patient prognoses depend upon tumour location, 
further suggestive of distinct aetiologies and functional consequences (Artinyan et al., 2008). 
 
Further studies in different ethnic groups are required to determine the molecular mechanisms 
leading to disease in diverse populations, whilst patient out-reach programmes furthering 
medical education in particular communities is likely to be of broad benefit and can include 
modern approaches such as social media and community health groups to help alleviate the 
fears associated with cancer and the medical community in general. 
 
 
Figure 1-2 A schematic of colorectal cancer development.  
From: Subramaniam et al, 2016. 
Cancer Research Frontiers. 2016 Feb; 2(1): 1-21. doi: 10.17980/2016.1                                                                          Review 
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compartment (14, 15). Wnt dependent signaling leads to 
a proteolytic degradation of APC as well as 
translocation of β-catenin to the nucleus (16). 
Furthermore, mutations in p53, K-Ras and BRAF are 
associated with the neoplastic changes of IECs during 
the sporadic colon cancer development; BRAF and K-
Ras mutations have been considered as prognostic 
markers for MSI (17). P53 and/or K-Ras mutations 
 
 
Figure 1: A. Process of sporadic colon cancer development. Cumulative mutations due to chromosomal instability, 
microsatellite instability, and epigenetic changes result in DNA damage and loss of tumor suppressor genes including APC. 
These changes lead to clonal expansion of mutated IECs. Sporadic colon cancer development initiates from hyperplasia to 
adenoma and eventually into adenocarcinoma. B. Process of colitis associated cancer (CAC) development. Epithelial 
regeneration signaling is activated as a repair mechanism in response to chronic inflammation. Increased oxidative stress, 
aberrant inflammatory and tissue repair signaling lead to p53 mutation, Wnt signaling and β–catenin activation, which 
initiate dysplasia in IECs. Dysplasia in IECs progress to low to high grade dysplasia and eventually to carcinoma. 
Sustaining inflammation is the key for the development of CAC. Genetic and epigenetic changes in DNA further contribute 
to CAC carcinoma at later stage of carcinoma. 
________________________________________________________________________________________ 
 32 
 
Disease progresses from polyps in the intestinal/rectal epithelium to cancer that is able  to 
invade the basement membrane and then metastasise. Candidate genetic triggers to oncogenesis 
are shown in the green boxes, and include the loss of DNA damage response protein functions 
(APC), oncogene activity (KRAS and BRAF) and loss of tumour suppressor gene function 
(p53), as we will discuss further. Importantly, the environmental triggers leading to poly 
generation and oncogenesis are not shown, but heavily impact upon genetic factors in cancer.  
 
 
1.2.4 Cancer prevalence  
 
At present, over 100 different types of cancer have been documented in humans, and according 
to the World Health Organisation, more than 90 million people had cancer during 2015, 
although diagnostics (especially relating to prostate cancer) are believed to account for a 
greater than 3% reduction in overall cancer incidence in males in the western world (Siegel et 
al., 2016). Fourteen million new cases are thought to arise every year. During 2015, cancer was 
estimated to be responsible for nearly 9 million deaths globally, or approximately 15% of all 
human deaths in that year; demonstrating the profound clinical and socio-economic burden of 
cancer worldwide.  
 
Worryingly, these numbers trend upwards in many diverse populations (Jemal et al., 2011), 
especially as life expectancy increases worldwide. Indeed, the risk of developing cancer is 
strongly associated with age in the majority of cases affecting adults (White et al., 2014). One 
in 2 Australia men and women will be diagnosed with cancer by the age of 85 (AIHW, 2017a). 
The most commonly diagnosed cancer in Australia is prostate cancer, followed by colorectal 
cancer, breast cancer, melanoma of the skin and lung cancer. These cancers are estimated to 
account for about 60% of all cancers diagnosed (AIHW, 2017a).  
The types of cancer most commonly causing death are lung, prostate and colorectal cancers in 
males and lung, breast and colorectal in women (AIHW, 2017a).  
The most common cancers in children are acute lymphoblastic leukaemia and cerebral 
tumours, with approximately 150,000 children diagnosed  with cancer worldwide per year (Pui 
et al., 2008). As we will discuss in Section 1.3, highly penetrant genomic lesions may 
predispose to cancer at younger ages, compared to older individuals, in which mutations and 
risk factors accumulate over time to cause pathology.  
 
It is important to note that amongst all types of cancer, the 5-year survival rate stands at 68% 
of patients based in Australia, a world leader in cancer diagnostics and treatment (AIHW, 
2017a). Of course, heterogeneous cancers are associated with different survival rates, and 
treatments can be more or less efficacious for different diseases, again highlighting the 
tremendous power of personalised genomic medicine to help target appropriate treatments to 
patients.  
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1.2.5 Colorectal cancer incidence and mortality 
 
The Australian Institute of Health and Welfare (AIHW) is a national agency that collects data 
on vital health statistics including cancer. Cancer of the large intestine and cancer of the 
rectum are collectively known as colorectal cancer. The information provided below is 
extracted from their salient book on colorectal cancer (AIHW, 2017b).  
Colorectal cancer was the third most commonly diagnosed cancer in Australia in 2013 however 
in 2017 it is thought that this will become the second most commonly diagnosed cancer. In 
2013, there were 14,962 new cases of colorectal cancer diagnosed in Australia (8,214 males 
and 6,748 females). In 2017 this is projected to increase to an estimated 16,682 new cases of 
colorectal cancer Australia (9,127 males and 7,555 females). Additionally in 2017 the risk of 
a person being diagnosed with colorectal cancer by their 85th birthday will be 1 in 13 (1 in 11 
males and 1 in 15 females). 
The mortality data is striking. In 2014, colorectal cancer was the second leading cause of cancer 
deaths in Australia. This is projected to remain the second most common cause of cancer death 
in 2017. We know in 2014 that there were 4,071 deaths from colorectal cancer in Australia 
(2,236 males and 1,835 females). In 2017, it is estimated that this will increase to 4,114 deaths 
(2,136 males and 1,978 females). 
Figure 1.3 shows the age-specific incidence and mortality rates for colorectal cancer, by sex in 
2017. 
 
 
 
Figure 1-3 Estimated age-specific incidence and mortality rates for colorectal cancer, by sex, 2017 (AIHW, 
2017b) 
 
 
 
1.2.6 Cancer risk factors – genetics  
 
When discussing specific risk factors, we will first consider genetics. Cancer is a loss of control 
over our genome. Estimates suggest that between 5-10% of cancers are due to heritable genetic 
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mechanisms (Garber and Offit, 2005). That does not include individuals who may be 
genetically predisposed to a particular phenotype (i.e. dysregulated inflammation) which 
interact with various environmental factors to accelerate cancer development. It is useful to 
consider genetics as what is underlying our ability to cope with the environment, to which we 
are all differently suited.  
 
When considering cancer genes, two major types are well described – oncogenes (which lead 
to cell division and growth) and tumour suppressor genes (TSG - which curtail cancer by 
limiting cell lifespan and growth. Promotion of the former and suppression of the later are both 
deleterious, with many examples showing considered risk with heterozygosity. Oncogenes are 
formed by mutations to proto-oncogenes, which normally regulate the cell cycle. TSGs, on the 
other hand, are involved in apoptosis, DNA repair, and again, the cell cycle.  
 
Well known examples of inherited cancer genes include BRCA1 and BRCA2, discussed earlier, 
which are major contributors to breast and ovarian cancer development (Ford et al., 1998).  
 
Further examples and mechanisms will be presented in Section 1.4, although other well-known 
cancer-associated genes worth considering (if only for their remarkable capacity to profoundly 
alter the cellular state) include MYC, which regulates cell cycle progression and apoptosis 
(Dang, 2012), and p53, the ‘guardian of the genome’, which inhibits angiogenesis, activates 
DNA repair proteins and arrests the cell cycle at the G1/S phase boundary (Ryan et al., 2001). 
Finally, the apoptosis regulator BCL-2 is also associated with many common translocation 
events (Czabotar et al., 2013); indeed, it was named B-cell lymphoma 2 due to the growth-
promoting activity of variants in cancer cells.  
 
As an aside: Perhaps disappointingly, given the amount of animals used in research, the 
majority of tumour models of disease focus on a limited subset of genes, such as KRAS, MYC 
and JUN, which are undoubtedly helpful for refining biological mechanisms, but they may 
have little similarity to cancers caused by other lesions, which far out-number those currently 
used. Despite their historic utility, murine models have recently come under criticism due to 
poor translation of medical findings to human subjects (Seok et al., 2013). Advances in induced 
pluripotent stem and the gene-editing technology, CRISPR, are also leading to increased 
impetus for the development of human in vitro models (Mali et al., 2013). 
 
In colorectal cancer, more than 50% of patient tumours carry mutations in a kinase  or 
phosphatase gene (such as PIK3CA) - families essential for positively and negatively regulating 
cellular function via post-translational signalling influencing differentiation and growth 
(Samuels et al, 2004). Given the erroneous activity of PIK3CA and its ability to drive 
oncogenesis, various drugs have been developed to target the enzyme and related factors, as 
we will discuss.  
 
As well as these examples of penetrant causal lesions, polygenic susceptibility to cancer has 
also been described. Researchers found over 20 loci to contain SNPs predisposing to the five 
most common types of cancer (Easton and Eeles, 2008). In terms of colorectal cancer, the 
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authors found a SNP within the EIF3H to be associated with disease (minor allele frequency 
0.77; odd’s ratio per allele 1.25), supporting work by Zhang and colleagues who described the 
gene that promotes oncogenesis when the h-subunit is overly phosphorylated (Zhang et al., 
2008). Additional variants predisposing to disease are likely to be identified in more powered 
studies benefitting from improved patient stratification. Crucially, it is not only the nuclear 
genome that is susceptible to mutation, with mtDNA coding and non-coding sequence variants 
being associated with diverse tumour types (Chatterjee et al., 2006).  
 
Aside from inherited risk, cancer at the cellular level is a truly genetic disease, meaning that 
changes in the somatic genomic code lead to pathology. Some cells may be more predisposed 
to cell-cycle dysregulation according to their genetic background. When compared to harsh 
environmental pollutants that directly damage DNA and lead to oncogenesis, such interactions 
in day-to-day life may be less determining and more insidious in nature. 
 
Further discussion of the molecular mechanisms of cancer is presented in Section 1.4.   
 
1.2.7 Cancer risk factors – environment 
 
However, the genetics is only one side of the story, as evidenced by the fact that monozygotic 
twins show discordance in cancer phenotypes (Castillo-Fernandez et al., 2014), and many 
environmental triggers have been defined. Indeed, environmental factors are thought to account 
for the majority of cancers – 90-95% of total cases (Anand et al., 2008). Viewed in this way, 
cancer can be seen as a disease arising due to DNA damage caused by the environment.  
 
It is not only cancer that is proposed to be highly dependent on environmental triggers, but also 
our body in general. Autoimmune and inflammatory diseases, such as coeliac disease (Han et 
al., 2013), and the functional state of your immune system (Maecker, 2012), are also 
hypothesised to be more greatly affected by your environment than by your genes (Brodin et 
al., 2015); with migration studies showing a higher incidence of autoimmune diseases in 
migrants to a new country (Li et al., 2009).  
Importantly, it is also widely accepted that cancer risk is higher in developed countries, where 
modifiable environmental risk factors (such as photoperiod modulation and western diets) and 
susceptible genetic variants may be more commonly found (Carrera-Bastos et al., 2011). In 
such complex environments, a trait for self-tolerance (i.e. to limit the deleterious effects of 
prolonged inflammation or autoimmunity directed against self-antigens) may limit the 
deleterious chronic inflammation associated with different complex polygenic diseases 
(Salmond et al., 2014), although predispose you to infectious disease otherwise covered by our 
immunological history. 
 
Environmental risk factors for cancer are many and diverse, and include chemicals (or 
carcinogens), diet and physical activity, infections, ionising/non-ionising radiation, inert 
agents; and how these interact with under-pressure genomic variants in modern environments. 
One cannot overlook the fact that the majority of cancer predisposition comes from modifiable 
environmental exposures – suggesting it is preventable. However, it is a considerable challenge 
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to prevent cancer, given that the number of cancer-promoting compounds and entities is 
diverse, and expanding rapidly. Thankfully, my generation may see the end of the internal 
combustion engine in the personal automobile, which is thought to account for 40,000 deaths 
per year in the United Kingdom (Roberts, 2016). 
 
Chemical carcinogens include substances like alcohol, tobacco, nitrosamines and polycyclic 
aromatic hydrocarbons, such as benzene, which can cause leukaemia (Miller and Miller, 1981). 
The list is large, and include natural and synthetic products in foods and our environments. 
 
The importance of diet to health cannot be understated, especially in respect to gastrointestinal 
cancer. Estimates suggest that 10% of cancer deaths are due to obesity, excessive alcohol 
consumption, a lack of physical exercise, and a poor-quality diet (Lopez et al., 2006). In my 
opinion, given the strong associations between diet and metabolic syndrome and dysregulated 
inflammation in various tissues (Esposito et al., 2004), the number of cases affected by diet is 
far higher.  
 
Although a myriad complex aetiologies lead to cancer, the known phrase, you are what you 
eat, really does ring true. It turns out that specialised lymphoid cells guarding the human 
gastrointestinal tract are only formed when the aryl-hydrocarbon receptor is properly 
stimulated, and the best described stimulants are organic compounds present in broccoli (Li et 
al., 2011); remembering that dysregulated inflammation is strongly associated with cancer. A 
balanced diet, rich in fresh produce (vegetables, fruits and limited amounts of animal products) 
providing carbohydrates, proteins, fats and vitamins), grains, and limited amounts of red meat 
is generally accepted to provide the body what is required for normal homeostasis (James et 
al., 2007). All in moderation, as toxicity occurs.  
 
In cases where individuals do not care for their diet, and consume mostly heavily processed 
food ill-balanced in the aforementioned substances, the body does not receive the optimal fuel 
for function. Dietary deficiencies are tales as old as books (Sommer, 2008), and chimpanzees 
use their known medicinal plants to treat their bodies in times of illness (Huffman, 1997). As 
we increasingly consume food sourced from far and wide, and mostly from industrialised 
farming origins, the quality is likely to be far below optimum (Rostagno, 2009). Indeed, much 
needs to be done to improve animal welfare in such settings, which will also affect the chemical 
(i.e. hormonal) composition of meat, for example. Cortisol and steroidal hormones in general 
are associated with stress and they are potent regulators of cell fate and function - they have 
been reproducibly associated with cancer development; as shown by the driving role of 
oestrogens in prostate cancer (Nelles et al., 2011).  
 
More specifically from whole food groups, a carcinogen is defined as a molecule that can 
promote carcinogenesis; through genomic mutation or metabolic dysregulation. Smoke from 
combustible organic matter contains many carcinogenic compounds, such as acrolein found in 
tobacco smoke, which permanently binds to guanine bases and induces mutations due to 
irreversible DNA alkylation (Alwis et al., 2015). Nicotine, also present in tobacco smoke, is 
not thought to be directly carcinogenic itself, although it does inhibit apoptosis, and thereby 
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may accelerate existing cancers in sub-clinical smokers (Cucina et al., 2012). The radioactive 
carcinogen 210Pb is also present in tobacco smoke; equivalent to 0.1pCi per milligram of smoke. 
Tobacco, is probably the best know cancer-associated factor, yet remains popular he world 
over. The risk is known, although people enjoy the effects, which may also have shaped human 
evolution - after all, nicotine is a potent parasympathomimetic. Tobacco is associated with 22% 
of all cancer deaths, and given the information available on the subject I refer you accordingly 
(WHO, 2017). 
 
Importantly, different chemicals can cause disease through different mechanisms. Alcohol, for 
example, is a known mutagen and the risk of developing cancer is higher in tissues directly 
exposed to it (Lachenmeier et al., 2009). Furthermore, acetaldehyde produced from alcohol 
metabolism is also carcinogenic. Thus, alcohol can predispose to cancer by inducing mutations 
in cells which do not die of exposure to high levels of it or its metabolites, or because loss of 
mature cells due to alcohol toxicity stimulates accelerated division of stem cells which 
accumulate potentially deleterious mutations normally associated with cell division; fewer 
divisions healthier stem cells.  
 
Radiation is also considered carcinogenic as it can directly damage DNA, however, given its 
ability to damage DNA, it is also harnessed therapeutically to eradicate tumours – see 
radiotherapy, discussed below. Up to 10% of cancers are associated with ionising and non-
ionising radiation, with the vast majority of non-invasive melanoma in humans arising from 
excessive ultraviolet radiation exposure (Anand et al., 2008). In terms of ionising radiation 
(which has the energy required to directly break molecular bonds, causing DSBs in DNA), 
models suggest that cancer risk increases in a linear fashion with radiation doses at a rate of 
5.5% per Sievert (ICRP, 2007). Radiation-induced tumours are believed to be particularly 
insidious in nature, with solid tumours taking between 10-15 years to cause a noticeable 
phenotype (Braunstein and Nakamura, 2013).  
 
Microorganisms are also important for cancer development as will be discussed in Section 1.4. 
In the developing world, approximately 10-20% of cancers are thought to be due to infectious 
disease (De Flora and La Maestra, 2014), such as those caused by hepatitis B and C viruses; 
which cause liver cancer. Epstein Barr virus infection is associated with non-Hodgkin 
lymphomas and nasopharyngeal cancer (Carbone et al., 2008), human immunodeficiency virus 
is associated with Kaposi sarcoma (Hoffmann et al., 2017), and papilloma viruses can cause 
cervical and penile tumours (Crosbie et al., 2013). The mechanisms used by viruses to 
transform human cells and dysregulate their function are diverse, and can afflict the genome, 
metabolome and proteome of the host cell.  
 
Given the many environmental risk factors associated with the development of different forms 
of cancer, it is not surprising to learn that front-line medical advice for cancer avoidance 
includes: moderating alcohol intake; maintaining a healthy weight; getting vaccinated; 
maintaining good personal hygiene; avoiding tobacco consumption; and partaking in moderate 
and regular physical exercise.  
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1.2.8 Risk factors for colorectal cancer  
 
Although the majority of rectal and colorectal cancers are thought to be predisposed to by an 
environmental trigger, several conditions of familial tumours have been described and the 
erroneous genes and syndromes identified. Furthermore, a familial history of cancer, 
inflammatory bowel disease, Crohn’s disease and ulcerative colitis – all pathologies with a 
genetic component) are also associated with increased risk of rectal cancer (Eaden et al., 2001; 
Freeman, 2008; Kim and Chang, 2014); further suggesting that cancer arises from situations in 
which cell damage is increased. 
 
Familial adenomatous polyposis, or Gardner syndrome, is caused by mutations in the 
adenomatous polyposis coli (APC) gene which mediates cellular adhesion; and is thought to 
contribute to a loss of barrier integrity in the intestine, necessitating increased cellular turnover 
and neoplasia (Galiatsatos and Foulkes, 2006). APC is defined as a tumour suppressor, and 
when its activity is reduced polyps form in the colon. Tumours can form directly in the rectum 
or arise there as a secondary site. Mutations in STK11, another tumour suppressor, and 
MUTYH, which makes the enzyme responsible for making the DNA repair protein MYH 
glycosylase, are also known genetic components in gastrointestinal cancers (Resta et al., 1998; 
Sampson et al., 2005). 
 
High-fidelity DNA replication is essential to avoid cancer, and of relevance to our specific 
interests is what is known concerning Lynch syndrome – where mutations in several DNA 
mismatch repair enzymes have been described to lead to colorectal cancer (Vasen et al., 1999). 
These include MLH1, MSH2, MLH3, MSH6, PMS1 and PMS2. In these cases, DNA replication 
is error prone and mutations accumulate.   
 
1.2.9 Why is cancer increasing in prevalence? 
 
Cancer is a non-communicable disease, at least in humans (so far), and as in all complex human 
diseases, genetics and environmental factors are known to cause disease. At present, we are 
living through the first period in human history in which more annual deaths are due to non-
communicable diseases (such as cancer, obesity, metabolic diseases and autoimmune 
pathologies) than infectious disease (Boutayeb and Boutayeb, 2005); although considerable 
infectious disease burdens persist. As economic development progresses worldwide, this 
disparity is predicted to continue getting bigger. It suffices to say that cancer is getting more 
common all the time.  
 
As we have discussed, increasing life expectancy and exogenous carcinogens are believed to 
be the direct causes of cancer, although how these interact with other physical features of our 
environment are largely unknown. For example, it can be argued that this shift in overall cause 
of death - occurring over a relatively short evolutionary time frame - is largely due to the 
discovery of microbes, and the discovery and development of antibiotics and vaccines, which 
drastically reduced the mortal burden from pathogens. The same pathogens which exerted 
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profound evolutionary selective pressure on the human genome, endowing it with the capacity 
to respond and exist in human environments of old and exist in harmony with our body (Okada 
et al., 2010). At the same time, we have completely redefined the human environment, bringing 
heating, fast/processed food, disinfectants and other harmful chemicals, pathogens and 
homeostasis-disrupting factors (such as artificial lighting, shift work and jet-lag; which disturb 
circadian rhythmicity and are associated with complex disease development, including cancer) 
into the fold (Wang et al., 2011). Therefore, determining the factors that interact with genes to 
cause diseases such as cancer is a daunting task.  
 
Furthermore, although we rarely consider ourselves as vertebrates, we respond to many of the 
same environmental cues, and also exist symbiotically with diverse and common species; i.e. 
as with Staphylococcus and Streptococcus in our skin and gut microbiomes, which help defend 
us from opportunistic pathogens, as in dogs and cats (Cho and Blaser, 2012). Some have 
famously posited that an absence of microbes and immune stimulation is degenerative and 
predisposes to autoimmunity; with nothing to attack, the body attacks itself (Okada et al., 
2010). Further along these lines, it is perhaps unsurprising that higher autoimmune disease 
incidence rates have been reported in individuals delivered by caesarean section, compared to 
natural births, where the mother’s flora is predicted to engender normal immunity (Neu and 
Rushing, 2011). Such habits of modernity are, therefore, disease-associated, and are likely to 
influence cancer.  
 
Furthermore, recent work from the United Kingdom has shown that humans across the world 
exhibit profound seasonal changes in gene expression and the cellular composition of organs; 
demonstrating the profound effect repeatable environmental changes, such as days/nights, 
months or years can have on how our body works (Dopico et al., 2015). In this study, the 
authors propose that seasonal changes may have evolved in-keeping with seasonal diets, 
pathogen burden, photoperiod and temperature; all of which we have largely removed from 
modern societies.  
 
Thus, it can be argued that the gene-environment interactions taking place in the modern era 
are very different from those evolutionary ancient triggers. Accordingly, the change in the 
aetiology of human deaths requires clinical and basic re-conceptualisation of the roots and 
causes of human diseases, and disentangling new gene-environment interactions in health and 
disease is the major focus for clinical medicine in the 21st century. Nowhere is this truer than 
in cancer. 
 
For many reasons, cancer is increasing, trends would need to be reversed. The global cancer 
burden is already considerable, and places significant socio-economic restrictions on societies 
worldwide (Jan et al., 2012). Even in high-income economies, such as the United Kingdom 
and Germany, public finances are not sufficient to cover the cost of certain novel anti-cancer 
treatments, such as anti-CTLA-4 (which costs hundreds of thousands of dollars per year), for 
the large number of patients who might benefit (Goldstein et al., 2016).  
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1.3 Screening, diagnostics and treatments for cancer 
 
Many treatment options exist for cancer, with available options dependent on the cancer type, 
tumour grade, location, and the other clinically-relevant features of the patient, such as age and 
immune status. 
 
Since we have shared knowledge on cancer, various people have made crucial leaps for our 
understanding of the disease and how to manage it. Hippocrates described cancer as a disease 
arising from a humoral imbalance, a view which prevailed for over 1,300 years. When various 
people saw tumour formation from isolates of lymphatic fluid in the 17th century, this view was 
refined (Sudhakar, 2009). However, Muller then demonstrated that lymph was not required, 
and his student Virchow showed that all cancer cells were derived from each other (Balkwill 
and Mantovani, 2001). Another considerable group of individuals maintained that parasitic and 
other infections caused cancer; and in 1911, Rous sarcoma virus was described to cause cancer 
in avian species (Weiss and Vogt, 2011). These principled understandings of the disease are 
remarkably accurate. However, between the 1800-1920s, the view that cancer arose due to 
trauma gained support, although this was poorly evidenced in the animal models at the time 
and subsequently.  
 
As discussed, various triggers can cause rectal cancer, and oncogenesis in general. This 
heterogeneity requires innovative technological methods to achieve greater resolution when 
analysing the genome, metabolome and proteome. System biology analyses could be used to 
define networks of interacting factors in dimensions beyond our easy comprehending (Werner 
et al., 2014). Indeed, such approaches have already yielded success in the cancer field. Nano-
sensors have a sensitivity of approximately 1 x 10-16 g ml-1 of protein in human serum samples 
(Kosaka et al., 2014). When this technology is used to detect the presence of cancer biomarkers, 
such as prostate specific antigen, it greatly reduces the amount of sample required, as well as 
allowing for cancer to be detected at a much earlier stage, when fewer malignant cells release 
their cancer-antigen contents into the blood (Kosaka et al., 2014). Such techniques could also 
be used to monitor the effects of treatment. 
 
As we introduced earlier on, such high-throughput and hypothesis-free (iterative) methods 
promise to greatly refine clinical medicine. For example, a cancer’s molecular profile can be 
generated before treatment is considered. Further, the fusion of such technology with 
biologically identified and verifiable biomarkers also promises to transform not just cancer 
detection, but for tissue-function profiling in general. 
 
1.3.1 Cancer screening and early detection  
 
Prior to reviewing the major means by which cancer is treated once diagnosed, we shall 
consider how we identify cancer. Indeed, a major limitation to successfully treating cancer is 
the time from disease origin to clinical phenotype (Ellis and Vandermeer, 2011). In many cases, 
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by the time a patient presents to his/her clinician for treatment, the disease is already advanced, 
making treatment more problematic and less likely to succeed.  
 
There are many reasons for why this interval is difficult to close. Firstly, in the patient, cancer 
is synonymous with morbidity and mortality, as demonstrated by the widespread fear 
associated with these pathologies in the wider public. Such emotions are problematic for cancer 
diagnoses; as patients will often put-off physician consultations for fear of the C-word. 
Remembering that a patient may not even notice or deal with his/her tumour, and serendipitous 
discoveries are the exception not the norm. Hopefully, these perceptions will change, especially 
as the internet and public healthcare education initiatives help individuals better understand 
their health and what can be done in the case of disease (Barros et al., 2014). Through 
education, important risk factors can be avoided.  
 
Unfortunately, it is also still difficult to collect a patient sample that can inform upon cancer 
status without an invasive biopsy. Ideally, cancer should be detected before a visible mass is 
present. Indeed, advances in cell capture, microfluidics and nanotechnology are transforming 
how we detect pathology.  
 
At present, screening mostly takes place at the genetic level and protein level in patient samples 
(Andriole et al., 2009). BRCA1 and BRCA2, both involved in breast, ovarian and pancreatic 
cancer development are routinely analysed for deleterious variants in those at increased cancer 
risk; i.e. those with a familial history. The genes encoding the DNA mismatch repair genes, 
MLH1, MSH2, MSH6, PSM1 and PSM2 are also typed with genetic tests given the increased 
relative risk for colorectal, uterine and stomach cancer associated with variants in these factors 
(Vasen et al., 1999).  
 
Other screening approaches of note include the screening test for human papilloma virus and 
mammography, which represents a physical method to analyse abnormal tissue morphology in 
situ (Gyllensten et al., 2012). Such approaches allow cancer to be identified and treatments 
commenced – the sooner identification takes place, the better. As we will discuss, novel 
methods are slashing diagnosis intervals.  
 
In respect to our studies, when a cancer is found, prognostic markers of tumour aggressiveness, 
and likely survival pre- and post-intervention can not only help the patient contextualise his/her 
situation, but also allows for treatments to be based on mechanism and the individual from the 
very beginning and improve patient quality of life. Reporting such biomarkers of patient 
outcomes following treatment not only refines disease mechanism but also take the patient to 
a different level of understanding his/her treatment. Thus, to improve cancer survival, 
biomarkers associated with the earliest events in cancer development need to be identified and 
rolled-out in the clinic.  
 
The old adage Prevention is better than cure is true for colorectal cancer. Removal of an 
adenoma, a precursor lesion to colorectal cancer, has been shown to prevent cases of colorectal 
cancer occurring (Winawer et al, 2011). 
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Blood originating from these precancerous polyps lining the rectum and colon can be detected 
in minute concentrations by a high-sensitivity faecal occult blood test (Clavarino et al., 2004). 
There are two main types of faecal occult blood tests (FOBT). The Guaiac FOBT is used to 
detect trace amounts of haem, whilst the faecal immunochemical test (FIT) uses antibodies to 
detect haemoglobin directly. It is important to remember that blood in stools may not be 
associated with cancer, and indeed, both tests can be associated with false positives.  
 
The Guaiac test has shown to be incredibly useful, reducing the number of deaths due to 
colorectal cancer by up to 33% when performed bi-annually in those aged between 50 and 80 
(Ouyang et al., 2005). Additionally, nucleic acids present in the stool can be analysed to 
determine whether a patient suffers from colorectal cancer (Imperiale et al., 2004). Recently, 
expression of SEPT9 mRNA in the blood has been used as an FDA-approved biomarker for 
colorectal cancer, although it is no more sensitive than the FIT test and is yet to be proven to 
reduce cancer deaths (Johnson et al., 2014). Nevertheless, it represents another way in which 
genomic techniques can be used to detect cancer. Multiplexing such assays in a quantitative 
manner is likely to further the definition of cancer detected. Protein biomarkers used to 
diagnose rectal cancer include carcinoembryonic antigen, or CEA (Markman et al., 2010).  
 
In these examples, sample collection is minimally invasive. Both require individuals to mail 
faecal samples to the analysis laboratory, with results being available in a matter of days. 
Subsequently, based on these results, patients can be referred for colonoscopy often through 
direct access clinics.  
 
We are fortunate in that the Australian government has funded the National Bowel Cancer 
Screening Program which provides faecal occult blood testing for free to all eligible 
Australians. The Program is currently expanding and by 2020 all Australians aged between 50 
and 74 years will be offered free screening every two years (CCA and ACN, 2005). The faecal 
immunochemical test has been selected as the preferred testing method.   
  
Colonoscopy – one of the most sensitive tests available for colorectal cancers – involves the 
use of the flexible colonoscope, a flexible tube containing a lens and tissue dissection tool. 
Patients need to maintain dietary restriction prior to the procedure, and risks of tears to the 
epithelium are a risk. A smaller alternative to colonoscopy that is particularly useful for rectal 
cancers (lower down the GI tract) is sigmoidoscopy, in which a light tube with a viewing lens 
is used to visualise tumours that can be simultaneously removed. Inert gases are commonly 
used to expand the colon to make visualisation easier higher up the GI tract. Regular screening 
with a sigmoidoscope and colonoscope is thought to account for a 60-70% decrease in colon 
cancer death in those over 50, with a single visit alone having a considerable beneficial effect 
(Atkin et al., 2010). Furthermore, as many polyps are benign, sigmoidoscopy allows biopsy 
samples to be collected. Subsequently, biopsies can be analysed histologically or using other 
molecular methods such as PCR to define carcinogenesis. Computed tomography can also be 
used as a virtual colonoscopy, where 3D reconstructions of the colon are generated by several 
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x-rays taken from outside the body (US Preventive Services Taks Force, 2016). Indeed, 
conventional X-rays on the lower abdomen are useful to identify cancer lesions. 
 
 
1.3.2 Rectal cancer clinical features  
 
Symptoms of rectal cancer include a change in bowel habits, such as constipation, unproductive 
straining, diarrhoea and abnormally-shaped faeces (Marley and Nan, 2016). General malaise 
and nausea is also commonly present, the appetite is decreased, energy levels are low, and 
cachexia arises. Rectal cancer is treated using a combination of surgical excision, radiotherapy 
and chemotherapy (Wolpin and Mayer, 2008). 
 
1.3.3 Surgery 
 
Surgery is very often the first-line treatment for a solid tumour, especially for colorectal 
neoplasia. Surgery involves resection of the tumour, and aims to leave no diseased cells present 
in the adjacent environment (Phang et al., 2002). Furthermore, surgery must avoid excessive 
tissue scarring which is known to contribute to the later successful seeding of any remaining 
tumour clones. For this reason, surgery is almost always applied with simultaneous chemo and 
radiotherapy, pre- and post-operatively. 
 
The difficulties associated with surgery, are again, well appreciated. For many thousands of 
years, cancer has been known to reoccur after resection of the visible mass. Surgery entered a 
new phase when anaesthesia became available in the 1840s, allowing surgeons at the time to 
explore adjacent body areas to where tumours may have spread. This lead to the common 
practice of removing the draining lymph nodes of the tumour; as lymph carries solutes and 
cells from diverse tissues in the environment for profiling by the immune system, and is a major 
channel through which body cells move (Sudhakar, 2009).  The practise also helped cement 
the notion that the periphery of the tumour environment is of primary importance to clinical 
outcome.  
 
Nowadays, we rely less on exploratory surgery, and more on advanced medical imaging 
techniques to first characterise tumour size, number and plan surgical approaches (Frangioni, 
2008). Imaging modalities of relevance to cancer surgery include, magnetic resonance imaging 
(MRI), ultrasound, computed tomography (CT; X-rays) and positron emission tomography 
(PET). As different modalities have different suitability to different tissues, they are used as 
appropriate. Unfortunately, the costs associated with some of these techniques often preclude 
thorough cancer diagnoses, even in wealthy countries.  
 
Tumours can be removed in increasingly less-invasive ways. For example, endoscopic 
techniques and high-resolution cameras allow for tumours to be directly aspirated from an 
internal surface, which will considerably reduce the tumour burden and facilitate concomitant 
chemotherapy. Tumours are also resected with lasers in more modern approaches, which 
allows for fine boundary control, and in situ destruction using liquid nitrogen has also been 
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successfully deployed (Sudhakar, 2009). And high-standard storage and processing of surgical 
samples is invaluable for understanding the basis of disease on an ad hoc basis.  
 
In order for colorectal cancer to be cured the malignant lesion needs to be totally resected 
including draining lymphatics. Smaller colorectal cancers that have yet to invade into adjacent 
structures can be treated by anterior resection (AR) with partial mesorectal excision (PME) or 
total mesorectal excision (TME) (Steele 1999), abdomino-perineal resection (APR) and 
transanal excision.  
 
For colorectal cancers invading deeply into the wall that are impossible to dissect by total 
mesorectal excision, abdomino-perineal resection (APR) is the treatment of choice. However 
this does mean that patients end up with a permanent colostomy (Dorudi et al, 2002). More 
superficial colorectal cancers (cancers not spread beyond submucosa) can be removed by 
transanal excision. Although postoperative outcomes are usually better a major limitation of 
transanal excision is incomplete removal of tumour and associated regional lymph nodes that 
can increase the risk of local recurrence (Endreseth et al, 2005). For rectal cancer the 
combination of chemoradiotherapy with transanal excision improves outcomes (Steele et al, 
1999; Duek et al, 2008).  
 
1.3.4 Chemotherapy  
 
Chemotherapy refers to the treatment of cancer (or alleviation of symptoms) using chemical 
entities that target rapidly dividing cells. Today, chemotherapy is more commonly used to 
describe non-selective intracellular poisons, most commonly targeting the mitosis inhibition. 
This is to separate it from targeted therapies that inhibit specific growth-promoting pathways, 
such as tyrosine receptor inhibitors and hormonal treatments. Chemotherapy can be given as 
an adjuvant therapy after surgery to kill any remaining cancer cells, and it can also be delivered 
as a neoadjuvant, to shrink the tumour prior to surgery – often employed in rectal cancer 
(Tubiana, 1987).  
 
Chemotherapy is described as being cytotoxic and anti-neoplastic, and is associated with a 
significant burden (Lung Cancer Guide Book, 2013). Indeed, chemotherapeutics are normally 
systemically administered and have the potential to affect many cells across the body. In 
addition, they are often combined with local treatments (such as radiotherapy) to ensure that 
the most rapidly-dividing cells succumb to their toxic effects. The most rapidly dividing cells 
in the body – those in the intestine, hair follicles and bone marrow – are those most commonly 
affected by such anti-mitotic drugs as they have a high turnover rate; leading to 
myelosuppression, alopecia and mucositis. Furthermore, different compounds are associated 
with additional specific side effects, as shown by the neuropathy caused by oxaliplatin (Saif 
and Reardon, 2005).  
 
Along these lines, many chemotherapeutic drugs are available to treat cancer, and they may be 
given in a palliative manner or with curative intent. The major classes are: alkylating agents; 
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antimetabolites; microtubule inhibitors; topoisomerase inhibitors; and cytotoxic antibiotics 
(Tol et al., 2009). Alkylating agents are derived from mustard gas, and crosslink DNA to 
generate DSBs (Fu et al., 2012). Cisplatin and carboplatin are known examples.  
 
Antimetabolites take a different approach to reduce the cancer burden. This class of 
chemotherapeutics resemble either a nucleoside or nucleobase, although they are specifically 
altered (Parker, 2009). Their modifications can, for example, prevent DNA replication after 
they have been incorporated into the genome of new daughter cancer clones. Other anti-
metabolites inhibit enzymes important for DNA synthesis to halt mitosis. Anti-folates such as 
methotrexate block the activity of dihydrofolate reductase (DHFR), reducing purine synthesis, 
and therefore, DNA-based cell division (Mikkelsen and Thorn, 2011).  
 
Chemotherapeutics have also been designed that target microtubules in cells to stop alpha- and 
beta-tubulin participating in cytokinesis, genome segregation and division. Vinca alkaloids 
(such as those from Catharanthusroseus) and taxanes are the two most known subgroups of 
these drugs (Crown and O’Leary, 2000). The alkaloids prevent microtubule formation, whilst 
the taxanes prevent their disassembly. In both cases, the cells cannot reorganise their intra-
cellular structure and die.  
 
Yet another mechanism is used by topoisomerase inhibitors. Opening (unwinding) the DNA 
helix during replication and transcription, leads to increased tension in the preceding unwound 
DNA yet to be transcribed/replicated. This tension can lead to breaks in the DNA (cueing 
apoptosis if the burden is too high) and is relieved by topoisomerases I and II (Hande, 2008). 
Inhibition of these enzymes therefore increased the mutation rate in cells, leading to increased 
cell death in rapidly dividing cells. Consequently, compounds like irinotecan and topotecan 
have been widely used in many cancers, including lung and ovarian cancer.    
 
Details on small molecule inhibitors of kinases and phosphatases  are beyond the scope of this 
thesis and are covered by excellent reviews by others (Hoelder et al., 2012). The final example 
of a chemotherapeutic to consider is cytotoxic antibiotics, such as mitomycin C, doxorubicin, 
and actinomycin – all of which again interfere with cell division through various means 
(Denard et al., 2012). Many such compounds were isolated from bacteria, which presumably 
also wanted to halt the replication of DNA perhaps foreign to themselves. These compounds 
are often combined with more targeted treatments aiming to inhibit specific pathways at work 
in the cancer.  
 
Indeed, many agents are commonly used in combination, as this not only provides additive 
effects of different tumour-inhibitory drugs, but also reduces the toxicity associated with 
metabolic degradation of each component. Chemotherapeutics are also widely used to maintain 
remission for a period after surgery, often at lower doses to negate the side effects as much as 
possible.  
 
The most commonly used adjunct chemotherapeutics include fluorouracil and capecitabine 
(Douillard et al., 2000). Fluorouracil is most commonly delivered intravenously one day prior 
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to radiotherapy, and is thought to act as a thymidylate synthase inhibitor, reducing the levels 
of nucleosides required for DNA replication. Calcium folinate is also commonly used to 
stabilise fluorouracil and increased its potency in vivo. Capecitabine belongs to the same family 
as fluorouracil, and is on the WHOs list of Essential Medicines (Hogerzeil, 2004). Indeed, it is 
metabolised to fluorouracil. Other chemotherapy protocols used in the management of 
colorectal tumours are described by Kelly and Cassidy (2007), and is dependent upon tumour 
grade, metastases and other clinical variables. 
 
Given the toxicity associated with chemotherapy, regional applications are sometimes 
employed, as shown when hepatic artery infusion is used to treat disease that has metastasised 
to the liver (Karanicolas et al., 2014). Furthermore, chemotherapy is delivered in treatment 
cycles typically lasting no more than a few weeks to allow patients to recover. Normally, 
several cycles of difficult chemotherapy are required.  
 
 
1.3.5 Radiotherapy 
 
Shortly after they were discovered, X-rays were already in the cancer clinic, in what must be 
one of the fastest times from discovery to widespread medical application in history (Teldo-
Pereyra, 2009). It was an important finding. X-rays can directly ionise atoms in DNA (which 
need to be repaired to prevent apoptosis), and also generate hydroxyl radicals by ionising water 
that also damage DNA. 
 
Radiotherapy (or radiation therapy) is now known to both cause cancer as well as kill cancer 
cells. In the most common treatment setting, ionising radiation is delivered by a linear 
accelerator to kill rapidly dividing cells, and is also commonly used as an adjuvant post-therapy 
to prevent remaining malignant cells from colonising the niche (Baskar et al., 2012). In 
brachytherapy, the radiation source is placed inside or adjacent to the area to be treated, and is 
useful for breast and prostate cancer. As ionising radiation can damage DNA in normal cells 
as well, the beam is focused to intercept the tumour from various angles to more selectively 
kill the tumour and not the healthy tissue. Where that boundary begins remains the matter of 
much debate. 
 
Interestingly, depending on the type of radiation used, the induction of DNA damage occurs 
by different mechanisms. This is important for treating tumours with a hypoxic centre which 
are more resistant to photon radiation therapy which works predominantly through hydroxyl 
radicals (Baskar et al., 2014). Other radiation sources, such as boron, carbon, lead and neon 
usually cause double strand DNA breaks (DSBs) through direct energy transfer, and are thus 
not affected by the low oxygen environment.  
 
Unsurprisingly, radiotherapy is associated with many negative and considerable side effects, 
although low dose palliative care is well tolerated (Lutz et al., 2014). The higher the dose, the 
higher the risk of unwanted side effects. Doses up to 80 Gy are commonly used, although 
oncologists consider various factors to determine the dose.  Advances in the field seek to refine 
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the uniformity and accuracy of radiation delivery, and include methods such as intensity-
modulated radiation therapy, which allows concave tumour shapes to be followed and targeted.  
 
In terms of patient side-effects, oedema first leads to acute pain in the treated and damaged 
area. Systemically, radiotherapy also causes nausea and vomiting, especially if head, neck or 
inner ears are treated (Standring, 2008). Infertility is also commonly reported during and after 
the treatment of testicular and prostate cancer, and the hypothalamic-pituitary axis is also 
commonly dysregulated by radiotherapy (Stubbe and Valero, 2013). In rectal cancer patients 
receiving radiotherapy, diarrhoea is common due to the epithelial and endothelial damage 
generated (Österlund et al., 2007) – and is treated with Lactobacillus supplementation. 
Damaged epithelial surfaces typically become fibrotic and exhibit dryness, and in some cases, 
cancers arise due to the radiation-induced mutations of treatment.  
 
However, although there are risks involved, X-ray therapy is still highly applicable to cancer 
therapy. In a study by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 
radiotherapy was found to reduce 5-year relapse rate by up to 19% (Darby et al., 2011), echoed 
by several specialised protocols and oncogenic pathologies. More commonly than not, 
radiotherapy is combined with chemotherapy to deliver better outcome measures for patients, 
as both approaches exploit different and combinatorial mechanisms useful to reduce cancer 
cell growth (Tubiana, 1987).  
 
For rectal cancer pre-operative radiotherapy has been shown to reduce local recurrence of rectal 
cancer after surgery (Colorectal Cancer Collaborative 2001). There are 2 preoperative 
radiotherapy regimens (Glimelius et al, 2003) available for the treatment of rectal cancer.  
The long course regimen delivers 1.8 to 2.0 Grays (Gy) of ionising radiation to the tumour site 
for at least 5 days per week. The accumulated total dosage is around 45 – 50 Gy over a typical 
5 week period. This may sometimes be augmented with chemotherapy. A 5-fluorouracil (5FU) 
infusion is provided over the first and last weeks of the long course. Surgery is carried out at 
least 4 weeks after the radiotherapy completion with that time delineated as a reasonable 
amount of time for any post-radiation oedema to subside.  
 
The short course regimen on the other hand delivers a larger radiation fraction at 5.0 Gy per 
day for 5 days. The short course regimen does not incur the oedema that is seen with the long 
course and thus surgical treatment of the rectal cancer can be carried out the following week 
(Glimelius and Isacsson 2001). The short course does have some advantages over the long 
course such as reducing the duration of the radiation course for patients and attendant 
reductions in overall financial burden. Although the total cumulative dosage (25Gy) of the 
short course is only half that of the long course (50Gy) the biological effective dosages of 
irradiation delivered by the two regimens are overall comparable (Glimelius and Isacsson 
2001). 
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1.3.6 Immunotherapy  
 
Recent publicity has led to the suggestion that immunotherapy is the biggest breakthrough in 
cancer care since the 1940s (Gattinoni et al., 2006). Indeed, cancers shown to be resistant to 
radiotherapy and chemotherapy have been shown to be susceptible to immunotherapeutic 
approaches, highlighting additional scope for treating clinically-resistant disease. The immune 
system is highly adapted not only to fight pathogens, but also in surveillance and remodelling 
of normal, healthy tissue, and has potent anti-tumour functions. Tumour antigen-specific T 
cells are known to directly destroy tumour cells, whilst antibodies against tumour antigen also 
aid in clearing oncogenic cells (Stockert et al., 1998).  
 
Amazingly, the tumour microenvironment expands and becomes highly specialised, as 
demonstrated through by active dampening of the immune response based on chemokine 
antagonism designed to inhibit cells responding to cancer antigens (Coussens and Werb, 2002; 
Johanna and Fearon, 2015; Kraman et al., 2010). Cancer immunotherapy refers to the use of 
the host immune system to reverse this imbalance and treat cancer. The immune system is 
ideally suited to this task, being able to selectively eradicate specific cells based on their 
molecular profile; compared to systemic chemotherapy which damages many cell types. This 
accounts for reduced levels of tissue destruction due to immunotherapy compared to systemic 
chemotherapy and errant radiation. As always, the difficulties lie in properly harnessing the 
power of the system in a safe manner; too much or too little inflammation is deleterious. 
 
Cancer immunotherapy is classified as active, passive or hybrid, and can be achieved with the 
use of different immunological components such as antibodies, T cell infusions and vaccines 
designed to engender responses to tumour-associated antigens (Voena and Chiarle, 2016). 
Active therapies dictate the immune system to destroy cancer cells based on the expression of 
tumour-associated antigens. Passive immunotherapies take a more global approach, and 
attempt to aid the efficiency of natural anti-tumour immune mechanisms.  
 
To date, despite the promise, no T cell infusion protocol has been approved for clinical use, 
although various means to clonally expand tumour-reactive autologous cells have been 
developed, and genetic engineering approaches allow for specific anti-cancer T cell receptors 
and co-stimulatory molecules to be introduced. The fate of the adoptively transferred cells 
remains a concern, with their potential to attack other self-antigens and potential to form cancer 
themselves often quoted as precautions (Kalos and June, 2013).  
 
A well-known target for immunotherapy is CD20, expressed on the surface of B cells and 
regulates B cell division and maturation towards plasma cells. An anti-CD20 monoclonal 
antibody, Ofatumumab, is FDA approved for the treatment of chronic lymphocytic leukaemia 
(Reagan and Castillo, 2014). Interestingly, monoclonal reagents directed against CD20 are also 
effective at alleviating autoimmune diabetes mellitus in mice, although the reason for this are 
still unclear (Barr et al., 2012). Blocking the T cell inhibitory molecule PD-L1 using a 
monoclonal antibody has also been reported to benefit different cancers (Festino et al., 2016). 
Furthermore, high doses of the potent T cell mitogen, IL-2, is used to treat melanoma and other 
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types of cancer (Oppenheim, 2007). Such examples help illustrate the central role of the 
immune system in surveying the body, and how this can be exploited to destroy cancer. Indeed, 
we must not forget that conserved, innate, anti-tumour immune mechanisms have been under 
evolutionary pressure for considerable time.  
 
In addition to these recent approaches, vaccines that prevent infections with oncogenic viruses 
have also been developed, and represent another means the immune system can be harnessed 
to fight cancer. Vaccines against human papilloma virus (HPV) decrease the risk of cervical 
cancer, and Hepatitis B virus vaccines help reduce liver fibrosis and cellular transformation 
associated with viral spread (Schlom, 2012).    
 
There is an emerging role for the use of immunotherapy for colorectal cancer. It is exciting to 
note that there has been recent successful use of checkpoint inhibitors in those persons with 
mismatch repair colorectal cancer that have a relatively high mutational burden (Lynch and 
Murphy, 2016). 
 
1.3.7 Palliative care     
  
The administration of non-curative treatments to reduce suffering and alleviate disease 
symptoms is very important for maintaining dignity and quality of life when suffering from 
cancer. In general, palliative care refers to any procedure in which the pain of disease or side-
effects is mitigated as much as possible. At the same time, palliative care aims to improve upon 
the psychological and social problems that cancer entails, and the use of community-based 
health workers able to provide spiritual and holistic support to patients should not be 
overlooked as a mechanism to improve health (Mariano, 2007). Palliative care also helps 
patients deal with many of the practical life issues during a very difficult time, such as rising 
financial and legal complications. 
 
Palliative care is given at any time during cancer treatment, often continuing for many years 
post-surgery, and increasingly, palliative care is delivered by specialised, multi-disciplinary 
teams able to appropriately deal with the patient’s emotional state and presenting symptoms 
(Jocham et al., 2006). These treatments can be based in patient groups, in hospices and other 
community health centres. The role of the healthcare professional in making a patient feel 
secure and confident to talk about their condition is of primary importance in medicine, and 
professionals should make every effort to foster open lines of communication to generate 
understanding and benefit health management and treatment compliance.  
 
Common palliative treatments include anti-inflammatory medications and pain killers, 
although cancer-effective agents such as radiation, chemotherapy and hormone therapy can be 
used to reduce the tumour burden, although treatment does not have curative intent.  
 
Specifically for colorectal cancer there are palliative measures that can be carried out to 
overcome bowel obstruction such as colonic resection, creation of a stoma or stenting (Costi et 
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al, 2014). Other types of palliative measures such as radiotherapy, laser therapy and transanal 
procedures exist for the management of problems such as bleeding and pain.  
  
1.3.8 Prognostic markers 
 
Prognosis is the major focus of our investigations, and again dates its origins to Hippocrates, 
who wrote about it 400 BC. Determining the likely course of a medical condition is crucial for 
patient welfare and disease management. For example, notifying a patient that they are likely 
to respond to their current treatment and live another 2 years, is considerably different to a 
situation in which a patient does not respond. Nevertheless, prognosticating is a difficult task, 
often with insidious disease like cancer, which can affect diverse tissues in an occult manner. 
Furthermore, when large sample sizes are used and read-outs highly quantitative, prognostic 
indicators can be very useful, although when sample sizes are small and changes highly 
dynamic, prognosis is more error prone. Prognosis is also variable through time, and patients 
must be repeatedly monitored to evaluate the disease state (Armitage and Southam, 2016).  
 
Following diagnosis, prognosis is impacted upon by a range of features in a patient. For 
example, disease-free survival time is known to be affected by: 
• The patient’s overall state of health, age and other co-morbidities, such as viral 
infection. 
• The stage of the tumour at diagnosis; i.e. whether a rectal tumour has progressed 
through the wall of the rectum, or whether it has spread to one or more lymph nodes or 
other tissues. Metastases are negatively correlated with survival from colorectal cancer.  
• The location of the tumour and burden across the affected tissue; i.e. does the entire 
rectum need to be removed? 
• Whether the scenario represents a relapse or a first event; where relapses are associated 
with a worse prognosis.  
 
It is also worth noting that although cancer incidence is lower in the developing world, cancer 
survival rates in the developing world are also lower (Kanavos, 2006); as often the resources 
required to effectively diagnose and treat the cancer are lacking in these environments. This 
necessitates the continual search for single panel biomarkers that can be effectively employed 
with minimal accessory equipment in isolated locations or where hospital infrastructure is 
lacking.  
 
Several prognostic protocols are already in the clinic for diverse cancers. The Manchester 
Score, for example, evaluates prognosis in small-cell lung cancer (Herbst et al., 2008). The 
Manchester Score is a combination of scores in 6 different biochemical and physical categories: 
serum lactadehydrogenase, serum sodium, serum alkaline phosphatase, bicarbonate, 
Karnofsky performance status, and the stage of disease. The International Prognostic Index is 
used to predict outcome in non-Hodgkin lymphoma in a similar manner (Solal-Céligny et al., 
2004). In many ways, these tests represent measures of dysregulated systemic function, and are 
not highly cancer specific.  
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Prognosis estimates are likely to further improve, however, as the molecular aetiology and 
nature of tumours is defined in real-time, and biomarkers of treatment effectiveness emerge in 
greater numbers. Furthermore, integration of vast –omic data with detailed clinical histories in 
cancer will also help predict those more likely to survive harsh treatment regimens. 
 
Biomarkers are highly useful prognostic markers, being representative of physiological states. 
The levels of blood pressure, CRP, low-density lipoprotein and p53 are well-known examples 
(Karadag et al., 2008; Lutz and Nowakowska-Swirta, 2002). Their utility before and after 
treatment is of particular interest, giving molecular details of on-going internal processes in 
minimally invasive manners; i.e. from blood, saliva or urine. Biomarkers are also required to 
be highly sensitive and be highly specific for their target to have a clinical utility.  
 
Many cancer biomarkers have been found to have prognostic value. For example, 
metallopeptidase inhibitor 1 (TIMP1) expression is associated with more aggressive forms of 
multiple myeloma (Guedez and Stetler-Stevenson, 2010), and a mutation in exon 11 of proto-
oncogene c-Kit predicts responsiveness to the biologic imatinib, a tyrosine kinase inhibitor 
(Growney et al., 2005). Recently, a Chinese group elegantly showed that hydroxy-2′-
deoxyguanosine (8-OHdG), the most common by-product of oxidative DNA damage, could be 
more easily detected in the urine of colorectal cancer patients with metastatic disease (Guo et 
al., 2016). Thus, although such a biomarker may be good for identifying advanced disease in a 
non-invasive manner, its ability to detect cancers at an earlier stage remains unknown. 
 
Further defining the multitude of molecular mechanisms at work in tumours of the lower GI 
tract is likely to allow for prognostic and treatment avenues to be pursued. However, the 
difficulty in defining a novel prognostic or treatment option is challenging. For a test/biomarker 
to have useful prognostic value, the mechanism must be common to all or a subset of 
individuals in the cohort. Given the genetic and cellular variability of cancer, identifying such 
biomarkers can be challenging. Often, biomarkers identify hallmark processes in the organism. 
As demonstrated by the clinically well-established increase of the inflammatory C-reactive 
protein (to measure inflammation) and interleukin-6, which mediate increased risk for 
cardiovascular disease (Dopico et al., 2015); another major non-communicable disease killer 
that can be largely avoided by reducing one’s exposure to the detrimental factors here 
discussed.  
 
As we evaluate the role of biomarkers, it is worth considering the avenues that could be taken 
with respect to the DNA damage response proteins here investigated (see Discussion section). 
 
1.3.9 Current state-of-the-art in cancer medicine  
 
Before moving on, it is worth summarising some of the most interesting developments in 
cancer medicine. In general, as we move towards personalised medicine, targeted and 
individually-tailored treatments are sought, to more specifically target tumour cells and 
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improve treatment efficacy based on the molecular mechanisms of disease. Advances in 
screening and patient care are equally important.  
 
Between 2015 and 2016, the USA Federal Drug Administration approved eight new cancer 
drugs for the US market, and allowed an additional 12 to be used in other oncology therapeutic 
areas (Buffery, 2015). Many of these represented advances against difficult to treat cancers, 
such as chronic lymphocytic leukaemia. This is the result of the vast amount of basic and drug 
development effort directed towards cancer. The National Cancer Institute in at the National 
Institutes of Health, USA, benefits from an approximate 5.4 billion dollar budget per year 
(https://www.cancer.gov). In Australia given the constraints of the current NHMRC grant 
funding system we look at the Medical Research Future Fund (MRFF) with a current pool of 
around $1 billion to see if this can assist towards the development of new cancer based 
therapies.  
 
In basic research, recent success is shown by efforts to define the earliest genes mutated along 
the path to melanoma from precursor lesions, including BRAF V600E mutations, NRAS, 
CDKN2A and PTEN, at the same time helping define the role of UV radiation in 
pathophysiology (Shain et al., 2015). Furthermore, when talking about the bench-bed 
transition, few avenues have been as successful as liquid biopsy screening. For example, in 
lung cancer cases where resistance to epidermal growth factor-related drugs develops (due to 
mutation in the receptor), the presence of the EGFR T790M variant can be screened for in the 
blood, helping refine treatments more likely to be efficacious. The ability of liquid biopsy to 
predict colorectal cancer recurrence highlights its relevance to our field (Tie et al., 2016), where 
biomarkers of the DNA damage response in peripheral fluids may also have clinical utility.  
 
As discussed previously, immunotherapy is providing considerable advances in cancer 
medicine, not least in unleashing T cells to more effectively target malignant cells. These 
studies are well complemented by consortia-based projects detailing genetic, epigenetic and 
transcriptional maps in diverse cancer cells and primary tumours (Baylin and Jones, 2011; 
Weinstein et al., 2013). Furthermore, novel monoclonal antibody-based reagents that target a 
range of proteins (such as the tyrosine kinases AXL, VEGFR2 and MET) in vivo have been 
shown to further extend survival in kidney cancer (Rini, 2005). VEGFR inhibitors have also 
been developed for the treatment of kidney cancer, and have recently been shown to be of 
benefit in clinical trials. Topical nicotinamide for the prevention of skin cancer also holds 
promise (Chen et al., 2015).  
 
Advancements in surgical techniques, such as laparoscopic-assisted resection, have also been 
used to improve outcomes in stage II and III rectal cancer (Fleshman et al., 2015).  With regards 
to improving patient care and quality of life, the drug Olanzapine has been found useful in 
reducing the nausea and vomiting associated with chemotherapy (Navari et al., 2016).  
 
Furthermore, increased focus on public education programmes will assist individuals in caring 
for the health more effectively and managing pathology when it arises. Patient non-compliance 
and self-harm contribute a major obstacle to human disease management, and methods to 
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overcome these barriers will be helped by more effective communication, which emphasises 
the positives of treatment (Cantor, 2007). 
 
 
 
1.4 Molecular mechanisms in cancer: focus on colorectal cancer 
 
1.4.1 Cancer development 
  
Cancer-associated mutations can be present in the germ-line, or be induced by exogenous 
factors, such as the carcinogenic compounds generated during cooking red meat which have 
convincingly been associated with bowel cancer risk (Wang et al., 2012).  
 
As we know, cancer arises due to cells accumulating mutations that allow them to escape 
normal regulatory mechanisms curtailing undesirable cell growth. These mutations are often 
so pervasive that cancer cells also demonstrate density-independent growth in vitro - unlike 
normal cells which halt the cell cycle by entering phase G0 when too many of them exist in the 
environment (Cooper and Hausman, 2007). Cancer-derived cell lines like the T cell Jurkat line 
exhibit continual, un-restrained growth; reminiscent of the massively enlarged thymus 
sometimes seen in immune-compromised mice (such as the NOD.scid; a model of 
autoimmunity), where thymomas occur more frequently due to abnormal immune homeostasis 
in the periphery (Huang et al., 2011). Indeed, cancer requires the loss of genomic control of 
systems that control cell division; proto-oncogenes.  
 
Theoretically, cancer can affect any cell type of the body, and tumours are classified according 
to their tissue and cellular origin. Carcinomas refers to cancer of epithelial origin, whilst 
sarcomas are malignancies of connective tissue, such as cartilage, muscle, bone and fibrous 
tissue (Cooper and Hausman, 2007). Lymphomas and leukaemias are those cancers arising 
from blood cell lineages and account for 8% of all cancers, perhaps due to their high turnover 
rate. Further classification of tumours is then dependent on the specific cell type involved.  
 
Wherever we are in the body, although some deleterious variants can cause cancer directly, 
given their central roles in guarding the cell cycle and signal transduction, for example, often, 
somatic mutations accumulating over time in different loci are responsible for oncogenesis; 
reflecting a gradual, more insidious loss of cellular control. This fits with our emerging, 
predominating view for complex diseases – that genes, environment, and stochastic factors 
lead to disease, but the loci, triggers and events are unique to the individual, as discussed. When 
aiming to eliminate cancer, it is perhaps not surprising that so much effort is directed towards 
personalised medicine, where genomes, and cancer transcriptomics, proteomics and 
metabolomics, can be together interrogated to determine better aetiology and treat the 
malignancy.  
 
On the whole, cancer is considered to be a clonal disease, where an individual cell with the 
required mutations for oncogenic transformation is the parent of all subsequently generated 
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cancer cells (Greaves and Maley, 2012). However, whilst cancer is thought to represent a 
lineage, it does not imply that the progenitor was a cancer cell from the very beginning, 
becoming progressively cancerous as it accumulates lesions. Importantly, once the cancer 
lineage is established, additional mutations can be acquired, driving diversification of the 
tumour microenvironment and expanding the genomic mechanisms contributing to pathology.  
 
As cells begin to lose genomic and regulatory integrity, mutations favouring proliferation, 
growth and signal transduction are selected for, the cells transformed into neoplastic cells and 
acquire the ability to proliferate. Support for this multi-step development model for cancer also 
stems from the age association with cancer development, although as we know, the molecular 
landscape is more complicated (DeGregori, 2013).  
 
Further support for this developmental model was also shown in early studies of colon 
carcinomas. Initially, abnormal proliferation of epithelial cells leads to polyp formation – at 
that time, a benign neoplasm. Additional mutation accumulation was then shown to transform 
such lesions into malignant ones, allowing for invasion of the basement membrane and 
metastases (Allen, 1995). However, alternative theories to explain cancer also merit attention. 
The cancer stem cell hypothesis posits that stem cells harbour the mutations required to drive 
oncogenesis in daughter cells, such that continual tissue replenishment is associated with a 
cancer predisposition; explaining why tumours return in the same patients. Presumably, such 
mutations affecting stem cells are encoded in the germ-line, or are acquired during early 
embryonic development. Regardless, cancer stem cells have been documented in the blood, 
prostate, breast, lung, liver, pancreas and colon (Rahman et al., 2011).  
 
Regardless of the mechanisms giving rise to the cancer in the first place, it is very often the 
case that cancer cells go on to develop autocrine growth signalling (as shown for IL-6 and 
WNT) and other features that allow them to expand independently of other cells (Grivennikov 
and Karin, 2008). Indeed, cancers do various things to modify their environment to favour their 
growth. A classic example is how tumours promote angiogenesis to divert nutrients to the 
tumour and allow mass increase (Weis and Cheresh, 2011). Another example is shown by the 
reduced expression of adhesion molecules in cancer cells, helping cancer cells escape their 
tissue of origin, as seen in colorectal cancer (Paschos et al., 2009).  
 
Cancer cells also normally lose contact inhibition of growth (as demonstrated by the cessation 
of fibroblast growth upon encountering a neighbouring cell), and secrete protease enzymes that 
digest the extracellular matrix to favour metastasis (Yin et al., 2009). Given these differences 
that favour the rapid expansion of cells above other considerations, it is perhaps not surprising 
that cancer cells do not differentiate along a given lineage in the same manner as normal cells; 
and thus, exhibit unique properties which may be important for disease management (Jögi et 
al., 2012).  
 
As we will discuss in the subsequent section, the DNA damage response is associated with 
cancer development (O’Connor, 2015). Normal cells with damaged DNA undergo apoptosis, 
to avoid erroneous function and deleterious variant propagation. However, in many cancers, 
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cells with acquired mutation do not undergo programmed cell death, a feature that may be due 
to variation in DNA damage response genes or their ability to correctly function. Furthermore, 
activation of the DNA damage response (including genes such as ATM and CHK2) has also 
been shown to be induced (in diverse cancers, including lung, colon, breast and bladder) early 
during tumorigenesis, prior to genomic instability and cellular transformation, and is 
hypothesised to restrain cancer progression (Bartkova et al., 2005). Thus, the ability of the 
DNA damage response to mediate errors in DNA also influences cancer development.  
 
A brief outline some of the best-described molecular mechanisms leading to tumorigenesis is 
presented below. 
 
1.4.2 Oncogenes  
 
Oncogenes were first discovered in the 1970s, with RAS being the first described (Fernandez-
Medarde and Santos, 2011). They have the potential to cause cancer (due to their normal roles 
in primordial cell functions) and are frequently found in mutated tumours. Mechanistically, 
oncogenes mediate cellular survival in the face of programmed apoptosis, allowing cancer cells 
to escape the Hayflick limit (Shay and Wright, 2000). 
 
A gene involved in such fundamental processes, such as cell division, that acquires a mutation 
leading to constitutive activation, will thereby become an oncogene; these are termed proto-
oncogenes. Examples of proto-oncogenes in humans include, RAS, WNT, ERK and TRK, and 
others described previously. All of these examples represent genes involved in signal 
transduction pathways. Tyrosine kinase members of the Src- and BTK-families have been 
associated with colorectal cancer (Grávalos et al., 2007). Signal transducing molecules and cell 
cycle control genes are not the only oncogenes, however. Many oncogenes produce hormones 
at high levels, cueing mitosis (Delellis and Xia, 2003; Schuchard et al., 1993). Such effects can 
be helped by additional mutations favouring intra-cellular signalling pathways. In general, 
different pathways can be affected by such highly penetrant variants.  
 
Another well-known example of a  translocation event leading to oncogenesis (in this case 
mostly chronic myeloid leukaemia) in diverse populations is the Philadelphia chromosome, 
which results in the formation of the oncogenic tyrosine kinase BCR-abl (a fusion gene) 
between segments of chromosomes 9 and 22 (Ren, 2005). The generation of this protein leads 
to myelogenous leukaemia as it shows restricted activity when phosphorylating a diverse range 
of substrates and aiding cell division. This translocation is also found in approximately 20% of 
acute lymphoblastic leukaemia cases, and sometimes found in acute myelogenous leukaemia) 
(Talpaz et al., 2006). Given the activity of the fusion gene, this cancer is treated with tyrosine 
kinase inhibitors, again highlighting how the mechanism drives treatment. Bone marrow 
transplantation is also an option.  
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1.4.3 Tumour Suppressor Genes (TSG) 
 
When a cell is under stress, and has suffered DNA damage, it employs mechanisms to halt 
growth and cue repair. These represent evolutionarily conserved anti-cancer mechanisms vital 
to genome integrity and multi-cellular life (Casás-Selves and DeGregori, 2011). In most cases, 
such TSG are transcription factors, which then activate/repress relevant genes. TSG may need 
to be turned on in the first place, which can be achieved by pattern recognition receptors in the 
nucleus and cytoplasm which sense, for example, degraded and free DNA.  
 
Amazingly, the prototypical tumour suppressor, p53 (TP53I), is estimated to be mutated in 
approximately half of all cancers and has various functions in regulating apoptosis, the cell 
cycle and metabolism (Soussi and Wiman, 2007). Indeed, p53 is hypothesised to control the 
switch from aerobic respiration to anaerobic glycolysis, the latter of which cancer cells use for 
growth. Rb is another tumour suppressor gene involved in cell cycle progression. BRCA1 and 
BRCA2, are also TSGs. 
 
1.4.4 Genomics of colorectal cancer 
 
The two major subtypes of colorectal cancer identified to date are defined according to the 
nature of genomic instability present in the tumour. Tumours with chromosomal instability 
(CIN) are most often found to carry mutations in APC, which regulates cell adhesion (Arends, 
2013). Tumours with microsatellite instability (MSI; 15% of cases) are often found to have 
defective DNA mismatch repair pathway. A CpG island hypermethylator phenotype (CIMP) 
in colorectal cancer has also been described, where several DNA repair genes are suppressed 
by promoter methylation (Arends, 2013).  
 
Overall, four different subtypes of colorectal cancer have been described based on their MSI 
and CIMP status, with differences in their incidences between populations. It is accepted that 
these different sub-types are associated with unique clinicopathologic and molecular features, 
meaning a different aetiology, and different treatment requirements (Kang, 2011); as 
demonstrated by the differing susceptibility of these subtypes to adjuvant therapy (Bae et al., 
2016).  
 
Genome, transcriptome, proteome and metabolome analyses in cancer cells will likely help 
define new subsets of colorectal cancer, as shown for breast cancer (Curtis et al., 2012), and 
delineating rectal and colonic tumours biologically. Early studies in colorectal tumours have 
shown that it is not only the cancer transcriptome that is altered and determines cancer 
functional capacity, the presence of a cancer-associated fibroblast (making up the tumour 
stroma) transcriptional signature has also been associated with worse prognosis (Isella et al., 
2015). Transcriptional studies in colon cancer cell lines have also helped cement the role of 
insulin-like growth factor I signalling in disease  (Diehl et al., 2005). Future work will expand 
upon these studies in a greater number of patients with more sensitive methods will advance 
prognosis and treatment options.  
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1.4.5 Carcinogens in colorectal cancer  
 
Links between colonic and rectal neoplasia and chemical compounds is abundant in the 
literature (Oddone et al., 2014). Historically, associations between colon cancer and asbestos 
were widely reported in dockyard workers who were also likely exposed to welding smoke and 
aromatic hydrocarbons (Puntoni et al., 1977). Higher incidences of colorectal cancer were also 
found in petrochemical industry workers (Rodu et al., 2001). It is not difficult to imagine a 
situation in such environments when abundant carcinogens become ingested.  
 
The presence of carcinogens in food and their association to colon cancer is most often reported 
in terms of red meat, now backed-up by the WHO (http://www.who.int/features/qa/cancer-red-
meat/en/). Nitrosamines are also present in smoked fish, dairy products and salted meats. 
Several other carcinogens in food also have the potential to drive disease, and many natural 
carcinogens are known to exist in diverse foods, such as tannins, hydrazines, safrole and 
flavonoids (Koriech, 1994). Heterocyclic amines are a good example of synthetic compounds 
driving oncogenesis, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine has been shown 
to induce colonic tumours in rats independently of p53 involvements (Nagao and Sugimura, 
1993).  
 
Thankfully, advances in health and environmental policy and food production have led to fewer 
of such chemicals being present in our food – although new putative carcinogens are discovered 
on a regular basis (Unicomb, 2009). Indeed, the synthetic content of our food is likely to 
increase in future – with lab grown burgers already on the menu (Post, 2012). Continual 
monitoring of environmental chemicals and atmospheric composition, as well as our practices, 
will be required to identify new harmful entities and define which compounds are associated 
with different cancers. Documenting incidence and accurate clinical classification will be 
required to elucidate new understanding (Baxevanis and Bateman, 2015).  
 
1.4.6 How many mutations does it take, and where? 
 
It has been widely accepted for the past three decades that you require two-hits (Knudson’s 
Two-Hit hypothesis), in TSG to drive cancer. This was supported by the fact that most TSG 
are usually recessive, and encode loss-of-function mutations, and oncogenes are usually 
dominant, and encode gain-of-function mutations (Cooper and Hausman, 2007). Activation of 
one allele (cancer mutation) in a proto-oncogenes is sufficient to drive a dose-response, and 
both alleles need to be removed in the TSG to see an effect. However, as TSG mutations are 
recessive and can be passed in the germ-line, a single hit later in life is the second. However, 
many examples of haplo-insufficiency variation according to genetic 
background/environmental trigger exist (Rose and Bhattacharya, 2016). Furthermore, many 
TSGs have related proteins that carry out similar functions in their absence, meaning that loss 
of one allele may depend on the state of accessory factors.  
 
High-resolution cancer genome sequencing will further our understanding of the genetic 
bottlenecks and regulatory processes in cancer. However, it is not as if we know less about 
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cancer genetics now than we did previously. The work of the 1970s-90s revealed a world of 
conserved mutations (sometimes called driver mutations) and structural genomic events to be 
associated with diverse forms of cancer. This conservation of cancer elements between people 
suggests that the genes responsible for cancer are under selective pressure and are highly 
important to other biological processes; otherwise, these genes would have found regions DNA 
less susceptible to large-scale DNA changes such as chromosomal losses and translocations.  
 
Small base-pair insertions, substitutions and deletions, amplifications of short DNA stretches, 
and microsatellite variations have all been found to aid tumour progression, including in 
colorectal cancer. Any type of mutation has the possibility to affect gene expression, function 
and/or regulation; demonstrating the many genetic pathways to cancer. Given the somatic 
heterogeneity observed between different somatic cells across the human body, mutations will 
also have cell type-specific effects (MacPherson et al., 2004). Considering the burden of 
reactive oxygen species in our cells, and the amount of carcinogens afflicting us daily, our body 
does a good job at preventing neoplasia in general. There is a lot of cellular turnover. 
 
The number of the essential cancer cell mutations and the rate, varies between tumours and 
individuals. However, commonality between patients does exist, as shown by the work of 
Laura Wood and colleagues, who analysed exonic regions in colorectal tumours, and found 
that one group of genes were commonly mutated, and another group were also mutated, but at 
lower frequency (Wood et al., 2007). The authors called this pattern, mountains and hills, 
referring to driver and passenger mutations in the cancer; of which 15 and 60 were described, 
respectively. When such observations are coupled to the common structural changes described 
(i.e. BCR-abl), it tells us that some mutations are more oncogenic than others; and their 
frequency is also constrained by genetics and environment.  
 
On top of such base-altering mutations are epigenetic marks, such as cytosine methylation, 
which adds a functional group to the DNA sequence that can regulate gene expression and 
DNA replication. Indeed, various methylation marks have been associated with cancer 
development. For example, hypermethylation of different tumour suppressor genes (or 
intergenic regions) leads to their inactivation, and cancer development (Kulis et al., 2013). 
Thus, the identification of endogenous genes and proteins and exogenous factors mediating 
cancer-associated methylation changes require further exploration; as do other epigenetic 
marks present in cancers, like the increased deacetylation of histones H2 and H3 that 
predispose to tumorigenesis. Another, partly epigenetic mechanism involved in tumorigenesis 
involved microRNA silencing. In humans and other vertebrates, microRNAs are potent 
regulators of gene expression, and many important regulatory microRNAs are found to be 
heavily methylated and silenced in cancers – allowing erroneous gene expression to proceed 
(Garzon et al., 2009).  
 
Importantly, in cells, the effects of many diverse forms of genomic lesions are often self-
amplifying and additive. For example, mutations in DNA proof-reading enzymes often lead to 
mutation accumulation with normal division (with more mutations accumulating with every 
cellular generation), and accumulating additional mutations in putative oncogenic regions, can 
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both further a tumour’s capacity to rapidly divide. This can be thought of as a chain reaction, 
in which one error leads to ever more errors, and disease. When cancer cell clonal expansion 
is considered, the proportion of cells dying due to the accumulation of deleterious variants is 
unknown. It is likely that along the oncogenic path, the mutation burden can also terminate 
cancer.  
 
The mutations themselves, however, are not the be all and end all of tumour development. 
Other factors are often able to propagate or inhibit cancer progression in tandem with 
deleterious variants. In many scenarios, mutated cells require the action of growth promoters 
to cue proliferation. Oestrogens are well known mediators of breast and endometrial cancer in 
women (Travis and Key, 2003). Progesterone can be used to antagonise the effects of oestrogen 
clinically. It all depends on how the cancer cell can exploit the environment in which it finds 
itself. Ovarian cancers might arise more frequently when mutations in endometrial cells lead 
to constitutive steroid hormone receptor expression, driving cellular growth and proliferation. 
The gene-environment interaction again rears its head. 
 
1.4.7 The role of infections in colorectal cancer development 
 
The significance of the gene-environment interaction is highlighted by the role of infectious 
pathogens in carcinogenesis. Indeed, the vast evolutionary pressure put upon anti-pathogen 
genes during human evolution has been often cited as a genetic arms race (Ingle et al., 2006); 
where the pathogen alters its genome slightly to evade the  pattern recognition receptors of the 
immunoregulatorysystem of the human body.  
 
The remarkable selective pressure exerted by pathogens is evident in malaria. People with a 
single mutant copy of the haemoglobin S gene are highly protected from malaria, whilst those 
with two mutant alleles have severe anaemia, or alpha-thalassaemia (Mockenhaupt et al., 
2004). In regions endemic for the parasite, up to 40% of individuals carry the pathogen-
protective allele; balancing a foe with our capacity to transport oxygen. If we consider this, 
pathogens are likely highly important in many tumours, and indeed several viruses, helminths, 
bacteria, protozoa and plants have been associated with diverse forms of cancer.  
 
We live life surrounded by microorganisms, and the toll and benefits they exert on us is only 
beginning to be understood, in part by multi-dimensional analyses of the human microbiome. 
There are more bacterial genes in your intestine than there are in all of your body cells 
combined – 150-fold (Proctor, 2011). Shen and colleagues have recently shown that the content 
of adherent bacterial populations in the mucosa of patients with colorectal adenomas is 
different to healthy controls (Shen et al., 2010). Higher numbers of Proteobacteria and lower 
numbers of Bacteroides species were observed in cases. Cases were also found to have a wider 
diversity of bacterial species present, which may allow for opportunistic pathogens to find a 
vacant niche.  
 
Helicobacter pylori (a class I carcinogen) represents one such organism, and it has been 
repeatedly associated with rectal cancer (Burnett-Hartman and Newcomb, 2008). However, 
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other studies have shown it not to be associated (Moss et al., 1995); again the mechanisms are 
likely in different individuals. The bacterium is present ubiquitously in human environments, 
with some estimates suggesting that some Japanese populations are 90% positive. 
Undoubtedly, we interact strongly with this pathogen globally (The EUROGAST Study Group, 
1993).  
 
Helicobacter adheres to gastric epithelial cells and is responsible for stomach ulcers and 
neoplasia. Here, the bacterium uses the protein CagA to activate human SHP2 and drive 
continual signalling in the phosphatase – driving cell cycle progression. A meta-analysis of 
studies carried out between 1991 and 2002 showed a significant association between colorectal 
cancer (of which rectal cancer accounts for one third) and Helicobacter infection (Zumkeller 
et al., 2006). These results are still disputed, however (Sung et al., 2005). Future 
epidemiological studies are likely to refine this view.  
 
Numerous studies have also linked Streptococcus bovis to intestinal polyp formation and 
neoplasia (Tjalsma et al., 2012). This bacterium is a normal commensal, which accounts for 
between 4-8% of the human intestine bacterial population, although its dysregulation could 
trigger neoplasia, and it has been shown to potently dysregulate inflammation, which will 
influence the epithelial barrier and integrity. Serology from colorectal cancer patients have 
shown higher IgG antibody titres against the pathogen compared to controls. 
 
Bacteria aside, viruses have also been associated with colorectal cancer, with JC human 
polyomavirus being the best example. JCV infection was first implicated as a potential risk 
factor for colorectal cancer with the observation by Laghi and colleagues (1999) that 96% of 
the 24 colorectal cancer tissues they examined contained JCV DNA sequences. This virus 
inhibits p53 via its large T antigen (Staib et al., 1996), reducing TSG function. The large T 
antigen has also been shown to induce chromosome instability in colorectal cancer cell lines 
(Ricciardiello et al., 2003). Despite this evidence, the epidemiology does not yet back up the 
proposition, making further definition of disease aetiology in this respect difficult.  
 
Human papilloma virus represents another well-discussed risk factor for colorectal cancer. 
Indeed, given its ability to infect genital epithelial cells and cause cervical cancer, much has 
been defined about the cancer-causing capacity of this family of viruses. Types 16 and 18 are 
those most commonly associated with cervical cancers (70% of cases) (Muñoz et al., 2003). 
The viral protein E7 again inhibits p53 and Rb, and induces telomerase, to avoid chromosomal 
shortening with each replication (Stirdivant et al., 1992); which was shown in cells of the 
anogenital tract. To date, however, conclusive epidemiology is not available, highlighting the 
difficulties associated with determining viral (or bacterial) presence, potential pathogenicity, 
and logistics associated with such studies; especially when dealing with organisms present 
widely in the environment with many sub-clinical infections. Again, given the genetic 
background and the incidence of other environmental factors, the ability of a virus to trigger 
cancer could be affected.  
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Before concluding this section, I would like the draw the reader’s attention to an insightful 
schematic illustrating the mechanisms in colorectal cancer development and progression 
(Figure 1.4).  
 
 
 
Figure 1-4 Molecular mechanisms in colorectal cancer development and progression.  
With kind permisswion from Qiagen: Website link:  
https://www.qiagen.com/cn/shop/genes-and-pathways/pathway-details/?pwid=133&task=show&action=Accept   
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1.4.8 The DNA damage response and cancer 
 
As the focus of our work concerns the role of DNA damage response proteins in cancer 
pathophysiology, we will now review the evidence implicating such processes with cancer.  
 
The specific genes of interest in our investigations were, MRE11, ATM, RAD50 and NSB1. All 
five are well-characterised members of the DNA damage response and have been implicated 
in cancer development previously (Lord and Ashworth, 2012). To further explore the role of 
our candidate factors in rectal cancer, we carried out histological analyses on primary patient 
tumour samples and defined new expression patterns predictive of radiotherapy response and 
prognosis. Supporting the importance of the DNA damage response in cancer, and its utility to 
evaluate treatments and derive prognostic information. Furthermore, as we focus on a limited 
number of genes, we hope to further refine the capacity of such elements as biomarkers 
common to diverse patient groups. 
 
For the reader’s convenience, a more detailed background to each candidate gene and the 
evidence for its association with the cancer DNA damage response, will be presented at the 
start of each results chapter; one chapter per gene. Below, I will introduce the damage response 
in a broader context. 
 
1.4.8.1 Molecular pathways of the DNA damage response 
 
The first evidence that cancer arose from damaged DNA was provided by researchers working 
at the The Institutes of Cancer Research in the United Kingdom in the 1950s (Venitt and 
Phillips, 2012). Until such studies came to light, cancer was thought to arise by carcinogens 
inhibiting/potentiating the effects of proteins, and not DNA. Brookes and Lawley (1964) 
showed that poly-aromatic hydrocarbons, such as those found in tobacco smoke, were able to 
directly bind DNA, and not proteins, changing the genomic code. This was a turning point in 
cancer research and medicine, also explaining why some cancers ran in families; allowing the 
hunt for cancer genes to commence.  
 
The DNA damage response is a collective term for the many pathways and factors involved in 
maintaining genome integrity in the face of normally-occurring errors in DNA replication. To 
date, more than 450 factors have been identified as being involved in these repairs (Pearl et al., 
2015); some of which may be drug-able candidates involved in tumour progression. Figure 1.4 
illustrates the complexity of the mechanisms at work. The 2015 Nobel Prize in Chemistry was 
awarded to Tomas Lindahl, Paul Modrich and Aziz Sancar for their contribution to defining 
these factors and how they work. 
 
How much DNA repair occurs depends on several factors, with metabolic and other chemical 
factors and biological processes impinging on the mutation burden. For example, older cells 
have accumulated more mutations, and may exhibit increased damage repair. Many DNA 
damage response genes are associated with human lifespan (Browner et al., 2004). When DNA 
damage response mechanism cannot repair the DNA accurately enough, three things can 
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happen: cell cycle arrest; apoptosis; cancer. Delineating the mechanisms underlying these fates 
will likely help develop new cancer treatments. 
 
When DNA damage is sensed by the cell, a variety of things can happen to prevent the cell 
entering a defective functional mode (due to such errors) and pass on the mutated genes. These 
mechanisms include halting DNA replication, inducing cell-cycle arrest and/or apoptosis; 
depending on the extent of the damage encountered (O’Connor, 2015). Given the diversity of 
factors involved in DNA damage repair, different types of damage (such as single-strand 
breaks, SSBs, DSBs, and bulky adducts) are repaired by different mechanisms, as illustrated 
in Figure 1.5 – with redundancy occurring to a differing degree between the pathways.  
 
The most common type of lesion arising in cells are SSBs, which occur approximately 20,000 
times per day (Lindahl et al., 1995). These lesions are repaired by the base excision repair 
pathway (Caldecott, 2014). Base excision repair deals with the majority of small-scale changes 
to the DNA code, and uses the proteins poly(ADP-ribose) polymerase 1 and 2 to sense DNA 
damage and signal additional repair proteins to the lesion. The damaged DNA is excised and a 
newly synthesised template is used to correct the gap.  
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Figure 1-5 The myriad of genes and proteins modulate the DNA damage response and maintain genomic 
integrity.  
In the image taken with permission from a review article by Lord and Ashworth (2012), different proteins 
involved in repairing different types of DNA damage are shown, although more examples abound. Furthermore, 
the tumour types usually affected by different DDR pathways, and the drug classes used to treat tumours with 
these defects, in shown. BER, base excision repair; NER, nucleotide excision repair; NHEJ, non-homologous 
end-joining.  
 
Double-strand breaks, which are more genotoxic, are repaired by either non-homologous end 
joining (NHEJ), or homologous recombination, although these mechanisms often result in 
imperfect repair; especially NHEJ, which directly ligates the two ends of the DSB, which often 
leads to in-frame mutation generation. Mismatch repair (carried out by enzymes such as MSH2 
and MLH1) deals with single nucleotide insertions and substitutions, whilst nucleotide excision 
repair handles nucleotides distorting the three-dimensional structure of the DNA helix 
(O’Connor, 2015). In general, all repair pathways follow the same three basic steps to repair: 
(i) DNA damage detection; (ii) accumulation of repair factors at the lesion; (iii) physical lesion 
repair (Lord and Ashworth, 2012).  
 
It is worth also considering that translesion synthesis and template switching – which allow 
DNA replication to progress whilst lesions are being repaired – are also part of the DNA 
damage response (Jansen et al., 2015). Indeed, as DNA replication progresses, template strands 
can be switched and high-fidelity polymerases transiently replaced with less-stringent ones 
when correcting the lesion, before switching back (Lord and Ashworth, 2012). Furthermore, 
when repairing DNA, it is important to note that the stage of the cell cycle at the time will 
determine part of the success of repair. For example, the absence of sister chromatids during 
G1 phase means that lesions occurring during this time rely on NHEJ, a pathway more error-
prone than template-dependent homologous recombination. Exogenous factors affecting the 
DNA damage response, as well as germ-line mutations in any auxiliary factors, will also 
influence repair success. As discussed, although in many instances single mutation/structural 
events lead to cancer, cancer can also be viewed as a polygenic disease, where variations 
between individuals can predispose to pathology.  
 
As discussed, the nature of the base-pair sequence (and its epigenetic state) determines whether 
cancer develops. Accordingly, mechanisms to maintain high fidelity DNA usage are abundant 
and widespread in the cell. When DNA is damaged, or mutated, replication fork stalling and 
adduct formation trigger the cellular DNA damage response. For example, after a DSB, 
chromatin remodelling carried out by histone modifying enzymes (responding to 
phosphorylated H2AX) causes relaxation at the target site. JNK then phosphorylates SIRT6, 
which recruits PARP1 to the damaged DNA (Van Meter et al., 2016). At the lesion, PARP1 
produces poly-ADP-ribose sensed by ALC1. This allows the DNA repair enzyme, MRE11, to 
get to work.  
 
The DNA damage response also needs to maintain the cell in cycle arrest. Key sensors of DNA 
damage that activate the G1 restriction check point are the kinases ATM (Ataxia telangiectasia 
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mutated) and ATR (Ataxia telangiectasia and Rad3 related). These kinases phosphorylate the 
cell-cycle check point kinases Chk1 and Chk2, which facilitate the degradation of Cdc25A, 
required to drive exit from G1. A loss of ATM is highly deleterious, as evidenced by the 
development of lymphoma in absence of its function (Schaffner et al., 2000). At the same time, 
Chk1 and Chk2 phosphorylate residues on the TSG p53, thereby stabilising it. Active p53 is 
then able to work as a transcription factor to drive the expression of genes involved in DNA 
damage repair and maintaining the cell in a non-replicative state.  
 
Different mechanisms are at work depending on the stage of the cell cycle DNA damage 
occurs, and the metabolic state of the organism. After DNA has been replicated, during the S 
phase, the cell undergoes growth (G2). Prior to entering the proliferative mitotic (M) phase, 
the cell again pauses to survey DNA damage. ATM and ATR are again involved, as are cyclin-
Cdk complexes, and is reviewed elsewhere (Branzei and Foiani, 2008).  
 
1.4.8.2 The DNA damage response in colorectal cancer 
 
As the DNA damage is response is central to cancer, much is known about how the function 
of these pathways differs between malignant and healthy cells. In fact, the expression of DNA 
repair proteins is used in screens testing potentially carcinogenic compounds in cell lines (Pool-
Zobel and Leucht, 1997). Besides what may occur in somatic cells, inherited mutations in the 
DNA mismatch repair enzymes, such as MSH2 and MLH1, have been associated with increased 
risk of colorectal cancer development (Gille et al., 2002).  
 
Erroneous mismatch repair is believed to account for the changes in microsatellite length 
associated with up to 15% of sporadic colorectal malignancies. In hereditary cases, mutations 
in the mismatch repair enzyme MLH1 are associated with polyp generation and colorectal 
cancer; overall, 13% of colorectal cancer suffer mutations in mismatch repair enzymes 
(Truninger et al., 2005). Whether these variable length repeats contribute to cancer 
development directly remains to be fully determined, although they do highlight the difficulties 
faced by colorectal cancers in maintaining genomic integrity and stability (Jiricny, 2006). 
Markers of these processes, therefore are likely to be highly informative in patient cells when 
attempting to diagnose cancer or evaluate its response to treatment.  
 
Furthermore, the very early stages of tumorigenesis are typified by the constitutive activation 
of several DNA damage response proteins, such as ATM, CHK2, H2AX and p53, which is 
thought to help limit cancer growth (Bartek et al., 2007; Oka et al., 2010). This can be viewed 
as a protective response, which may be stronger in some individuals over others. In cells 
progressing to malignant phenotypes, such control barriers have often been depleted or lost. 
Along these lines, most cancers have been found to suffer from an absence of one or more 
DNA damage response proteins – which help cancer develop, and places additional strain on 
various compensatory pathways, as illustrated previously. That said, many cancer do not have 
observable genetic defects in DNA damage response genes, although they do have links to 
DNA damage response dysfunction; again, epistasis between genes is different between 
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tumours and healthy tissue, adding to the complexity of defining factors contributing to 
individual pathologies (Wang et al., 2014).  
 
In contrasting and interesting recent studies, the essential anti-viral gene, STING, was found to 
be suppressed in colorectal tumours. Loss of this protein led to a reduced DNA damage 
response as well as a reduction in the cytokine IFN-gamma which recruits tumour-specific T 
cells and allows for tissue remodelling by other phagocytes of the immune system (Xia et al., 
2016). Thus, these results are highly predictive of STING being a controller of oncolytic DNA 
viruses.  
 
Together these studies demonstrate the importance of the DNA damage response to colorectal 
cancer, something which we hope to further refine through our investigations here presented.  
 
1.4.8.3 Towards elucidating biomarkers of radiotherapy sensitivity  
 
Before concluding this introductory chapter and describing our experimental approach, I would 
like to put our studies in a more specific clinical context. Something that we touched upon 
previously, in the section considering prognostic and clinically-informative biomarkers. In 
other words, what are we trying to do, why is what we here present important, what new 
knowledge do we hope to provide, and where can this work be used to benefit patients? 
 
At present, patients with advanced rectal or colorectal cancers receive pre-operative 
radiotherapy as a first line treatment prior to the surgical resection of tissue (Kye and Cho, 
2014). Thus, when the physical and observable tumour burden is reduced during surgery, 
radiation has already cued apoptosis and necrosis in rapidly-dividing cells in the vicinity of the 
lesion (Hellevik and Martinez-Zubiaurre, 2014); remembering that rapidly-diving cells, such 
as tumour cells are more sensitive than quiescent cells to radiotherapy for the various reasons, 
as discussed. It is also possible that the physical destruction of tumour tissue using radiation 
leads to a heightened immune response against the tumour (Park et al., 2014). Indeed, 
conserved anti-tumour T- and B-cell epitopes have been widely reported (Carmi et al., 2015; 
Han et al., 2014; Li et al., 2016; Shalapour et al., 2015); although the quantitative benefit of an 
immune response against the tumour in vivo is difficult to evaluate and report clinically.  
 
Regardless, radiotherapy aims to downstage the tumour prior to surgery, which can be 
monitored through histological tumour regression; described in Chapter Two. Post-surgery, 
radiotherapy is often continued (Glimelius, 2002), given the risk to recurrence. Knowing who 
responded to pre-operative therapy would help avoid unnecessary treatment, help radiation 
dose tailoring, and help a patient manage his/her condition (Butow et al., 1997).  
 
In all cases, radiotherapy aims to deliver a dose of radiation appropriate to the size and 
pathology of the tumour and the patient, noting that healthy cells have their own radio-
sensitivity threshold; which can be different between people.  
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Radiotherapy is especially important in the context of rectal cancer, where confined space 
within the pelvis places rectal tumours in close proximity to additional viscera that may serve 
as sites for metastasis (de Wilt et al., 2007). Furthermore, the distal rectum does not benefit 
from an enveloping free serosa, potentiating metastatic potential. With this in mind, the use of 
non-invasive radiotherapy (and chemotherapy) becomes more important as a means for curing 
the disease. Survival times have been found to be lower for rectal cancer patients compared to 
colonic cancer patients, although this has been disputed (Lee et al., 2013); the importance to 
both is not contested. As we have discussed, and will do, a number of clinical, research and 
lifestyle variables could explain such discordancy. 
 
Thus, radiotherapeutic treatments in rectal cancer are widely adopted for the beneficial effects 
on a patient’s overall survival time, as well as for reducing disease recurrence. Indeed, during 
surgery, the likelihood of spreading tumour cells to new areas within the body (where they can 
seed new tumours or be transported further afield) increases (Supriya et al., 2008), and pre-
operative radiotherapy is thought to hamper metastatic spread by killing escaping clones; 
remembering that a single dose of radiation post-surgery had no effect on reducing the 
occurrence of metastasis in malignant mesothelioma patients (Bydder et al., 2004).  Regardless 
of whether chemotherapy is used or not, radiotherapy aims for tumour regression 
independently. Too much radiation can lead to nausea, incontinence, diarrhoea, 
thromboembolic disease, and other co-morbidities that reduce a patient’s quality of life 
(Standring, 2008).  
 
To date, although radiotherapy in rectal cancer has been associated with histological regression 
(Suzuki et al., 2014; Wheeler et al., 2002), the effects on long-term patient survival remains 
controversial (Colorectal Cancer Collaborative Group, 2001, Glimelius et al., 2003) It is 
important to remember that the radiation beam is focused upon the primary tumour and does 
not penetrate draining lymph node or associated tissues that may harbour cancer cells.  
 
Despite the benefits associated with radiotherapy (which can be curative (Gérard et al., 2003)), 
there is a highly variable response to it between patients (tumour regression in the resected 
bowel) (Camma et al., 2000), and given the toxicity of ionising radiation it must be used 
sparingly and efficaciously. For instance, patients can either show a very good level of TRG, 
or a very low one. Now despite this apparent dichotomy the TRG score itself is not an ideal 
score and can lead to a lack of conformity and reproducibility (Kim et al., 2016). Being based 
on a human-derived score on a 1-5 scale, scope for variability between researchers and 
practitioners exists with regards to TRG scoring. That said, many studies in other diseases do 
show concordance between TRG and overall survival (Minsky and Rodel, 2014). Again, in the 
future, mRNA, miRNA and protein signatures from tumour tissue will help build a fuller 
picture of the tumour and its microenvironment.  
 
Leaving aside the variation between laboratories and practices, the problem is that at present, 
we do not know which patients stand to benefit from the treatment the most, and which will 
not respond at all. This is a complex issue. Indeed, response (i.e. tumour regression) to 
preoperative radiotherapy is plausibly associated with several confounders, such as: age; sex; 
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disease stage; genetics; lifestyle factors/environment; and management and treatment. But 
before we get too distracted with the additive effects of our patient’s clinical history and 
genetics, let’s consider molecularly how our cells respond to radiation - something touched 
upon previously - which will help explain our reasons for investigating DNA DSB repair 
proteins.  
 
When a patient receives ionising radiation, the incident energy generates oxygen-derived free 
radicals in the exposed cells (Cadet and  Wagner, 2013). These radicals exceed the cell’s ability 
to contain them, and damage proteins and nucleic acids (Dröge, 2002). These free radicals lead 
to DSBs that cue to action of the MRN complex proteins.  
 
Cancer is often described as a double-edged sword (Hagemann et al., 2007; Tian et al., 2015). 
As we have seen previously, many tumours carry lesions in DDR proteins – be they germ-line 
or somatically-acquired defects. These proteins can also be post-translationally impaired in 
tumours (Oberle and Blattner, 2010). These mechanisms and genomic lesions in DDR proteins 
allows for cell division and growth, and the expression of diverse phenotypes, to go un-
regulated, benefitting tumour growth and functional development. However, when radiation 
causes DSBs in DNA (affecting a critical gene, say) and it cannot be repaired, the cancer cell 
will die, while a healthy cell (with intact DSB repair) may fix the problem.  
 
The entire process of radiation-induced cell death is dependent on there being oxygen available 
in the target tissue (Rockwell et al., 2009), with low levels oxygen and high levels of the 
hypoxia-sensing HIF-1-alpha transcription factor being associated with a non-response to 
radiotherapy. In the presence of molecular oxygen and related oxygen species, HIF-1-alpha 
remains in an inactive state, although when the concentration of its activating species’ decline, 
it remains in an intact, nuclear-localised state, where it results in anti-apoptotic and 
proliferative gene expression - including AKT, mTOR- and PI3K-regulated pathways (all of 
which aid the growth of tumour cells) (Courtnay et al., 2015; Hudson et al., 2002; Semenza, 
2003).  
 
The centres of tumours, and other regions of the tumour microenvironment (depending on the 
anatomy of the pathology), have been repeatedly found to be hypoxic (Brown, 2007). Thus, 
HIF-1-alpha in these environments hampers the success of radiotherapy, and the gene remains 
an intense focus of investigation in cancer and other fields. To overcome this, radiation is 
typically delivered in intermittent doses (Kye and Cho, 2014), allowing surface-exposed, non-
hypoxic cells to die during the first dose, and healthy tissue time to regenerate before the 
second. Subsequently, the previously-hidden, previously-hypoxic cells from the tumour centre 
become surface residents (due to dose one) and increase their oxygen consumption and 
metabolism (Barker et al., 2015). Given their roles in responding to radiation and oxygen, 
perhaps HIF-1-alpha, mTOR components and PI3K-pathway components could additionally 
serve as markers of radiotherapy success.  
 
Following the identification of a double strand break, as occurs following radiotherapy, the 
DSB repairs proteins of the MRN complex - RAD50, NBS1 and MRE11 – create single-strand 
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DNA regions with their inherent nuclease (and other) ability, as we will discuss later 
(Friedberg, 2003). These proteins are essential for detecting and repairing damaged DNA. 
Subsequent to lesion recognition by the MRN complex, ATM is recruited and cues cell cycle 
arrest and apoptosis through a variety of mechanisms (Thompson et al., 2005). Thus, we 
believe these are good candidates to explore with regards to predictive value in rectal cancer. 
Figure 1.6 comes from our review paper looking at predictive markers of radiotherapy-induced 
rectal cancer regression and pictorially highlights the key role that these proteins play (Shin et 
al, 2014).  
 
 
Figure 1-6 Potential markers of radiotherapy response in rectal cancer (Shin et al, 2014) 
 
 
The biochemistry and mechanisms of action of each of these four proteins (RAD50, NBS1, 
MRE11, ATM) has started to be introduced, and additional details of how they function as part 
of the MRN complex is described in the corresponding Results Chapters. Here, it suffices to 
say that these proteins are integral to maintaining genome stability, and as we will discuss, and 
many are lethal at an embryonic level if absent in mammals. Variations within these genes is 
also associated with severe clinical phenotypes; please see Results.  
 
Despite their well-understood roles, proving the clinical utility of these proteins in the context 
of rectal cancer radiotherapy is not straightforward. For example, MRE11 is thought to be 
responsible for initiating the MRN complex response via its sensing of DNA damage (Kondo 
et al., 2013), therefore, its absence is expected to correlate with increased radiation sensitivity; 
something that has been shown in cell lines (Xu et al., 2004). However, its clinical utility in 
rectal cancer has not been established. As we will discuss, however, MRE11 has been (and 
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NBS1, ATM, and RAD50) associated with survival and radiotherapy responses in other types 
of tumours, demonstrating their utility to interrogate the disease pathogenesis.  
 
Demonstrating a predictive role of any of these proteins in the rectal cancer response to 
radiotherapy would represent an important first step in monitoring and stratifying these patients 
for therapy.   
 
Beyond proteins that are involved in the DDR, proteins such as VEGF (which mediates tumour 
angiogenesis and is an important component of carcinogenesis) could also be monitored in 
response to radiotherapy in rectal cancer. Indeed, a recent study of 62 rectal cancer patients, a 
complete response to radiotherapy was seen in patient tumours where VEGF expression was 
low or absent (Zlobec et al., 2005). Furthermore, a meta-analysis by Kuremsky recently 
suggested 36 potential biomarkers for rectal cancer, based on surveying more than 1,200 peer-
reviewed papers on the molecular and clinical nature of the disease. In this report, the genes 
highlighted included, p53, Ki-67 (involved in cell proliferation), epidermal growth factor 
receptor (EGFR), BCL-2 (an anti-apoptotic protein), and thymidylate synthase – all key 
proteins involved in cell growth (Kuremsky et al., 2009). Still, these candidates have not been 
validated in independent patient cohorts, and many studies included in the meta-analysis were 
candidate gene studies (and not hypothesis-free genome-wide screens), biasing the output of 
the meta-analysis. 
 
Thus, although it might seem like a frustrated venture in terms of genetic prognostics and rectal 
cancer, several important DNA repair proteins are currently used to inform on disease 
pathology in patients (Peltomaki, 2001). In this case, the markers are used for prognostication 
and the response to adjuvant therapy. The best-established markers in this context are the DNA 
mismatch repair proteins, MLH-1, MSH-2, MSH-6, PMS-2, the lack of expression of which 
defines colorectal cancers with microsatellite instability (MSI) (Arends, 2013), as discussed – 
variable numbers of tandem repeats are present due to a lack of ability to detect lesions by 
MMR proteins. This presumably leads to diminished chromosomal integrity and poor mutation 
repair on the genome-wide scale.  
 
Importantly, colorectal cancers with MSI have their own unique features – such as being 
relatively poorly differentiated, subjected to an increased immune response, and with a greater 
tendency to be mucinous – and are not rectal cancers, highlighting the requirement to establish 
markers for other subtypes of CRC and rectal cancer specifically.  
 
Thus, as radiotherapy remains a mainstay of rectal cancer treatment (Häfner and Debus, 2016), 
we here attempt to identify markers that are predictive of a successful response to radiotherapy 
in these patients. As we enter the genomic age (Hua and Bromham, 2017), a focus will be on 
the stratification of patients into more refined clinical cohorts, where treatment and aetiology 
are more specific to the individual, so that novel molecular associations can be defined. 
Importantly, histological assessment, of the nature we here employ, is widely applicable 
globally to diverse patient cohorts, and benefits from being able to analyse heritage and 
contemporary tissue samples to learn about disease (De Souza and Greenspan, 2013).  
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Here, we investigated whether expression of the MRN complex proteins or ATM (in tumour 
sections), was associated with rectal cancer survival and the response to radiotherapy in a local 
rectal cancer patient biobank; as well describing correlations found with other 
clinicohistopathological features.  
 
1.5 Study Aims  
 
Rectal cancers represent approximately one third of all colorectal cancers worldwide, are 
associated with considerable morbidity and mortality, and their incidence is increasing 
worldwide.  
To date, a large number of molecular mechanisms have been associated with the development 
and progression of rectal and other colorectal cancers, including aberrant functioning of the 
DNA damage response, as discussed.   
Despite detailed descriptions of many molecular players in cancer, understanding the precise 
sequence of events causing disease, as well as how and when to intervene in a particular patient, 
remains a major challenge, as does the ability to prognosticate. 
A primary means by which disease mechanism in an individual patient can be understood, and 
patients stratified, is through the use of biomarkers, which highlight common mechanisms 
associated with a particular process, i.e. cancer development. 
Given the large heritage literature concerning DNA damage response proteins and cancer 
pathophysiology, we here sought to establish whether any such proteins (and a subset of DNA 
mismatch repair proteins) were expressed in rectal tumours, and whether their expression was 
predictive of various clinicohistopathological features, such as: overall survival, disease-free 
survival, tumour regression, and metastasis. The proteins of interest in our study were: ATM, 
MRE11, NBS1 and RAD50.  
Importantly, although radiotherapy represents a first-line treatment for rectal cancer, highly 
variable treatment responses have been documented between patients. Therefore, we also set 
out to investigate whether expression of our candidate proteins – central to repairing damaged 
DNA generated by radiotherapy – in tumours was associated with patient responses to 
radiotherapy. 
Finally, we also sought to determine whether the expression of these DNA damage response 
proteins could be considered in combination, within a patient, to increase the predictive power 
of any putative single biomarker alone.  
In order to achieve our aims, we stained (using immunohistochemistry) representative rectal 
tumour sections from a cohort of 263 rectal cancer specimens collected from the Sydney South 
West Local Health District (SWSLHD) and analysed protein expression via quantitative 
means. 
 
1.6 Hypotheses 
 
Given the complex role of DNA damage repair proteins in maintaining genome integrity in the 
face of double strand breaks (as well as the complex, genetic, oncogenic picture), we 
hypothesise that several scenarios (and their opposites) are possible: 
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• Low expression levels of DNA damage response protein expression will be associated 
with improved radiotherapy responses, and consequently, patient survival; as a lack of 
DDR to radiation-induced DSBs will facilitate cancer cell apoptosis.  
• High levels of DNA damage response protein expression in the absence of radiotherapy 
will be associated with increased disease-free survival 
• High/low levels of DDR protein expression will be associated with high/low grade 
disease subgroups; high DDR protein levels suggestive of increased genomic lesion 
burden, as occurs in high-grade rectal cancer.  
• A combination of DDR protein biomarkers (combinatorial panels), will improve 
predictive power in this setting over single markers alone.  
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2.1 Introduction 
 
The results presented in subsequent sections concern the value of DDR proteins in informing 
rectal cancer prognosis. In total, the expression levels of four key DDR proteins (ATM, 
MRE11, NSB1 and RAD50) were analysed in rectal tumour sections using histological staining 
with well validated antibodies. All samples were previously collected and stored from a local 
rectal cancer cohort, and each protein of interest was analysed independently of the others – 
aside from experiments in which MRE11 and ATM together served as an informative marker 
panel, as we will discuss. Accordingly, the results concerning each protein will be presented as 
individual results chapters, with the combinatorial panel presented in Chapter Four. 
 
2.2 Ethical considerations and approvals  
 
Robust ethical standards and protocols - with regards to patient welfare and safety, and 
scientific conduct - are essential to safely and accurately progress biological and clinical 
research (Emanuel et al., 2000). Indeed, since Hippocrates, medical practitioners have 
appreciated the importance of patient confidentiality, respect, communication and privacy. The 
past two decades have witnessed a welcome expansion in the controversial medical ethics 
public and private sectors, which now employs diverse committees of experts, philosophies 
and specialist administrators to better safeguard participants and their data whilst allowing the 
scientific community to benefit from medical advancements (Edwards et al., 2007; Jamrozik, 
2004).  
 
However, ethics does not only concern patient and data security, but also scientific conduct; 
although this is more dependent and susceptible to personal intervention. Along these lines, 
academic and private science sectors have been besieged by erroneous, irreproducible 
publications in recent history (Baker, 2016); which may be a consequence of the highly 
competitive environment in academic research, where one must “publish or perish” (Neill, 
2008). As a responsible author, I here guarantee the integrity of the data presented. Every effort 
has been made to evaluate data in a statistically-stringent, blinded and objective manner. All 
stages of our study have been frequently and critically evaluated by collaborators and 
professional colleagues, allowing feedback to be incorporated in real-time.  
 
In order to secure a strong ethical framework for our studies, we sought approval for our work 
from the local ethics committee. Following review and discussion, ethical approval for the 
ATM, MRE11 and NSB1 studies was granted on the 22nd June 2012 by the South-Western 
Sydney Local Health District (SWLHD) Human Research Ethics Committee (HREX); 
reference number HREC/12/LPOOL/102. Specifically, this allowed for the assessment of 
paraffin-embedded rectal cancer tissues and retrospective survival analyses, and was 
conducted under issued protocol numbers X01-0138 and X03-0291. Ethical approval for the 
histological studies concerning RAD50 was also granted by the SWLHD HREC; reference 
number HREC/14/LPOOL/186, project number 14/103.  
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Given the retrospective and exploratory nature of our study, all projects were deemed to be of 
low or negligible risk to participants. Accordingly, the aforementioned ethical committee 
waived the need for written and informed consent from participants, facilitating samples access 
and our studies. Despite this waiver, and in all cases, to avoid the introduction of experimental 
biases and safeguard patient identity, all identifiable information was anonymised and coded 
prior to use by researchers. Furthermore, all data analyses were carried out in a (researcher) 
blinded-manner, and only after the experimental protocol had been completed for all samples 
within the experiment. Furthermore, all histological scoring was carried out by independent 
pathologists and results averaged. 
 
All data arising from this work will be deposited in the public domain via this thesis and peer-
reviewed publications, thus ensuring open public access to our findings.   
 
2.3 Patient Samples  
 
All patient samples (paraffin wax embedded tumour cores) used in our studies were obtained 
from the local SWLHD Pathology Database (Australia), which maintained a high-quality 
collection of primary tumours, involved regional lymph nodes, and healthy tissue from rectal 
cancer patients.  
 
All samples were collected from patients undergoing tumour resection therapy in the district 
between 2000 and 2011, and stored for distribution to different research groups upon 
application. All slides from each case were available for review. In our cohort, surgery (for 
rectal or rectosigmoid tumours) consisted of total mesorectal excision with anterior or 
abdominoperineal resection, and samples were collected post-operatively for comparative 
analyses, as described (Tut et al., 2015).  
 
Throughout the study period, patient follow-up consisted of specialist clinic visits, routine 
blood biochemistry analyses, colonoscopy, and gastrointestinal imaging - based on the 
recommendations of the administering physician and requirements of the patient at the time. 
 
2.4 Radiotherapy and chemotherapy treatments  
 
As radiosensitivity is influenced by proteins involved in the DDR, this subgroup of patients is 
highly relevant to our studies. The patients enrolled in our study that underwent radiotherapy 
treatment, as in the ATM or RAD50 experiments (please see Results Chapters), received either 
a 25 Gy dose over five treatment fractions, or a 50.4 Gy dose over 28 fractions. Furthermore, 
all of these patients also received 5-fluorouracil-based chemotherapy and were under the care 
of professionals within the SWLHD. 
 
2.5 Outcome measures 
 
In order to evaluate whether the DDR proteins of interest had a predictive purpose in rectal 
cancer, patient disease course was considered. Outcome measures across our studies included: 
 93 
disease-free survival (DFS) time; overall survival (OS) time; and histological tumour 
regression grade (TRG) in the resected bowel. DFS was defined as the time between diagnosis 
and the first recurrence of disease, and OS was defined as the time between diagnosis and the 
last follow-up date or death.  
 
In patients receiving adjuvant radiotherapy, the short-term response to treatment was measured 
by TRG, according to the guidelines set out in the 7th edition of the American Joint Committee 
on Cancer manual (Edge and Compton, 2010; Hari et al., 2013), and modified by Ryan et 
al(Ryan et al., 2005). Accordingly, TRG is described on a scale of 0 – 3: 0 represents a 
complete response, without any viable malignant cells being detected; 1 represents a moderate 
response, with small groups of malignant cells still detectable; 2 represents a minimal response 
to treatment, with fibrosis outgrowing residual malignancy; while 3 typifies a poor response, 
with abundant residual malignancy. TRG scoring was carried out by two (or more) independent 
pathologist researchers in a blinded manner.  Patients categorised as having a TRG score of 0, 
1, or 2 were considered responders, in our studies, whilst those with a TRG score of 3 were 
considered non-responders.  
 
To gain additional insight into disease pathophysiology, additional variables of interest were 
interrogated after staining the tissue sections. Clinicohistopathological variables of interest 
across our studies included: age, sex, pathological TNM stage, tumour grade, the presence of 
vascular or perineural invasion, the level of tumour-infiltrating lymphocytes, and treatment.  
 
2.6 Sample preparation and tissue microarrays 
 
Archival formalin-fixed, paraffin wax embedded tissue blocks from postoperative rectal 
cancers were retrieved for each patient in the study. From each tissue block, two cores (0.6 mm 
in diameter) were obtained from each of five different sampling sites, namely: the tumour 
centre (TC); the tumour periphery at the invasive edge (TP); normal mucosa close/adjacent to 
the tumour (NCT); normal mucosa more distal (away) to the tumour (NAT); and any involved 
regional lymph nodes (LN). For all samples, corresponding (previously-prepared) hematoxylin 
and eosin-stained sections were reviewed to determine the most representative areas of 
oncogenesis and associated normal colorectal mucosa for our sampling and analyses.  
 
Tissue microarrays (TMAs) are now well recognised to provide an efficient means to achieve 
high-throughput screening of biomarkers from tissue sections. Thus, we exploited array 
profiling technology for our investigations. Originally, such microarrays were designed to 
interrogate a single biomarker in samples from a large number of patients (Kononen et al, 
1998); as TMAs work by placing several samples on a single glass slide. Each sample is 
approximately 0.6 – 2.0 mm diameter (Horvath and Henshall, 2001).  
 
The process of constructing a TMA is here described. A 37 x 24 x 5 mm sized mould was 
created from the recipient paraffin wax block. From H& E stained histological sections, a 
manual tissue arrrayer (Beecher Manual Tissue Arrayer, Model-MTA-1, Beecher Instruments, 
Inc.) was used to take 1 mm diameter tissue cores, creating a hole in the wax block (Cardano 
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et al., 2013).  Tissue cores were subsequently inserted into pre-punched wells. Samples can be 
arranged in up to 8 rows and 10 columns, with each sample being 2 mm apart from the adjacent 
specimen. Human error is reduced by the fact that each position on the TMA can be identified 
by a coded recorded pertaining to the sample.  
 
A schematic representation showing the steps involved in the manual construction of a tissue 
microarray (TMA) is shown in Figure 2.1 (Horvath and Henshall, 2001). After construction of 
TMA blocks, they were heated for 7 minutes at 60C; to seal any gaps between tissue cores 
and surrounding wax. TMA blocks were left at room temperature for 5 minutes before being 
heated again to 60C for 5 minutes. After removal from the oven, TMA blocks left to cool at 
room temperature. The heating and cooling cycle can be repeated to facilitate gap closing. 
TMA blocks were store at 4°C overnight. Tissue paraffin cores were shaved into thin sections 
(4µm) in the manual microtome (Microm HM325 Germany GMBH, Thermo Scientific, Cat 
No: 902100) and the shaved thin sections were then added to a circular paraffin section flotation 
bath (Thermo Scientific Cat No: 3120059) before being added to specially-coated slides 
(Bancroft and Gamble 2002, Bancroft and Gamble 2008). It is important to remove all paraffin 
wax present on the slide, as this will facilitate aqueous antibody solution penetration into the 
tissue. Then the glass slide was fixed and stained by H&E.  
 
Detailed TMA maps were constructed from blocks and are available for access upon request 
in an Excel password protected file containing patient identifiers. A TMA map example is 
shown in Figure 2.2 as an example, with patient surnames abbreviated to an initial to preserve 
privacy. Positive controls were included in the TMA blocks. Antibodies selected for the studies 
were commercially tested by companies in different methods including immunocytochemistry 
staining, western blot, immunofluorescence staining and immunoprecipitations with strong 
specificity in human tissues and cells.  
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Figure 2-1 Immunohistochemistry tissue microarray 
(A) The histopathological tumour lesion is first identified on the donor paraffin blocks, which has already been 
stained with H & E, as described.  
(B) A cylindrical core tissue biopsy (between 0.6 - 2.0 mm in diameter) was then cut from donor paraffin block 
and inserted into a pre-prepared recipient block. Samples are arranged in a grid for easier high-throughput analysis.  
(C) In our study, samples from one patient were placed adjacent to one another, repeating the punching and 
depositing procedure.  
(D) The newly-filled recipient paraffin block can then be sectioned to produce various tissue sections from the 
same tumour core.  
(E) TMAs are then sent for light microscopy analysis.  
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Figure 2-2 Original TMA blocks presented with patient identifiers removed and corresponding TMA maps 
constructed   
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2.7 Immunohistochemistry 
 
The different DNA damage response proteins of interested were analysed in overlapping sets 
of biopsy/surgical samples from the named Pathology Database, as described: ATM expression 
was quantified in 263 rectal cancer patients, 54 of which received preoperative radiotherapy; 
MRE11 expression was quantified in tumours and involved regional lymph nodes from 262 
patients, 54 of whom also underwent neoadjuvant radiotherapy; NSB1 expression was analysed 
in tumours and regional lymph nodes from an overlapping set of 260 patients; and RAD50 
expression was quantified histologically in a collection of 266 rectal cancer patients receiving 
chemotherapy and radiotherapy. Detailed cohort descriptions are presented in their respective 
results chapters.   
 
Slides were deparaffinized in xylene and rehydrated in graded ethanol. Slides were pre-heated 
in the oven at 60oC for 1 hour and 30 minutes, before the slides were fully immersed in 
decreasing concentration ethanol solutions (100%, 95%, 70%, 50% EtOH) for 6 minutes each. 
Antigen retrieval was performed with Envision™ FLEX Target Retrieval Solution, pH 9.0, in 
a 98°C water bath for 10 minutes for ATM and 45 minutes for MRE11, NBS1 and RAD50. 
This method has been previously described for colorectal tumour staining (Holck et al, 2015).  
This was followed by incubation for 5 minutes at room temperature with Envision™ FLEX 
Peroxidase-Blocking Reagent to block endogenous peroxidases.  
 
Blocked and washed slides were then incubated with the chosen primary (unconjugated) 
antibody raised against the DNA damage response protein epitope of interest, as detailed:  
• ATM expression was analysed with the murine monoclonal 2C1(1A1) obtained from 
Abcam, UK or Sapphire Bioscience, Australia. 2C1(1A1) was used at a 1:800 
dilution for a minimum of 30 minutes.  
• MRE11 expression was analysed with the murine monoclonal 12D7 obtained from 
Abcam, UK. 12D7 was used at a 1:600 dilution for a minimum of 30 minutes. 
• NSB1 expression was analysed using the antibody clone NBP1-06609 obtained 
from Novus Bioscience, USA. This reagent was used at a 1:800 dilution for a 
minimum of 30 minutes. 
• RAD50 expression was analysed with the murine monoclonal 13B3/2C6 obtained from 
Abcam, UK. 13B3/2C6 was used at a 1:400 dilution for a minimum of 30 minutes. 
• Following antigen retrieval in the ATM experiments (Chapter Three), primary 
antibodies MLH1 (clone ES05, dilution 1:50; Dako), MSH2 (clone FE11, dilution 1:50; 
Dako), MSH6 (clone EP49, dilution 1:50; Dako), and PMS2 (clone EP51, dilution 1:40; 
Dako) were applied to the slides for 15 minutes using the DAKO Autostainer in 1 mM 
EDTA buffer, pH 8.0. 
 
The antibody’s specificity and reproducibility are two key elements in antibody validation and 
verification. Particularly, when it comes to IHC, standardization can be quite challenging due 
to the number of pre-analytical, analytical and post-analytical factors known to influence 
staining in the TMA assay. In our laboratory with a standardised analytical procedure setup we 
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included both positive (using colorectal normal tissue samples) and negative (IgG only) 
controls to ensure the antibody’s reproducibility in the IHC assays. 
 
All primary antibodies were incubated with the sample slides for 30-60 minutes 
(depending on the antigen and antibody) at room temperature. Subsequently, slides were 
washed twice in TBST (as before) and incubated for 15 minutes with DAKO mouse/rabbit 
linker, as per the manufacturer’s instructions.  Slides were again washed with TBST solution 
prior to being incubated for 60 minutes with an anti-mouse/rabbit secondary antibody for 
primary antibody detection. Following incubation with secondary antibodies, slides were 
thoroughly washed three times in TBST, as before, to remove unbound antibody and 
background staining levels.   
 
The peroxidase substrate used for development and antigen detection was a mixture of 
Envision™ FLEX DAB + Chromogen DM827 and Envision™ FLEX Substrate Buffer DM823 
(DAKO, Denmark), which was incubated with the slides for 2-5 minutes, or until a brown 
colour developed on the stained section. As soon as any brown colour had developed and was 
noticeable by eye, the stained sections were immediately washed twice in TBST.   
 
Sections were then counterstained in an automated stainer with haematoxylin solution for 10 
seconds before being washed with cold water, and dipped 10 times in Scott Bluing solution. 
Haematoxylin, the oxidized forms of haematin, needs a metallic salt to act as a mordant in 
linking with nuclear chromatin (anionic cellular components). Eosin binds to collagen and 
cytoplasm (cationic components) of the cell reciprocally (Bancroft and Gamble 2002, Bancroft 
and Gamble 2008). Slides were then immediately rinsed with cold water prior to dehydration 
and mounting with Water-Based Immuno Mount (ThermoFisher, USA). 
 
2.8 Histological scoring  
 
For all samples, scoring was carried out in a blinded manner by two independent, experienced 
pathologists, who evaluated the intensity and proportion of positive immunohistochemical 
staining in each sample objectively and blinded to identifiable information. In all cases, scoring 
was based upon the methods previously described, with differences in the scoring method 
representing the antibodies and antigens in question.  
 
In all cases, immuno-stained sections were examined by manual counting of cells in each tissue 
microarray dot, with the observers blinded to clinical outcomes. Briefly: 
• ATM expression was scored as the product of percentage and intensity of staining, 
based on the work of Angèle and colleagues (2004). The percentage of positive 
staining was categorised as: < 25% (1), 25-50% (2), 50-75% (3), or > 75% (4); whilst 
the intensity of staining was graded as null (0), low (1), moderate (3), or high (5). Both 
scores were multiplied to create a composite score between 0 and 20, which allowed 
for accurate comparison of ATM expression between tissues. ATM expression was 
then categorised into negative (0) or positive (1-20) groups and analysed against 
available clinicohistopathological and clinical outcome data. This protocol has 
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previously been published and reliable results have been achieved (Ho et al, 2016; Ho 
et al, 2017; Ho et al, 2018).  
• MRE11 expression was quantified in a similar manner, as described by Rodel et al 
(2010). The percentage of positively-staining cells and the staining intensity were 
scored. Intensity was graded as: negative (0), weak (1), moderate (2), or strong (3). 
The percentage of positive cells was graded as: < 5% (0); 5%–25% (1); 26%–50% (2); 
51%–75% (3); and > 75% (4). These two measures were multiplied to produce a 
weighted score between 0 and 12, and dichotomized into low (0–5) or high (6–12) 
expression.  
• NSB1 expression was scored into either a negative expression group (score: 0) or 
positive expression group (score: 1-12). 
• RAD50 expression was scored in a similar manner to MRE11, and as described in our 
publication arising from this work, Ho et al (2017). Intensity was graded as: negative 
(0); weak (1); moderate (2); or strong (3). The percentage of positive cells was graded 
as: < 5% (0); 5%–25% (1); 26%–50% (2); 51%–75% (3); > 75% (4). These two 
measures were multiplied to obtain weighted scores ranging from 0–12. Again, 
samples were categorised into either a low expression group (0–5) or a high expression 
group (6–12). 
• ATM and MRE11 combinatorial panel scoring was achieved as follows. Firstly, both 
ATM and MRE11 staining intensity were analysed as described for each individual 
antigen. Subsequently, all cases were categorised into either a low expression group 
(score range: 0-5) or a high expression group (score range: 6-32), in which both 
proteins are considered. All immunohistochemical scoring system for both MRE11 
and ATM was based on the methods published previously (Ho et al, 2016; Ho et al, 
2018). 
• MRE11, NBS1 and RAD50 combinatorial panel staining was scored as follows. Two 
independent pathologists scored the intensity and percentage of positive 
immunohistochemical staining in each sample. Protein expression was calculated as 
the product of the staining percentage and intensity (Ho et al, 2018). Intensity was 
graded as: 0, negative; 1, weak; 2, moderate; or 3, strong. The percentage of positive 
cells was graded as: 0, <5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–75%; or 4, >75%. 
These two measures were multiplied to obtain weighted expression scores ranging 
from 0–12. All tumour samples were categorized into either a low (score range: 0–<6) 
or high (score range: 6–12) expression group. The two scores for each biological 
sampling site were averaged, yielding final average weighted scores. 
 
2.9 Statistical Analyses 
 
All statistical analyses were carried out in SPSS Statistics for Windows 20.0 (Chicago, IL, 
USA). 
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2.9.1 ATM 
 
Differences in ATM expression between tissue types were analysed using paired-sample t-
tests. ATM expression was compared with MMR protein expression and 
clinicohistopathological data using Pearson χ2 and Fisher's exact test. Survival analyses were 
performed separately in patients who received preoperative radiotherapy and those who did 
not. Disease-free and overall survival data were analysed using the Kaplan-Meier method and 
a log-rank test. Univariate and multivariate analyses were performed using Cox proportional 
hazards survival modelling for ATM expression in the TC and TP. Covariates included sex, 
age, TNM stage,  tumour grade, vascular invasion, perineural invasion, treatment with 
chemotherapy and radiotherapy, and TRG. P<0.05 was considered statistically significant. 
 
2.9.2 MRE11 
 
Paired t-tests were used to compare weighted scores between the low and high expressing 
MRE11 groups in the TC and TP. The scores between the tumour and healthy tissue were also 
analysed in this way. The Fisher’s exact test was used to test for associations between MRE11 
status and the available clinicopathologic variables for our cohort. For these tests, the 
significance threshold was set to P< 0.05.  
 
Furthermore, Cox regression models were used to test for univariate associations between the 
clinicopathological variables according to MRE11 status in the TC and TP. The assumption of 
proportional hazards was tested using log minus log plots; where variables met the assumption 
of proportional hazards if the plot showed a parallel curve between the groups over time. An 
interaction term with time was created for variables that did not meet the proportional hazards 
criteria and that interaction term was added to the model (grade did not meet the criteria for 
proportional hazards). If a variable was significant in one or both MRE11 groups for TC and 
TP in the univariate analysis, it was included in the multivariate analysis. Variables were 
excluded until only significant variables remained in one or both of the MRE11 groups. Two-
way interactions between the remaining variables were explored and included in the models if 
they were significant. Subgroup analysis was performed on lymph node-positive subjects and 
adenoma-positive subjects to determine whether there was a difference in survival between 
these groups according to MRE11 high or low status. 
 
2.9.3 ATM/MRE11 combinatorial panel  
ATM expression was compared with clinicohistopathological data using Pearson’s χ2 test, 
and the association of MRE11 expression with clinicohistopathological variables was 
assessed by Fisher’s exact test. ATM and MRE11 expression levels were compared and 
combined by binary logistic regression, as described previously. Survival analyses were 
performed in the overall cohort and separately in patients who received preoperative 
radiotherapy. Univariate and multivariate analyses were performed using Kaplan Meier 
curves and Cox’s proportional hazards survival modeling for the combined two-marker 
expression levels from cancer core and periphery samples. Covariates were sex, age, TNM 
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stage, grade, vascular invasion, perineural invasion, treatment with chemotherapy and 
radiotherapy, and TRG. Univariate analysis by the Mann–Whitney U test was also used to 
assess associations between the single and combined two-marker expression levels in rectal 
tumour tissue with TRG, which was further characterized with receiver operating 
characteristic—area  under curve (ROC-AUC)  analysis.  P<0.05 was considered statistically 
significant. 
 
 
2.9.4 NSB1  
 
Survival analyses were conducted both for the entire cohort, and separately, in samples from 
patients who received pre-operative radiotherapy, as has been described previously. In 
addition, further subgroup analysis was conducted with early tumour stage and low-grade 
tumours as covariates. Univariate and multivariate analyses were performed using Kaplan–
Meier curves and Cox’s proportional hazards survival modelling for NBS1 protein expression 
in the TC and TP. The covariates included were sex, age, TNM stage, tumour grade, vascular 
invasion, perineural invasion, chemotherapy and radiotherapy, and TRG. Univariate analysis 
was performed using the Mann–Whitney U test. P < 0.05 was considered statistically 
significant.  
 
2.9.5 RAD50 
 
Survival analyses were conducted both for the entire cohort, and separately, in samples from 
patients who received pre-operative radiotherapy. In addition, further subgroup analysis was 
conducted with early tumour stage and low-grade tumours as covariates. Univariate and 
multivariate analyses were performed using Kaplan–Meier curves and Cox’s proportional 
hazards survival modelling for RAD50 protein expression in the TC and TP. The covariates 
included were sex, age, TNM stage, tumour grade, vascular invasion, perineural invasion, 
chemotherapy and radiotherapy, and TRG. Univariate analysis was performed using the Mann–
Whitney U test. P < 0.05 was considered statistically significant.  
 
2.9.6 MRE11, NBS1, RAD50 combinatorial panel  
 
Statistical analysis was performed with SPSS Statistics for Windows 20.0 (Chicago, IL, USA). 
Survival analysis was conducted both for the entire cohort and, separately, in patients who 
received preoperative radiotherapy. MRE11, RAD50, and NBS1 expression were compared 
and combined by binary logistic regression (detailed raw data available upon request). 
Univariate and multivariate analyses of the combined expression of the three proteins at the 
TC and TP were performed using Kaplan–Meier curves and Cox’s proportional hazards 
survival modelling. Covariates were sex, age, TNM stage, histological grade, vascular 
invasion, perineural invasion, chemotherapy, and radiotherapy. Univariate analysis was 
performed using the Mann–Whitney U test. P<0.05 was considered statistically significant. 
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3.1 Introduction  
 
Surgical resection remains the definitive treatment option for colorectal cancer, and advances 
in surgical techniques, will continue to serve patients well. However, as we will discuss in this 
and subsequent sections, in order to improve patient diagnoses and prognoses, we need to 
precisely determine the molecular mechanisms underpinning cancer development, progression 
and treatment in the individual; with markers of these processes serving not only to improve 
patient welfare and lifespan (i.e. by using biomarkers of radiotherapy responses, or cancer 
phenotypes, tailoring treatment), but also resource usage in under-pressure public healthcare 
systems.  
 
Such approaches are particularly pertinent to rectal cancer, as anatomy limits surgical access 
to the pelvic space, and the close proximity of the rectum to other potential sites for metastases, 
make surgical approaches more complicated than for colon cancer. That said, laparoscopic 
techniques continue to advance and improve patient outcomes in rectal cancer, as it reduces 
the time spent in surgery, results in a more rapid return of normal bowel function and reduces 
other comorbidities, such as intestinal adhesions and postoperative abdominal bleeding 
(Trastulli et al., 2012). In all cases, advancements will come from the laboratory-clinic 
interface, which serves to unite fundamental biology with clinical manifestations, increasingly, 
in the individual (Chan and Ginsburg, 2011; Di-Paolo et al., 2017).   
 
As introduced previously, the DNA damage response is central to cancer development and 
progression, and has been repeatedly associated with clinical utility, with various participating 
members of the response being associated with patient survival times and the response to 
radiotherapy (Bartkova et al., 2005; Choudhury et al., 2010). Here, we will describe the utility 
of a single DDR protein biomarker, namely ATM protein expression in tumour tissue, to inform 
upon prognosis and disease-free survival in a cohort of rectal cancer patients.  
 
Importantly, a subset of the cohort received pre-operative (neoadjuvant) radiotherapy, allowing 
us to investigate any associations between treatment and biomarker expression. Preoperative 
radiotherapy attempts to downstage the tumour, improving outcomes after surgical resection. 
However, the response to radiotherapy is highly heterogeneous, with some patients responding 
to a much greater degree than others, as discussed. Across all cancers, approximately 60% of 
patients show a response to pre-operative radiotherapy (Jaffray and Gospodarowicz, 2015), 
whilst a third of these will display what is judged as a complete response. This variation in 
radiotherapy sensitivity is likely due to a combination of genetic, stochastic and environmental 
factors between individuals, and ultimately, the oncogenic mechanisms at work. That said, 
Kalady and colleagues suggest that the greatest biological determinant of pathological 
complete response in rectal cancer patients is an extended interval between the completion of 
neo-adjuvant radiotherapy and surgery (Kalady et al., 2009). 
 
Crucially, predictive markers of radiotherapy sensitivity will help target treatment protocols 
and reduce exposure to potentially harmful radiation in patients unlikely to benefit; patients 
that already carry a genetic burden predisposing towards cancer. As radiation therapy remains 
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central to the clinical management of diverse cancers, with more than 50% of cancer patients 
estimated to receive some radiotherapy protocol during treatment (Baskar et al., 2012), markers 
helping guide these treatments would ultimately help save more lives.   
 
3.1.1 ATM: biochemistry and mechanisms of action  
 
The focus of our investigations in this Chapter, is the serine/threonine protein kinase, ATM; 
also known as ataxia-telangiectasia mutated, due to its pathological association with disease, 
as we will discuss. In this section, we will review what is known about the protein’s function, 
and consider some specific examples in which the gene/protein has been implicated in cancer 
pathology, listing clinical applications where appropriate. 
 
ATM is a very highly-conserved gene, being found in Arabidopsis, Drosophila, and Xenopus, 
to name some non-mammals or birds (Zdobnov et al., 2017). Across all species containing the 
gene, nucleotide and amino acid sequence homology is high, and across taxa the gene has been 
described to carry out many similar functions concerning DNA repair (Zdobnov et al., 2017). 
A good example comes from work in flies, where the authors report that the ATM orthologue, 
dATM, mediates the DNA damage response to ionising radiation, or that arising due to normal 
tissue development. An absence of dATM led to pupal or larval death (Song et al., 2004).  
 
In humans, the ATM gene is located on chromosome 11 and encodes a protein of 3,056 amino 
acids in length, with the major isoform weighing approximately 350 kDa(Gately et al., 1998). 
It is member of the phosphatidylinositol 3-kinase-related kinases (PIKKs) superfamily, which 
has six-members (ATM, ATR, PRKDC, MTOR, SMG1, TRRAP), all of which share sequence 
homology with phosphatidylinositol 3-kinases (PI3Ks). PI3Ks themselves are potent 
intracellular signalling enzymes that regulate cellular growth, division, differentiation, 
apoptosis, mobility, and are themselves associated with cancer (Fruman and Rommel, 2014).  
 
ATM has been extensively characterised, given its prominent role in human disease. The full-
length protein is described to have five known functional domains, from the N- to C-terminus 
being: a HEAT repeat domain (composed of two alpha helices connected by a linker region 
that mediates binding to the C-terminus of NBS1, a protein we will discuss in its own right in 
later Chapters); a FRAP-ATM-TRRAP, or FAT, domain; a kinase domain; the PIKK-
regulatory domain; and another short FAT domain of 30 amino acids, called FATC (Wang et 
al., 2016). The consensus model at present states that the FAT domain stabilises the activatory 
kinase domain, whose activity is regulated by both the PIKK-regulatory domain and FATC 
(Jiang et al., 2006). As PI3K and PIKK families are widespread and signalling molecules that 
participate in a range of processes, the functions of ATM are not limited to DSB, as we will 
discuss later.  
 
For our interests, however, we will focus on the role of ATM in DSB repair. In the absence of 
DSBs in DNA (which may be induced by various mechanisms), ATM is held in an inactive 
state in cells. This inactivation is mediated by ATM’s tendency to form dimers or higher-order 
multimers, which allows the kinase domain to associate with serine 1,981 of the FAT domain 
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to enter an activated state (Bakkenist and Kastan, 2003). Dimer and multimer dissociation can 
presumably be triggered by a range of events in the cell, and ionising radiation has been shown 
to cue the auto-phosphorylation of serine 1,981 required for activated ATM monomers to be 
produced. However, the extent of ATM triggers remains to be fully determined, and could 
include small molecule metabolites and a number of auxiliary factors guiding ATM to where 
it is required. Subsequent to de-dimersation, auto-phosphorylation of serines 367 and 1,893 
drives the full activation of ATM monomers. Doses of ionising radiation as low as 0.5 Gy have 
been found to trigger monomer formation, as can a limited handful of DSBs, demonstrative of 
the fine sensitivity of the ATM sensor (Kozlov et al., 2011). In the context of evolution, and 
given the remarkable conservation of the gene in plants and other species, it is likely that ATM 
represents one of the major ways in which organic life responds to the threat damaging 
radiation poses to the genetic code; making the gene a great candidate when it comes to 
evaluating the effects of neoadjuvant radiation on cancer progression; as are MRE11, NBS1 
and RAD50. 
 
To facilitate DNA repair, ATM collaborates with members of the MRN complex – MRE11, 
RAD50 and NBS1, the other foci of our investigations. In eukaryotic organisms, the MRN 
complex is responsible for detecting and processing double-strand breaks immediately prior to 
homologous recombination, or NHEJ (Lamarche et al., 2010). The remarkable affinity of the 
complex for DSBs is shown by its association with such lesions in vitro, implying strongly 
conserved structural motifs at the damaged DNA ends underlie lesion recognition. Such innate 
structural recognition is presumably essential for the rapid tethering of broken strands in vivo.  
 
The rest of the MRN complex is responsible for recruiting ATM to the site of the DSB, where 
the complex may serve to tether the free ends whilst awaiting repair. A fully assembled and 
functional MRN complex is required to recruit ATM to DSBs (Uziel et al., 2003). This 
association between the MRN complex and ATM is mediated by binding of ATM to the protein 
MDC1 (Eliezer et al., 2014), which in turns binds to MRE11, a central MRN complex member, 
discussed in Chapter Four. ATM kinase activity as part of the MRN complex is dependent 
upon the interaction of the kinase with NBS1 via the HEAT domain (Lee and Paull, 2007). 
Once associated with NBS1, ATM is able to phosphorylate the serine at position 139 of H2A 
histone family member X (H2AX). ATR and PRKDC (other PIKK family members) are also 
able to carry out this phosphorylation, ensuring redundancy in this essential pathway (Stiff et 
al., 2004).  
 
Phosphorylation of H2AX by ATM is likely to have a number of consequences for DNA DSB 
repair. Firstly, it may allow for DNA de-condensation and fewer spatial restrictions for lesion 
repair, and secondly, it has been shown to allow for the recruitment of additional DDR proteins 
to the site. This recruitment is thought to be dependent on adaptor proteins possessing a BRCT 
domain (often found in proteins involved in cell cycle checkpoint regulation, such as BRCA1), 
which are then able to recruit some familiar regulators of the cell cycle, such as the TSG p53 
and checkpoint kinase 2 (CHK2) (Baldock et al., 2015).  
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However, histone modifications are only one aspects of ATMs functions as part of the MRN 
complex, and the DDR can take different paths; with many others, likely to be described in the 
future. However, in all cases, it is thought that conformational changes, induced first by the 
DNA DSB on the MRN complex, and then by the MRN complex on ATM, allow for the repair 
to proceed (Lee et al., 2013); again, presumably allowing a rapid response to lesions. Such 
changes are thought to underpin an increased affinity of ATM for some of its substrates, 
although the precise contacts and interactions are unknown. Recent advances in cryo-EM 
methodology could be particularly useful for further refining the mechanism of action of ATM, 
for which no crystal structure has been solved to date. However, given sequence and functional 
homology, it is thought to function in a similar manner to another member of the same 
superfamily, PRKDC, which uses a head and neck region to wrap around DNA after 
conformational changes in the molecule (Hill and Lee, 2010). 
 
Regardless of the precise motifs and cues dictating ATM function, the protein is known to halt 
cell cycle progression in the face of DSBs via various biochemical means. In one pathway, 
ATM (when associated with the MRN complex) has been shown to phosphorylate CHK2, 
which leads to its activation (Matsuoka et al., 2000). CHK2 encodes a TSG with various 
functions in DNA repair, cell cycle regulation and apoptosis. After being phosphorylated by 
ATM, CHK2 then goes on to phosphorylate one of its key targets, the phosphatase CDC25A 
(Donzelli and Draetta, 2003). The phosphorylation of CDC25A by CHK2 leads to its 
degradation by the proteasome. In the absence of CDC25A, CDK2-cyclin remains in a 
phosphorylated state of its own, cueing cell cycle arrest at the G1/S transition (Donzelli and 
Draetta, 2003).  
 
However, given the rapid kinetics and dynamic of the intracellular environment, where lesions 
can just as easily progress as be fixed, it is perhaps not surprising to learn that ATM can further 
delay cell cycle progression. This is achieved via the effects ATM has on two additional 
substrates, p53 and MDM2 (Khosravi et al., 1999). Phosphorylation of p53 by ATM (and the 
ATM target CHK2) leads to its stabilisation and the engagement of gene expression 
programmes designed to keep cells in a quiescent state or undergo apoptosis (Morgan and 
Kastan, 1997). Indeed, if DSB repair is unsuccessful, ATM is able to cue apoptosis by 
activating p53 and BID, a BCL2 family member, and inhibiting MDM2 and MDMX (Kamer 
et al., 2005). ATM also participates in the recruitment of DNA ligase IV to the DSB lesion site, 
allowing closure of the break (Jackson, 2002).  
 
The ATM gene is also known to have a number of other important functions in the cell worth 
considering before evaluating the results with regards to the DDR and rectal cancer. For 
example, ATM has recently been found to be an important mediator of mitochondrial 
autophagy, where old organelles are recycled and new ones produced (Valentin-Vega and 
Kastan, 2012). ATM is also known to be important for meiotic prophase, and is highly 
expressed in testes and oocytes, compared to somatic cells (Plug et al., 1997). In germ cells, 
ATM is known to repair DSBs (along with other DDR proteins), although its expression in 
these cells declines with age, allowing for mutation accumulation over time. An absence of the 
gene causes premature ageing of reproductive germ cells and infertility in man and other 
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mammals (Elson et al., 1996). Furthermore, as ATM has a wide range of substrates, defects in 
its activity have far-reaching, debilitating consequences. To date, ATM has been reported to 
be involved in apoptosis (Maclean et al., 2007), translation initiation (So and Ouchi, 2014), 
insulin signalling (Yang and Kastan, 2000), gene expression regulation (Heinloth et al., 2003), 
telomere maintenance (Tong et al., 2015), and G1/S and G2/M check-point control (Goodarzi 
et al., 2003), to name but a few known functions of the gene.  Some key target proteins of ATM 
kinase activity are shown in Figure 3.1. 
 
 
 
Figure 3-1 A schematic representing ATM and some of its best-known target proteins that halt cancer 
development.  
Image taken from Oberle and Blattner, 2010. 
 
 
3.1.2 Associations between ATM and cancer 
 
As alluded to in the previous section, ATM is known to be central to many cancers. Indeed, 
ATM was so named for its association with Ataxia telangiectasia, a rare, autosomal recessive 
human disease in which patients exhibit marked radiation sensitivity, cerebellar degeneration, 
and a predisposition to cancer (Chun and Gatti, 2004). Indeed, the discovery of extreme 
radiation sensitivity in A-T patient cells first stimulated the intense research that has 
accompanied this gene for the past three decades. In all cases, Ataxia telangiectasia is caused 
by mutations in ATM, with clinical symptoms typically manifesting first during early 
childhood, where affected patients first appear to lack co-ordination, and develop oculomotor 
apraxia, dysphagia and infections of the respiratory tract, before succumbing to systemic 
disease burden (Rothblum-Oviatt et al., 2016). Importantly, A-T shares many 
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pathophysiological features with cancer, not least because patients with the disease struggle to 
repair DSBs. 
 
To date several different types of cancer have been associated with mutations in, or aberrant 
activity of, ATM, including: Mantle cell lymphoma, T cell lymphoma, and B cell chronic 
lymphocytic leukaemia (Stankovic and Skowronska, 2014). If spontaneous cancers are 
considered – i.e. those in patients not known to have a family history of the disease, and as 
surveyed by the Catalogue of Somatic Mutations in Cancer – heterozygous ATM mutations 
have been found in approximately 11% of haematopoietic cancers, 7% of lung cancers, 5% of 
colon cancers, and 2% of both kidney and lung cancers (Forbes et al., 2017). ATM allelic 
imbalance and p53 gene mutations have also been found to occur during the progression from 
diploid to aneuploid cell populations in multiploid colorectal carcinomas (Sugai et al., 2001).  
 
The precise means by which ATM lesions predispose to cancer are likely to be different 
depending on the tissue of origin and the other variants driving oncogenesis. For example, 
recent work concerning pancreatic ductal adenocarcinoma, demonstrates ATM to be essential 
for avoiding the increased epithelial-mesenchymal transition that predisposes to such cancers 
in mice and man (Russell et al., 2015), highlighting the tissue-specific phenotypes and 
dysregulation arising from ATM variants. Subsequent work has shown pancreatic lesions 
deficient for ATM to have a higher mutation burden and that disruption of the gene accelerates 
Kras-mediated oncogenesis, without altering the tumour phenotype (Drosos et al., 2017).  
 
Given such associations and what is known about the gene, many studies have attempted to 
explore whether ATM variants lead to phenotypic differences in cancer phenotypes, similar to 
the approach we have taken. For example, Balleine and colleagues undertook histopathological 
analyses of breast cancer carried the ATM variants, IVS10-6T → G, 2424V →G or 1420L→F 
(and lacked known disease variants in BRCA1 and BRCA2), to determine whether clinically-
relevant differences could be determined (Balleine et al., 2006). However, in contrast to the 
results we will present in the following sections, the authors did not find any significant 
differences in histopathological features between ATM variant breast cancers, and those lack 
such lesions. This is in agreement with other studies that conclude IVS10-6T → G does not 
confer an increased breast cancer risk, with germ-line variants in ATM only occurring rarely 
familial breast cancer cases (Szabo et al., 2004). Balleineet al did, however, find the ATM 
tumour phenotype to be different to that of tumours carrying BRCA1/2 mutations, 
demonstrating that different oncogenic mechanisms are at play depending on the causal lesion. 
 
Of direct relevance to our work is that of Heike Grabsch and colleagues, who show that tumour 
histology with panel of two anti-ATM and -BRCA1 antibodies can predict survival in 
colorectal cancer patients (Grabsch et al., 2006); remembering that ATM regulates BRCA1 and 
BRCA2 expression after DSB recognition. In this study, tumours from 330 patients with 
colorectal adenocarcinoma were analysed, with the authors reporting increased survival in 
patients in whom ATM expression was highest – equating to an approximate 20% difference 
in survival 12 years post-surgery. Furthermore, patients receiving adjuvant radiotherapy were 
also found to have a higher disease-free survival interval if ATM expression was increased.  
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In a recent study from Feng and colleagues, low ATM expression in the tumour and tumour-
associated stroma both served as independent prognostic factors in breast cancer (Feng et al., 
2015). More specifically, in hormone-negative and -positive breast cancer, patients with low 
ATM expression levels showed reduced survival times, compared to patients with high levels 
of expression. These associations were found to be independent of tumour size and draining 
lymph node status (Feng et al., 2015). The authors suggest that low levels of ATM allow the 
cell division to progress in the face of accumulating DSBs, and the study demonstrates the 
potential utility of ATM as a prognostic cancer marker. In this case, it is possible that oncogenic 
variants in the gene lead to low protein expression, of the protein’s function is suppressed by 
other mechanisms at work in the tumour – both of which would facilitate cancer development.  
 
Aside from ATM lesions characterised directly from patient tumours, studies in cell lines have 
also shed light on the role of ATM in the aetiology of colorectal cancer. In the work of Ejima 
and colleagues, 50 sequence alterations in the ATM gene region were identified in 16 colon 
tumour cell lines (Ejima et al., 2000). In the five lines tested that displayed microsatellite 
instability, the most common lesions identified (accounting for 62% of identified lesions in 
these lines) were deletions within the intronic mononucleotide tracts of ATM. These deletions 
were found to disrupt ATM splicing before exons 8 and 12, leading to reduced levels of the 
protein – highlighting that ATM is a target of microsatellite instability in colorectal cancer.  
 
Finally, apart from what we know about changes in the base pair sequence altering ATM 
function, epigenetic mechanisms affecting the ATM gene region have also been associated with 
oncogenesis. For example, 73% of brain tumours have been found to contain the gene promoter 
in a hyper-methylated state (Mehdipour et al., 2015), leading to reduced levels of ATM mRNA, 
and a blunted DDR that facilitates unregulated division. Similar observations were made in 
early-stage breast cancer samples, where between 53-78% of all tumours from a heterogeneous 
cohort were found to have a hyper-methylated ATM promoter (Delmonico et al., 2015), and in 
squamous cell carcinoma of the head and neck where 42% of samples showed the phenotype 
(Bolt et al., 2005).  
 
Together, these associations demonstrate the importance of the gene with regards to 
maintaining genomic integrity and cellular fidelity, and that it can serve an important predictive 
value in different cancers – suggestive of common genetic mechanisms. Although somatic 
cancer-causing mutations in ATM are much less common than in other important TSG genes, 
such as p53 (Vogelstein et al., 2013) (probably due to the redundancy in the DDR), they remain 
an important contributor to pathology. As advancement of cancer cataloguing projects continue 
– at ever higher genetic and epigenetic resolution in large numbers of clinically well-
characterised patients (Hudson et al., 2010; Stratton et al., 2009; Wheeler and Wang, 2013) – 
we will further our understanding of the genes regulating different types of cancers, and how 
they interact to cause disease.  
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3.2 Hypothesis and study overview 
 
Given the prominent role of ATM in mediating DNA DSB repair, we hypothesise that variants 
within the gene that reduce protein expression levels in rectal tumours, will hamper DSB repair, 
increase genomic instability, and result in more tumour cell death following radiotherapy.  
 
The expression of ATM in tumours (as measured by immunohistochemistry) was compared to 
the mismatch repair proteins, MLH1, MSH2, MSH6 and PMS2; deficiency of these proteins is 
responsible for microsatellite instability in colorectal cancer.  
 
A primary interest is determining whether ATM expression in tumours can be used as a 
corollary marker for radiation sensitivity in rectal cancer patients. Furthermore, we investigate 
any associations between ATM expression and: available clinicohistopathological data; 
mismatch repair protein expression; and survival outcomes in the cohort.  
 
*Part of the results here described has been presented previously at a scientific meeting prior 
to the completion of this thesis. I contributed to the design and analysis of these experiments. 
Citation: Revoltar, M., Shin, J., Lim, S., Tut, T., Dissanayake, I., Descallar, J., Ho, V., Chua, 
W., Ng, W., Lee, M., et al. (2016). Early marker of DNA damage response, atm, as a predictor 
of clinical outcome following radiotherapy in rectal cancer patients. Pathology 48, s153. 
 
3.3 Results  
 
3.3.1 Patient Populations 
 
Cohort characteristics for this study are laid out in Table 3.1. All samples represented tumours 
isolated from rectal cancer patients during surgery, as previously described. 
 
The median age of participants in this study was 71 years (and ranged between 35 to 100), 
making this a predominantly elderly cohort. Notwithstanding the age associations with cancer, 
it is important to remember that younger cells have a lower mutation burden, and any 
associations here reported for ATM expression in older adults require validation in cohorts 
with lower mean ages.  
 
In total, one hundred and seventy-five out of 263 (66.5%) patients analysed were male, whilst 
88 (33.5%) were female, a consideration discussed in detail in the Discussion Chapter. 
Seventy-six patients (from 245 for which data is available; although missing data can be a 
problem for analyses in limited sample sizes, this dataset on the whole benefits from detailed 
patient annotations) (31.0%) received a radiotherapy treatment protocol during the course of 
their disease, and 54 of these (71.1%) also received preoperative radiotherapy (i.e. prior to 
sample collection). A chemotherapy regimen was used in 98/219 (44.7%) patients involved in 
the study, and disease-free and overall survival data were available for 215 and 248 patients, 
respectively.  
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Local recurrence of disease was documented to have occurred in 82/215 (38.1%) patients in 
the study, with the median time to recurrence being 2.12 years. At the time of our study, 
141/248 (56.9%) patients were alive, and the median time to death in the cohort was 2 and a 
half years following surgery (ranging between 0 − 11.1 years). Amongst those patients who 
received preoperative radiotherapy, local recurrence occurred in 23/54 (42.6%) patients, and 
the median time to recurrence was found to be 2.08 years (ranging between 37 days − 10.5 
years). Of these, 21/23 had died by the completion of the study. Median time to death following 
recurrence was 3.81 years (range 0.6−10.9 years). 
 
Table 3-1 Patient cohort characteristics 
 All Patients Preoperative Radiotherapy Group 
Total, n 263 54 
Sex, n (%) 
Male 
Female 
 
175 (66.5) 
88 (33.5) 
 
38 (70.4) 
16 (29.6) 
Mean age, yrs. 71.0 66.6 
pT category, n (%) 
T1-2 
T3-4 
 
86/257 (33.5) 
171/257 (66.5) 
 
17/54 (31.5) 
37/54 (68.5) 
pN category, n (%) 
N0 
N1-2 
 
137/256 (53.5) 
119/256 (46.5) 
 
28/54 (51.9) 
26/54 (48.1) 
pM category, n (%) 
M0 
M1 
 
220/237 (92.8) 
17/237 (7.2) 
 
52/53 (98.1) 
1/53 (1.9) 
Grade, n (%) 
1-2 
3 
 
243/263 (92.4) 
20/263 (7.6) 
 
50/54 (92.6) 
4/54 (7.4) 
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Vascular invasion, 
n (%) 
Absent 
Present 
 
 
198/260 (76.2) 
62/260 (23.8) 
 
 
46/54 (85.2) 
8/54 (14.8) 
Perineural invasion, 
n (%) 
Absent 
Present 
 
 
218/260 (83.8) 
42/260 (16.2) 
 
 
41/54 (75.9) 
13/54 (24.1) 
Radiotherapy, n (%) 
Total 
Neoadjuvant 
Adjuvant 
 
76/245 (31.0) 
54/76 (71.1) 
22/76 (28.9) 
 
 
54/54 (100) 
0/54 (0) 
Tumour regression grade, n (%) 
0 
1-2 
3 
 
- 
- 
- 
 
0/51 (0) 
9/51 (17.6) 
42/51 (82.4) 
Chemotherapy, n (%) 
Total 
Neoadjuvant 
Adjuvant 
 
98/219 (44.7) 
38/98 (38.8) 
67/98 (68.4) 
 
38/54 (70.4) 
31/38 (81.6) 
27/38 (71.1) 
Surgery alone, n (%) 130/218 (59.6) - 
Median follow up, years 3.2 3.2 
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3.3.2 ATM Expression  
 
ATM protein in tumour tissue sections was immuno-stained and analysed in 259 central, and 
260 peripheral cores.  
 
Two hundred and eighteen samples (from a total of 259; 84%) taken from the central core of 
the tumour displayed positive ATM expression; quantitated as previously described in Chapter 
2. Negative expression was scored in 41/259 (16%) tumour central cores. Samples from 
peripheral cores were positive in 205/260 (79%) samples, and negative in 55/260 (21%).  
 
Representative ATM staining examples are shown in Figure 3.2.  
 
 
Figure 3-2 Representative positive and negative ATM staining in rectal cancer samples from our patient cohort. 
Positive ATM staining is shown by the brown colour present in tumour cells, whereas an absence of staining is 
shown by the right-hand panel.  
 
 
Based on continuous variable scoring, the observed expression differences between the tumour 
central and peripheral tissues was found to be significant (MA-B=1.56, t (256) = 4.40, P< 0.001). 
ATM expression was found to be higher in the tumour centre than periphery. Given these 
differences, available clinicohistopathological and clinical outcome data were analysed 
separately for associations between central and peripheral tumour ATM expression. 
 
In order to accurately quantitate ATM staining, and to have a biological comparator in the 
experiment, we stained ATM using the same protocol in 250 tumour-adjacent tissue samples, 
and 228 distal samples from the same patients. ATM expression was observed in 199/250 
(80%) tumour-adjacent cores, and in 204/228 (89%) distal cores. ATM expression was found 
to be higher in samples in closer proximity to the tumour (MA-B = 2.19, t (218) = 4.59, P< 
0.001), suggestive of a spreading mutation burden associated with the malignancy. 
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In support of this, ATM expression was also found to be significantly higher in both central 
and peripheral tumour samples than in distal healthy mucosa (MA-B = 2.80, t (246) = 5.79, P < 
0.001 and MA-B = 1.16, t (247) = 2.75, P = 0.006, respectively).  
 
 
3.3.3 Association between ATM and mismatch repair protein expression 
 
To evaluate the association between ATM and other mis-match repair proteins, MLH1, MSH2, 
MSH6 and PMS2 were stained for in the same samples. Unfortunately for our analyses, in our 
cohort there were no MSI-high (MMR-negative) cases of rectal cancer. All cases were positive 
for MLH1 and MSH2 expression. Therefore, these two proteins were excluded from all further 
analyses. Expression of MSH6 and PMS2 was found to be negative in only 2/257 (0.8%) and 
9/253 (3.6%) cases, respectively. No associations between MSH6 or PMS2 expression and 
ATM expression, in either central or peripheral tumour samples, were found in this dataset (P> 
0.1). 
 
3.3.4 Associations between ATM expression and clinicohistopathological variables 
 
To further explore the implications of ATM expression levels and rectal cancer, we next sought 
to determine whether the immunohistochemical score (product of proportion and intensity) 
correlated with known clinicohistopathological variables.  
 
Firstly, we found negative ATM expression in the tumour periphery to be associated with older 
age (χ2 = 6.21 (1, n = 260), P = 0.013) and higher grade of disease (P = 0.044) (Table 3.2), 
again suggesting that older age is associated with increased DNA damage.  
 
However, expression of ATM in tumour centres was not found to be associated with any 
clinicohistopathological variables associated with the patient samples. Additionally, we did not 
observe there to be any correlations with sex, TNM category, vascular invasion, or perineural 
invasion.  
 
Table 3-2 Associations between ATM expression and clinicohistopathological data 
 Tumour centre  Tumour periphery  
Negative 
n (%) 
Positive 
n (%) 
P Negative 
n (%) 
Positive 
n (%) 
P 
Sex 
Male 
Female 
 
26 (15) 
15 (17) 
 
146 (85) 
72 (83) 
 
0.658 
 
 
36 (21) 
19 (22) 
 
136 (79) 
69 (78) 
 
0.902 
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Age 
≤70 yrs. 
>70 yrs. 
 
17 (14) 
24 (17) 
 
103 (86) 
115 (83) 
 
0.496 
 
 
17 (14) 
38 (27) 
 
102 (86) 
103 (73) 
 
0.013 
 
pT category 
T1-2 
T3-4 
 
13 (16) 
28 (17) 
 
71 (84) 
141 (83) 
 
0.824 
 
 
20 (24) 
33 (19) 
 
64 (76) 
137 (81) 
 
0.417 
 
pN  category 
N0 
N1-3 
 
19 (14) 
21 (18) 
 
116 (86) 
96 (82) 
 
0.401 
 
 
30 (22) 
24 (20) 
 
104 (78) 
95 (80) 
 
0.667 
 
pM  category 
M0 
M1 
 
38 (18) 
0 (0) 
 
178 (82) 
17 (100) 
 
0.083 
 
 
45 (21) 
3 (18) 
 
173 (79) 
14 (82) 
 
1.000 
 
Grade 
1-2 
3 
 
36 (15) 
5 (25) 
 
203 (85) 
15 (75) 
 
0.333 
 
 
47 (20) 
8 (40) 
 
193 (80) 
12 (60) 
 
0.044 
 
 
 
Vascular invasion 
Absent 
Present 
 
 
 
32 (17) 
9 (15) 
 
 
 
162 (83) 
53 (85) 
 
 
 
0.712 
 
 
 
 
45 (23) 
9 (15) 
 
 
 
150 (77) 
53 (85) 
 
 
 
0.150 
 
 
Perineural invasion 
Absent 
Present 
 
 
37 (17) 
4 (10) 
 
 
177 (83) 
38 (90) 
 
 
0.210 
 
 
 
48 (22) 
6 (14) 
 
 
167 (77) 
37 (86) 
 
 
0.242 
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Tumour regression 
grade 
1-2 
3 
 
 
2 (25) 
7 (17) 
 
 
6 (75) 
34 (83) 
 
 
0.628 
 
 
5 (56) 
8 (19) 
 
 
4 (44) 
34 (81) 
 
 
0.036 
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3.3.5 Associations between ATM expression and Tumour Regression  
Grade  
 
Next, we sought to evaluate the relationship between ATM expression and TRG following 
radiotherapy, helping us determine whether expression of the protein can be an informative 
marker of radiotherapy outcomes.  
 
TRG scores were available for 51/54 (94.4%) patients in the study cohort. Of these, 42 (82.4%) 
showed a poor clinical response to radiotherapy, and nine (17.6%) showed a minimal-to-
moderate response (Table 3.1). No tumours displayed a complete response to radiotherapy in 
these patients.  
 
In these patients, we found positive ATM expression in the tumour periphery to be associated 
with higher TRG (i.e. a poorer response to radiotherapy) (P = 0.036). This relationship was not 
observed between ATM expression in central tumour cores (Table 3.2). 
 
 
3.3.6 Associations between ATM and MMR protein expression, 
clinicohistopathological variables, and disease-free and overall survival: in 
patients receiving preoperative radiotherapy 
 
As discussed previously, predictive biomarkers hold much promise for cancer diagnosis and 
treatment. Accordingly, we next sought to determine whether ATM expression in rectal 
tumours was associated with clinical outcome measures, namely survival.  
 
To this end, disease-free and overall survival outcomes were analysed in the 55 patients in the 
cohort that had received preoperative radiotherapy (Figure 3.3). A longer disease-free survival 
interval was found in patients with negative ATM expression in the tumour periphery (P = 
0.025). However, negative ATM expression in the tumour centre was not associated with 
survival measures (P = 0.140). Nonetheless, the association between disease-free survival and 
negative ATM expression at both sites was found to be significant after adjusting for known 
confounders in our multivariate analysis (Tables 3.3 and 3.4) [ATM, tumour centre (HR = 
6.948 (1.192−40.504), P = 0.031); and ATM, tumour periphery (HR = 34.636 
(2.160−555.293), P = 0.012)]. Overall survival was not found to be affected by ATM 
expression in either central (P = 0.203) or peripheral (P=0.570) tumour cells. 
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A B 
 
C      D 
 
 
Figure 3-3 ATM expression associations with DFS and OS. Association between ATM expression in the tumour 
centre and (A) disease-free survival and (B) overall survival of patients. Association between ATM 
expression in the tumour periphery and (C) disease-free survival and (D) overall survival of patients. 
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Table 3-3 Multivariate analysis of ATM expression with disease-free survival in patients who received 
preoperative radiotherapy 
 Disease-free survival 
HR (95% CI) P 
ATM, tumour centre 
Positive vs. negative 
 
6.948 (1.192−40.504) 
 
0.031 
Grade 
3 vs. 1-2 
 
22.167 (3.086−159.215) 
 
0.002 
Vascular invasion 
Presence vs. absence 
 
9.216 (2.506−33.884) 
 
0.001 
 Disease-free survival 
HR (95% CI) P 
ATM, tumour periphery 
Positive vs. negative 
 
36.717 (2.103− 641.065) 
 
0.014 
Grade 
3 vs. 1-2 
 
92.465 (7.039− 1214.575) 
 
0.001 
Vascular invasion 
Presence vs. absence 
 
5.735 (1.656− 19.863) 
 
0.006 
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Table 3-4 Multivariate analysis of ATM expression with overall survival in patients who received preoperative 
radiotherapy 
 Overall survival 
HR (95% CI) P 
ATM, tumour centre 
Positive vs. negative 
 
2.748 (0.612−12.337) 
 
0.187 
Sex 
Male vs. female 
 
0.338 (0.118−0.970) 
 
0.044 
pM category 
M1 vs. M0 
 
11.705 (1.240−110.498) 
 
0.032 
Grade 
3 vs. 1-2 
 
9.388 (2.180−40.435) 
 
0.003 
 Overall survival 
HR (95% CI) P 
ATM, tumour periphery 
Positive vs. negative 
 
4.256 (0.994−18.222) 
 
0.051 
Sex 
Male vs. female 
 
0.267 (0.091−0.784) 
 
0.016 
pM category 
M1 vs. M0 
 
63.865 (4.007−1017.971) 
 
0.003 
Grade 
3 vs. 1-2 
 
26.337 (4.567−151.891) 
 
<0.001 
 
 
 
 
Multivariate analysis in patients receiving preoperative radiotherapy, revealed that a higher 
histological grade negatively impacted disease-free survival [ATM, tumour centre [(HR = 
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22.167 (3.086−159.215), P = 0.002) vs. ATM, tumour periphery (HR = 58.640 
(4.867−706.503), P =0.001)]. A higher histological grade also negatively impacted overall 
survival [ATM, tumour centre (HR = 9.388 (2.180−40.435), P = 0.003) and ATM, tumour 
periphery (HR = 26.337 (4.567−151.891), P<0.001)].  
 
Furthermore, the presence of vascular invasion was found to be associated with a poorer 
disease-free survival interval [ATM, tumour centre (HR = 5.735 (1.656, 19.863), P =0.006) 
and ATM, tumour periphery (HR = 9.216 (2.506−33.884), P = 0.001)], and males were also 
found to exhibit longer overall survival than females [ATM, tumour centre (HR = 0.338 
(0.118−0.970), P = 0.044) and ATM, tumour periphery (HR = 0.267 (0.091−0.784), P = 
0.016)].  
 
Finally, the presence of metastatic disease significantly reduced overall survival (ATM, tumour 
centre (HR=11.705 (1.240−110.498), P=0.032) and ATM, tumour periphery (HR=63.865 
(4.007−1017.971), P=0.003)]. 
 
3.4 Concluding remarks 
 
In these studies, we have demonstrated that there is a higher level of ATM expression in rectal 
tumour cells compared to normal mucosa, suggestive of genomic instability in the lesion. 
Furthermore, we found ATM expression to be lower in the tumour periphery than in the centre, 
and tumours with negative ATM expression in the periphery displayed a better response to 
radiotherapy. Finally, low ATM expression in peripheral tumour cells was also found to be 
associated with improved disease-free survival, and expression patterns from central tumour 
cells were also found to be significant after adjusting for confounders, demonstrating the 
biomarker potential of ATM in this scenario. 
 
In general, in this dataset, the peripheral tumour tissue proved to be more informative than the 
central cores, which is representative of the distinct microenvironments and mechanisms 
present in the evolving tumour. 
 
Unfortunately, given the extremely low frequency of MSI in the patient cohort studied, 
associations between dysregulated MMR and ATM expression, as previously reported, could 
not be undertaken. 
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4.1 Introduction  
 
This Chapter will further investigate the role of the DDR protein, MRE11, in rectal cancer. 
Similar to the ATM study, the major focus was determining whether expression of MRE11 in 
colorectal tumour tissue samples is associated with patient survival and related 
clinicohistopathological features.  
 
MRE11 has a long history of association with colorectal cancers (Hoeijmakers, 2001). Indeed, 
it is known that 15-20% of all colorectal cancers carry mutations in the DNA mismatch repair 
genes resulting in defective mismatch repair. These cancers are typically characterised as 
displaying microsatellite instability (as a result of destabilisation of simple repeat sequence 
repair), and there is an increase in genetic mutations in microsatellite instability. These cancers 
are often found to harbour mutations in the DDR proteins MRE11 and RAD50, which will 
cover in a subsequent chapter. In a 2007 study by Miquel and colleagues, the vast majority of 
MSI-positive colorectal tumours had lesions leading to ablation of MRE11 expression at the 
protein level; allowing error-prone replication to proceed unsupervised (Miquel et al., 2007). 
From this study and others, it is clear that DNA metabolism, in general, is associated with 
colorectal cancer development and progression, with other implicated genes including ATR, 
MSH6 and POLD3 (Peltomaki, 2001). 
 
4.1.1 MRE11: biochemistry and mechanism of action 
 
Double-strand break repair protein (meiotic recombination protein 11), or MRE11, is encoded 
on human chromosome 11 (11q21), as is ATM. Similar to ATM, MRE11 is highly-conserved 
amongst present day species, carrying out analogous DDR functions in yeasts, fish, plants and 
diverse birds, not to mention mammals (Zdobnov et al., 2017). An orthologue of MRE11 has 
recently been documented in the archaeon Sulfolobusacidocaldarius, which lives by volcanic 
vents at 82oC and pH 2-3. When this organism is subjected to experimental radiation, Mre11 
participates in DSB repair along with RAD50 (Quaiser et al., 2008); and suggests that this gene 
evolved from prokaryotic lineages.   
 
In humans, MRE11 has a molecular weight between 70-90 kDa, with the predominant isoform 
consisting of 708 amino acids, making it less than a third the size of ATM, discussed 
previously. The N-terminus of the protein encodes the di-manganese-dependent 
phosphoesterase domain, whilst the C-terminus possesses two unique DNA-binding domains 
(Lamarche et al., 2010). Compared to many proteins, MRE11 has a relatively simple structure, 
perhaps a key feature allowing it to participate in diverse biochemical processes. As has been 
discussed for ATM, conformational changes are key to the protein’s function; that is considered 
ancient and pleiotropic proteins malleable and applicable to many tasks. For example, 
structural data has recently revealed that a RAD50-ATP-driven conformation switch in MRE11 
controls the exonuclease function of the latter (Hopfner et al., 2001). MRE11 is also known to 
be controlled by a number of post-translational mechanisms to influence its localisation, 
function and longevity. For example, in order for ATM to function in DNA damage repair, it 
has to be arginine methylated by PRMT1 (Boisvert et al., 2005).   
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The most notable functions of MRE11 are described in the context of the previously introduced 
MRN complex, which it forms along with RAD50 and NBS1. As part of this macromolecular 
assembly, MRE11 participates in the repair of DSBs using a combination of homology directed 
repair, and classical and alternative non-homologous end-joining. Overall, the predominant 
function of the MRN complex is to repair DSBs via homology directed repair between sister 
chromatids (Bressan et al., 1999). Furthermore, in addition to MRE11’s DNA-binding roles, 
described below, the protein also has exo- and endo-nuclease activity against both single- and 
double-stranded DNA. Importantly, although MRE11 is a potent sequence modifier, it does 
not possess the 5’-3’ exonuclease activity required to generate 3’ single-strand overhangs 
required for homologous recombination (Lamarche et al., 2010). Therefore, auxiliary factors 
are likely recruited to the MRN complex to assist with homologous recombination, and to date, 
several 5’-3’ exonucleases, such as XRN2, have been identified in man (West et al., 2004).  
 
In-keeping with its best described functions, MRE11 has a mostly nuclear localisation, 
endowing it with close approximation to the genomic material it aims to repair. However, it is 
also able to translocate to the cytoplasm, as required, to carry out other functions. A good 
example is illustrated by the instructive role of MRE11 in driving type I interferon signalling 
and STING trafficking in response to detecting pathogen dsDNA in the cytoplasm (Kondo et 
al., 2013); which also highlights an important unrelated role of the protein. Although it is useful 
to consider the sub-cellular localisation of proteins when considering their potential functions, 
much remains to be determined by using more modern microscopy approaches that allow 
spatial and temporal dynamics to be interrogated in response to different stimuli (Lanzano et 
al., 2015). 
 
The nuclear MRN complex as a whole, has a large central globular domain, where MRE11 and 
NBS1 associate with RAD50 via the latter’s extended coil-coil and Walker A and B domains 
(Stracker and Petrini, 2011). It is also the globular domain that mediates nucleic acid binding, 
usually as part of a higher-order assembly of multiple entities (De Jager et al., 2004), and is 
dependent on MRE11 and RAD50, but not (according to the majority of studies) NBS1 
(Schiller et al., 2014). Furthermore, it is known that dimerization of MRE11 is required for 
DNA binding, with dimerization being mediated by the N-terminal region of the protein; and 
persists in recombinant MRE11 in vitro(Williams et al., 2008). Unfortunately, the crystal 
structure of the entire assembled globular domain is yet to be determined, which would help 
address these points relating to function further; although again, advances in cryo-EM may 
overcome this limitation in the near future. With respect to MRE11, however, crystallographic 
data has revealed that the protein contacts DNA via 17 conserved residues distributed across 
DNA recognition loops, with the aforementioned residues forming minor-groove sugar-
phosphate contacts (Stracker and Petrini, 2011). This dependency on sugar-phosphate contacts, 
and not nucleotide bases for DNA binding, allows MRE11 to bind a wide array of sequences, 
irrespective of the base pair sequence – a feature shared with ATM. 
 
Given the ancient nature of the proteins discussed thus far, it is perhaps unsurprising that the 
DDR is a major function of MRE11. For example, in our species, and in quite remarkable 
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experiments, Schwartz and colleagues also found the MRN complex to also be a potent 
mediator of anti-viral immunity. In cells infected with parvoviruses, MRN complex dissolution 
led to the accumulation of MRE11, RAD50 and NBS1 on viral inverted terminal repeat regions 
(Schwartz et al., 2007), suggesting the complex is able to detect foreign nucleic acids as well 
as those of host origin. Work by Deng and colleagues has also shown multiple roles for MRE11 
at the telomere end (Deng et al., 2009). In elegant work, the authors show that in the absence 
of TRF, MRE11 is able to remove 3’ telomeric overhangs, allowing for chromosomal fusions, 
and protects nascent strands from NHEJ. Essentially, MRE11 is involved in sensing telomere 
dysfunction and maintenance. This work came on the back of that of Zhong and colleagues, 
who showed that an absence of the MRN complex resulted in reduced telomere maintenance 
(Zhong et al., 2007). This study also showed, as have others, that a knock-down of MRE11, 
leads to a knock-down of the entire MRN complex, highlighting the central role of this DNA 
binder to one of the most studied biochemical complexes. Furthermore, in mice, expression of 
a hypomorphic Mre11 allele caused the premature elimination of oocytes harbouring DNA 
mutations, although oocyte attrition took much longer than in animals with a fully competent 
MRN complex (Inagaki et al., 2016). Thus, variants that alter the expression level or isoforms 
of MRE11 will need to be considered as putative pathological variants, and may lead to an 
increased oocyte and sperm mutation burden with disastrous consequences for the offspring.   
 
Before moving on to consider some of the specific associations between MRE11 and cancer, 
it is worth considering the distribution of this gene’s expression to learn more about its potential 
function and importance to cancer. According to the human tissue-wide compendium of 
mRNA expression, BioGPS, MRE11 mRNA is highly expressed in haematopoietic lineages, 
especially in cell lines derived from leukaemia and lymphoma patients (Wu et al., 2013). 
Highly proliferative B cells, or lymphoblasts, also express high amount of MRE11 mRNA, in 
keeping with its important role in genomic integrity maintenance in cells with a high turnover 
rate, such as those of the immune system. Adult human tissues at baseline expressed MRE11, 
but not significantly above mean levels; suggesting that MRE11 has more important functions 
in some lineages over others.  
 
In agreement with such a distribution in mammals is data from the publicly available 
Immunological Genome Project (Heng and Painter, 2008) and Symatlas (Su et al., 2004). In 
these datasets, which analyse gene expression across the finely-dissected mouse, show the bone 
marrow, testis, and the embryo between days 6 and 10 of gestation, to have the highest 
expression levels. Interestingly, gastrointestinal inflammation, of diverse forms, is implicated 
with colorectal and rectal cancer development and progression (Kim and Chang, 2014; Tjalsma 
et al., 2012). If drivers of inflammation coincide with developmental processes typified by a 
high cell turnover rate, perhaps the foundations of cancer can be laid. Although much remains 
to be determined with regards to the aetiology of rectal cancer, immune cell dysregulation in 
specialised gastrointestinal microenvironments (such as Peyer’s patches) can drive 
oncogenesis arising in other lineages (Chapkin et al., 2007; Nascimbeni et al., 2005; Sipos and 
Muzes, 2011).  
 
Much remains to be determined about the aetiology of rectal cancer, although it looks 
 132 
increasingly likely that individual clinical histories, and high-resolution analysis of our 
different organ systems (such as the microbiome) will be increasingly important in identifying 
causality – in line, of course, with our expanding knowledge of how genetics underpins and 
responds to environmental cues.   
 
4.1.2 Associations between MRE11 and cancer  
 
In this section, we will consider some additional and relevant recent associations discovered 
between MRE11 and cancer.  
 
To date, MRE11 variants have been associated with diverse forms of cancer, including those 
affecting the rectum/colon, uterus, breast, bladder, or ovary (Damiola et al., 2014; 
Koppensteiner et al., 2014; Rebbeck et al., 2011). Indeed, missense variants of MRE11, such 
as 140C→T and 1773_1774delAA have been in the germ-line and have been associated with 
cancer development; this is not to mention the wide array of mutations reported to lead to A-T 
and cancer like pathophysiology (Kim et al., 2017). Furthermore, when germ-line mutations 
were surveyed in 5,552 colorectal cancer cases and 6,792 healthy controls, 16% of familial 
colorectal cancer cases were found to carry highly-penetrant variants in POT1, POLE2 and 
MRE11 (Chubb et al., 2016). Low-frequency alleles with moderate effects were not identified 
in this study. Amongst cases of colorectal cancer, 17 colorectal cancer cells lines studies 
typified by microsatellite instability were found to harbour mutations in the polyT(11) tract of 
MRE11 intro 4 (Vilar et al., 2011). When the frequency of this variant was analysed in primary 
tumour samples from the MECC study, 82% of samples were found to carry the same variant 
in intro 4; suggesting that in cases of microsatellite instability, colorectal cancer progression 
leads to reduced MRE11 function. The ablation of MRE11 expression in colorectal cancers 
positive for microsatellite instability has been well reported (Giannini et al., 2002), although 
the mechanisms leading to this phenotype could be diverse, as we will discuss in subsequent 
sections.  
 
Very relevant to the work presented in this thesis, is that of Choudhury and colleagues, who 
show that MRE11 expression serves a predictive purpose in muscle invasive bladder cancer 
(Choudhury et al., 2010); which may represent sequelae of metastatic disease. The study 
samples were collected prior to radiation therapy. Specifically, the authors show that low 
MRE11 expression (RAD50, NBS1, ATM and H2AX levels were simultaneously reported but 
not associated) is associated with worse cancer survival after radiotherapy, in two independent 
cohorts of bladder cancer patients. The study also exploited immune-histology of archived 
samples to make the observation, providing strong evidence to support and pursue our 
investigations. When developing truly applicable biomarkers for patients, an understanding of 
inter-cohort heterogeneity and known independence/dependence of clinical variables is 
paramount (Elefsinioti et al., 2016).  
 
Thomas Pavelitz and colleagues also undertook an investigation of the effect of MRE11 
expression levels and colorectal cancer development (Pavelitz et al., 2014). Out of the 625 
tumour samples analysed, 11% contained mutations in the familiar polyT (11) tract, which 
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could be bi-allelic or mono-allelic, and reduced expression of MRE11 protein. These patients 
with mutations in the T11 tract were found to have an increased long-term DFS and OS, with 
the study demonstrating the utility of MRE11 expression in guiding prognosis. 
 
Finally, in a recent study taking a very similar histological approach to ours in colorectal 
cancer, Ihara and colleagues found MRE11 expression at the protein level was also found to 
predict the response to oxaliplatin-based chemotherapy in colorectal cancer patients, further 
demonstrating its biomarker potential (Ihara et al., 2015). In this study, low expression of 
MRE11 (or negative expression) was associated with significantly better tumour volume 
reduction compared to tumours with a high expression – in-keeping with the hypothesis that 
low DDR proteins make tumours more susceptible to chemo- and radio-therapy. 
 
Together, these results provide compelling evidence to further explore associations between 
MRE11 expression and clinicohistopathological variables and patient outcomes in rectal 
cancer.  
 
4.2 Towards the development of a ATM/MRE11 combinatorial marker panel 
 
Whilst the study of MRE11 in tumour samples alone may be able to yield important insights 
into disease and prognosis, the analysis of groups of proteins together may facilitate the 
identification of similar and overlapping mechanisms in different patients, which may not share 
all features of a disease. Equally, combinatorial panels can shed light on the severity of disease, 
if many proteins involved in the same pathway are ablated, for example.  
 
Ultimately, when outbred, highly heterogeneous patient populations are analysed, having two 
markers as opposed to one may help increase the power to detect prognostic variables; 
especially when commonly mutated genes, such as ATM and MRE11, are considered. Although 
we have seen that MRE11 and ATM both have predictive value in different cancers, neither 
biomarker has been tested in large-scale, randomised clinical trials; increasing the speed of 
biomarker discovery and validation is essential to translate basic research findings to the patient 
bedside.   
 
Given our previously reported association between ATM expression and rectal cancer survival, 
and the results of MRE11 here presented, we sought to determine whether a combinatorial 
panel including both markers could serve a predictive purpose in rectal cancer. As discussed, 
of interest will be determining whether single- or multi-marker panels are more sensitive and 
specific for quantifying patient outcome measures, which we will discuss in more detail in the 
Discussion Chapter.  
 
The results of the combinatorial panel experiments are shown in Chapter Six. 
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4.3 Hypothesis and study overview 
 
Given the prominent role of MRE11 in mediating DNA DSB repair, we hypothesise that 
variants within the gene that reduce protein expression levels in rectal tumours, will hamper 
DSB repair, increase genomic instability, and result in more tumour cell death following 
radiotherapy.  
 
We hypothesise that reduced ATM/MRE11 expression in a combinatorial panel would result 
in the similar outcomes to either marker alone.  
 
We will also determine whether the expression levels of MRE11 in tumours is associated with 
various clinicohistopathological variables available to us as part of the dataset.   
 
4.4 MRE Results  
 
4.4.1 Patient Populations 
 
A total of 262 patients (66% male, 34% female) were used to study MRE11 expression in rectal 
tumours. The median age of participants in this study was 71 years (ranging between 35–100 
years). With regards to tumour characteristics, 33% of lesions were classified as stage T1/2, 
whilst 67% were classed as T3/4. Ninety-three percent were M0, 54% were lymph node 
negative, 92% were of tumour grade 1/2, 76% did not show evidence of vascular invasion, and 
84% did not show any evidence of perineural invasion. Twenty-two percent of study the 
patients received neo-adjuvant radiotherapy, and 30% received adjuvant therapy. The median 
OS in the cohort was found to be 3.2 years (ranging between 0–12.6 years). A detailed 
breakdown of the cohort characteristics is shown in Table 4.1. 
 
Table 4-1 Cohort characteristics for MRE11 and MRE11/ATM studies 
 All Patients (%) Preoperative Radiotherapy Group 
Total, n 262 54 
Age median 71 67 
Sex   
Male 174 (66.4) 38 (70.4) 
Female 88 (33.6) 16 (29.6) 
Tumour stage   
T1-2 86/257 (33.5) 17/54 (31.5) 
T3-4 171/257 (66.5) 37/54 (68.5) 
Node stage   
N0 137/256 (53.5) 28/54 (51.9) 
N1-2 118/256 (46.5) 26/54 (48.1) 
Metastasis stage   
M0 220/237 (92.8) 52/53 (98.1) 
M1 17/237 (7.2) 1/53 (1.9) 
Grade   
1–2 242/262 (92.4) 50/54 (92.6) 
3 20/262 (7.6) 4/54 (7.4) 
Vascular invasion   
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Absent 198/260 (76.2) 46/54 (85.2) 
Present 62/260 (23.8) 8/54 (14.8) 
Perineural invasion   
Absent 218/260 (83.8) 41/54 (75.9) 
Present 42/260 (16.2) 13/54 (24.1) 
Radiotherapy   
Total 76/245 (31.0) - 
Neoadjuvant 54/76 (71.1) 54/54 (100) 
Adjuvant 22/76 (28.9) 0/54 (0) 
Recurrence   
Absent 129/211 (61.1) 48/54 (88.9) 
Present 82/211 (38.9) 6/54 (11.1) 
Tumour regression grade   
0–2 (good response) - 9/54 (16.7) 
3 (poor response) - 45/54 (83.3) 
Chemotherapy   
Total 98/219 (44.7) 38/54 (70.4) 
Neoadjuvant 38/98 (38.8) 31/38 (81.6) 
Adjuvant 60/98 (61.2) 7/38 (18.4) 
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Patients were followed for a median period of 3.2 years during the study (ranging between 
0−12.6 years). Local recurrence of disease was documented to have occurred in 82/211 
(38.9%) patients, with the median time to recurrence being 2.12 years. At the time of the 
study, 141/248 (56.9%) patients were alive, and the median time to death was 2.5 years 
following surgery (ranging between 0−11.1 years). Among patients who received 
preoperative radiotherapy, local recurrence occurred in 6/54 (11.1%) patients, and the 
median time to recurrence was 2.61 years (ranging between 0.75−4.29 years). All of these 
six patients (100%) had died by the end of the study. The median time to death following 
recurrence was 3.81 years (range: 0.6 – 10.9 years).  
 
The pre-operative tissue sampling protocol was limited by sample size. Preoperative 
endoscopic biopsy tissues were available for analysis in only 66 patients. Nine biopsies were 
derived from patients who underwent preoperative treatment (neoadjuvant radiotherapy 
administered either alone [n=5] or as chemoradiotherapy [n=4]), whereas eight were obtained 
from patients treated postoperatively with either adjuvant chemoradiotherapy (n=3) or 
chemotherapy alone (n=5). 
 
4.4.2 MRE11 scores 
 
In order to determine whether any associations existed in the dataset, the weighted scores for 
MRE11 staining were generated by two independent, expert scorers. Scores between 0–5 were 
considered to represent low staining, whilst scores of 6–12 were considered to be high staining 
samples. The mean weighted MRE11 scores were 5.5 for the TC, and 5.8 for the TP. This 
difference in weighted scores between the TC and TP was found to statistically significantly 
(paired t-test, P< 0.05), although the difference between both sites is relatively small.  
 
The distribution of weighted scores in the TC and TP is shown in Figure 4.1. In the TC, 53% 
(n = 136) of patients were defined as having a low staining score, whilst 47% (n = 119) were 
found to have a high staining intensity. In the TP, 44% (n = 115) of participants had a low 
score, and 56% (n = 144) were found to have a high score.  
 
In order to compare expression between the tumour and adjacent and morphologically healthy 
tissues, MRE11 was analysed in NAT and NCT. The mean MRE11 score was 4.2 for both 
adjacent and distal normal tissue, which was significantly different from the score for both the 
TC and TP (P<0.001).  
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Figure 4-1 The distribution of weighted scores for MRE11 in the tumour centre and periphery 
 
 
4.4.3 Associations between MRE11 scores and clinicohistopathological 
characteristics  
 
In contrast to what we observed for ATM, in this dataset we did not find any evidence for there 
being significant associations between the MRE11 score in the TP or TC and 
clinicohistopathological characteristics (Table 4.2).  
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Table 4-2 Fisher’s test of association between MRE11 score in the tumour centre and tumour periphery (high 
vs. low) and clinicohistopathological variables 
   
Tumour centre Tumour periphery   
Low 
(%) 
High 
(%) 
p-
value 
Low 
(%) 
High 
(%) 
p-
value 
Sex Male 65.40 68.10 0.69 65.20 66.70 0.90  
Female 34.60 31.90 
 
34.80 33.30 
 
Age <71 48.50 42.90 0.38 42.60 48.60 0.38  
71+ 51.50 57.10 
 
57.40 51.40 
 
Tumour stage T1–2 33.10 33.60 1.00 30.40 34.80 0.50  
T3–4 66.90 66.40 
 
69.60 65.20 
 
Node stage Negativ
e 
49.60 55.50 0.38 46.40 59.30 0.06 
 
Positive 50.40 44.50 
 
53.60 40.70 
 
Metastasis stage M0 94.30 90.60 0.32 94.10 91.60 0.61  
M1 5.70 9.40 
 
5.90 8.40 
 
Grade 1–2 90.40 94.10 0.35 92.20 92.40 1.00  
3 9.60 5.90 
 
7.80 7.60 
 
Vascular invasion No 74.40 76.50 0.77 72.80 78.20 0.38  
Yes 25.60 23.50 
 
27.20 21.80 
 
Perineural invasion No 81.20 87.40 0.23 81.60 85.20 0.50  
Yes 18.80 12.60 
 
18.40 14.80 
 
Adjuvant therapy No 67.60 72.00 0.55 67.00 71.10 0.55  
Yes 32.40 28.00 
 
33.00 28.90 
 
Neoadjuvant 
therapy 
No 76.40 81.50 0.42 77.10 79.90 0.64 
 
Yes 23.60 18.50 
 
22.90 20.10 
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4.4.4 Survival analysis 
 
In order to determine whether MRE11 expression in rectal tumours was associated with patient 
outcomes, we next determined survival intervals according to MRE11 immunohistochemical 
score (product of proportion and intensity). By Kaplan–Meier analysis, patients found to 
exhibit a low level of MRE11 expression in the TC have a slightly higher OS than those with 
high MRE11 expression. This difference however is not significant (6.90 vs. 6.10 years, P = 
0.42; Figure 4.2).  
 
Similarly, the OS interval was found to be slightly shorter in patients with a low MRE11 score 
in the TP, although this also did not reach statistical significance (6.59 years in the low MRE11 
group, compared to 6.68 years in the high MRE11 group, P = 0.77; Figure 4.2). 
 
 
 
Figure 4-2 Kaplan–Meier survival curves for overall survival according to MRE11 weighted scores for the 
tumour periphery and tumour centre 
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4.4.5 Uni- and multi-variate analysis according to MRE11 expression in  
the TC 
 
As we did in the case of ATM, we next sought to define additional features of disease in the 
cohort using uni- and multi-variate analyses able to model the effects of different confounding 
variables. Firstly, we did not find any significant differences in survival according to gender, 
age, tumour stage, neoadjuvant status, or adjuvant status. However, we did find that patients 
whose tumours showed evidence of vascular invasion to have a lower OS than patients whose 
tumours did not. These associations were maintained in both the high (hazard ratio [HR] = 
0.42, P = 0.01) and low (HR = 0.55, P = 0.04) MRE11-expressing sub-groups.  
 
Patients classed as having high levels of MRE11 expression, who were also positive for 
metastatic disease, had a lower OS than those who were negative for metastasis (HR=0.09, P< 
0.01). Patients with high MRE11 expression who had negative lymph node status also had a 
better OS than patients who had positive lymph node status (HR = 0.48, P = 0.02). Furthermore, 
patients without perineural invasion were found to have a better OS than those with invasion, 
in both subgroups (low MRE11: HR = 0.36, P< 0.01; high MRE11: HR = 0.34, P< 0.01). 
Finally, patients with grade 1–2 disease showed better survival than those with grade 3–4 
disease, in both low MRE11 (HR = 0.15, P> 0.01) and high MRE11 (HR = 0.02, P < 0.01) 
subgroups, as might be expected. 
 
Table 4.4 depicts the multivariate analysis for MRE11 status in the TC. In these results, the 
absence of perineural invasion showed a protective effect in patients with low and high MRE11 
expression (low MRE11: HR = 0.39, P < 0.01; high MRE11: HR = 0.37, P = 0.05). 
Furthermore, metastasis stage was a significant factor in patients with a high MRE11 (M0 vs. 
M1, HR = 0.09, P< 0.01). Finally, in patients with low MRE11 score, tumours graded 1–2 
showed a protective effect versus those graded 3 (HR = 0.19, P = 0.01). 
 
 
4.4.6 Uni- and multi-variate analysis according to MRE11 expression in  
the TP 
 
Following on from our analyses of MRE11 staining intensity in the TC, we next extended our 
studies to investigate the TP. Table 4.3 shows the results of the univariate analysis for the 
clinicohistopathological variables associated with MRE11 staining intensity in both the MRE1 
low and MRE11 high subgroups, with regards to the TP.  
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Table 4-3 Univariate analyses of survival outcomes according to MRE11 score in tumour centre and tumour 
periphery 
 Tumour centre Tumour periphery 
   MRE11 low MRE11 high MRE11 low MRE11 high 
 HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
Adjuvant therapy 1.94 0.96 3.92 0.06 2.26 0.93 5.49 0.07 3.28 1.38 7.81 0.01 1.51 0.77 2.99 0.24 
(no vs. yes)                 
Neoadjuvant therapy 3.81 0.38 37.67 0.25 1.06 0.52 2.15 0.88 1.81 0.76 4.28 0.18 0.73 0.41 1.33 0.31 
(no. vs. yes)                 
Vascular invasion 0.55 0.31 0.96 0.04 0.42 0.22 0.80 0.01 0.57 0.31 1.04 0.07 0.41 0.23 0.74 <0.01 
(no vs. yes)                 
Gender 1.15 0.66 2.01 0.61 0.88 0.47 1.65 0.69 1.13 0.63 2.01 0.68 0.99 0.57 1.74 0.98 
(male vs. female)                 
Age group 0.84 0.49 1.44 0.52 0.63 0.33 1.19 0.15 0.78 0.43 1.40 0.40 0.65 0.37 1.14 0.13 
(≥70 years vs. <70 years)                 
Grade 0.15 0.04 0.48 0.00 0.02 0.00 0.23 <0.01 0.02 0.06 0.81 0.02 0.01 0.00 0.09 <0.01 
(1–2 vs. 3)                 
Tumour stage 0.63 0.35 1.14 0.13 0.53 0.26 1.08 0.08 0.58 0.30 1.10 0.10 0.73 0.40 1.33 0.31 
(T1–2 vs. T3–4)                 
Metastasis stage 0.48 0.15 1.56 0.22 0.09 0.04 0.21 <0.01 0.29 0.10 0.83 0.02 0.15 0.07 0.33 <0.01 
(M0 vs. M1)                 
Node stage 0.87 0.50 1.51 0.63 0.48 0.27 0.87 0.02 0.69 0.39 1.24 0.21 0.68 0.40 1.16 0.16 
(N0 vs. N1–2)                 
Perineural invasion 0.36 0.20 0.65 0.00 0.34 0.16 0.75 0.01 0.53 0.27 1.03 0.06 0.35 0.19 0.65 <0.01 
(negative vs. positive)                 
 
 
Patients with low a MRE11 score that did not undergo adjuvant treatment were found to have 
a shorter OS than those who received radiation treatment (HR = 3.28, P = 0.01), supportive of 
the positive effects of this treatment. Furthermore, patients in the high MRE11 subgroup, and 
with evidence of vascular invasion, also had a lower OS than those without invasion (HR = 
0.41, P< 0.01), again in-keeping with the aggressive disease phenotypes.   
 
As might be expected, the OS was lower in patients with metastatic disease, in both the low 
(HR = 0.29, P = 0.02) and high MRE11 (HR = 0.15, P< 0.01) subgroups. Patients found to 
have a high MRE11 and were also positive for perineural invasion also had a lower OS than 
those who were negative for invasion (HR = 0.35, P< 0.01). Patients with grade 1–2 disease 
showed better survival than those with grade 3–4 for both the low MRE11 (HR = 0.02, P = 
0.02) and high MRE11 (HR = 0.01, P < 0.01) subgroups. 
 
Subsequently, we carried out multivariate analyses considering MRE11 status in the TP, the 
results of which are presented in Table 4.4. Being negative for perineural invasion (HR = 0.24, 
P = 0.01) and metastasis also had a protective effect in the high MRE11 subgroup (HR = 0.19, 
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P < 0.01), and patients in both high and low subgroups had a lower OS if they did not undergo 
adjuvant treatment (low MRE11, HR=3.05, p=0.01; high MRE11, HR=3.02, p=0.02), further 
emphasising the importance of radiotherapy to cancer treatment. 
 
Table 4-4 Multivariate analysis of tumour centre and tumour periphery MRE11 scores for survival outcomes 
 
MRE11 Low MRE11 High  
HR 95% CI p-value HR 95% CI p-value 
Tumour periphery 
     
  
 
Adjuvant 3.05 1.27 7.34 0.01 3.02 1.19 7.62 0.02 
(no vs. yes) 
        
Perineural invasion 0.64 0.28 1.49 0.30 0.24 0.09 0.67 0.01 
(absence vs. presence) 
        
Metastasis stage 0.31 0.04 2.56 0.28 0.19 0.07 0.49 0.00 
(M0 vs. M1) 
        
Tumour centre 
        
Perineural invasion 0.39 0.20 0.76 0.01 0.37 0.14 1.00 0.05 
(absence vs. presence) 
        
Metastasis stage 1.05 0.29 3.77 0.94 0.09 0.04 0.23 0.00 
(M0 vs. M1) 
        
Grade 0.19 0.05 0.70 0.01 0.34 0.04 3.34 0.36 
(1-2 vs. 3)         
 
 
 
 
4.4.7 Lymph node-positive and adenoma-positive subgroups 
 
The study population used included 115 patients who showed evidence for lymph node 
involvement. Amongst these participants, the mean MRE11 score was found to be 5.00 (SD = 
3.00). In this subgroup of patients, MRE11 score (high [6–12] versus low [0–5]) was not found 
to be associated with OS in either the univariate or multivariate analysis (HR = 1.21, P = 0.48).  
The immunostaining method used for adenomas was the standard IHC procedure. However as 
so few tissue cores of these samples were available we did not include them in our data analysis 
as any interpretation will not be meaningful with such a small number.  
 
 
 
 
 
 
4.5 Results – ATM and MRE11 combinatorial marker panel  
 
Given the associations so far described between ATM, MRE11 and various features of rectal 
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cancer, we next sought to determine whether ATM and MRE11 could be used in combination 
to predict rectal cancer outcomes better than either marker alone.  
 
The results arising from this approach have been recently published. Citation: Ho, V., Chung, 
L., Revoltar, M., Lim, S.H., Tut, T.G., Abubakar, A., Henderson, C.J., Chua, W., Ng, W., Lee, 
M., et al. (2016). MRE11 and ATM expression levels predict rectal cancer survival and their 
association with radiotherapy response. PLoS One. 11, e0167675. 
 
4.5.1 Patient Populations 
 
The patient samples used for the study of ATM and MRE11 in combination is the same as 
described for MRE11, and is shown in Table 4.1. 
 
4.5.2 Establishment of the combined two-protein biomarker panel 
 
Firstly, ATM and MRE11 expression at the protein level in the TC were analysed in a forward 
and reverse binary logistic regression analysis, using a dataset of immune-histochemical 
scoring derived from 257 tumour samples and 255 normal tissue (NCT) samples. The final 
biomarker model gave an average receiver operator characteristic area under the curve (ROC-
AUC) value of 0.849 for both proteins combined.  
 
Similarly, ATM and MRE11 protein expression levels in the TP (tumour, n = 258; normal, n 
= 255) were also tested (see Table 4.5), with the model giving an average ROC-AUC value of 
0.837. The sensitivity and specificity of the two-protein combined panel were 80.9% and 
70.3% for the TC, and 61.6% and 48.8% for the TP, respectively.  
 
Table 4-5 Performance of the two protein panel classification models 
Model Tumour Normal Sensitivity 
(%) 
Specificity 
(%) 
Overall 
(%) 
ROC-
AUC 
Combined TC* 257 255 80.9 70.3 75.6 0.849 
Combined TP† 258 255 61.6 48.8 55.2 0.837 
*Tumour centre; †Tumour periphery 
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4.5.3 Relationship between ATM and MRE11 protein expression and 
clinicohistopathological features 
 
Given the promising results, we subsequently examined the association between ATM and 
MRE11 expression levels and clinicohistopathological variables independently.  
 
In order to do this, ATM protein expression was first analysed in 259 central and 260 peripheral 
tumour cores. Samples from the TC were found to display high levels of expression in 84% of 
cases, and low expression was detected in 16% of samples. The samples from the TP showed 
high expression in 79% of samples, and low expression in 21%. When both sites were 
compared, a higher level of ATM expression was found in the TC (mean (M) = 6.84) when 
compared to the TP (M = 5.28). This difference was found to be statistically significant (P< 
0.001). 
 
Within the cohort, ATM expression was found in 199/228 (87%) of adjacent normal mucosa, 
and 204/250 (82%) of distal normal mucosa samples. Furthermore, ATM expression was found 
to be higher in the normal mucosa taken from near the tumour (M = 6.43) compared to samples 
taken from sites more distal to the tumour (M = 4.25). Again, this observation was found to be 
statistically significant (P< 0.001). When comparing tumours and healthy tissue, ATM 
expression in both the TC and TP was found to significantly higher than in distal normal 
mucosa (P< 0.001 and P< 0.005, respectively), although expression was not significantly 
different to that in the adjacent normal mucosa. 
 
Low ATM expression in the TP was found to be associated with older patient age at the time 
of surgery (P = 0.013) and higher histologic grade (P = 0.044) (refer to Table 3.2). We did not 
find there to be a correlation with sex, TNM category, vascular invasion, or perineural invasion. 
In addition, expression of ATM in the TC was not associated with any clinicohistopathological 
variables. 
 
MRE11 expression in the TC was high in 45% of cases, and low in 52%. MRE11 expression 
in the TP was high in 56%, and low in 44% of samples, and the mean weighted scores were 
significantly different between TC and TP (5.5 versus 5.8, P< 0.05, by paired t-test).  
 
The mean MRE11 score was 4.2 for both adjacent and distal normal tissue, a score that was 
significantly different to that for both the TC and TP (P< 0.001). We did not find any significant 
associations between MRE11 score in the TC or TP, and clinicohistopathological 
characteristics (Table 4.6). 
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Table 4-6 Association between MRE11 expression and clinicohistopathological data 
 
Tumour centre Tumour periphery  
Low High P value Low High P value  
n (%) n (%) 
 
n (%) n (%) 
 
Sex 
      
Male 65.4 68.1 0.69 65.2 66.7 0.9 
Female 34.6 31.9 
 
34.8 33.3 
 
Age 
      
<71 48.5 42.9 0.38 42.6 48.6 0.38 
71+ 51.5 57.1 
 
57.4 51.4 
 
Tumour stage 
      
T1–2 33.1 33.6 1 30.4 34.8 0.5 
T3–4 66.9 66.4 
 
69.6 65.2 
 
Node stage 
      
Negative 49.6 55.5 0.38 46.4 59.3 0.06 
Positive 50.4 44.5 
 
53.6 40.7 
 
Metastasis stage 
      
M0 94.3 90.6 0.32 94.1 91.6 0.61 
M1 5.7 9.4 
 
5.9 8.4 
 
Grade 
      
1–2 90.4 94.1 0.35 92.2 92.4 1 
3 9.6 5.9 
 
7.8 7.6 
 
Vascular invasion 
      
Absent 74.4 76.5 0.77 72.8 78.2 0.38 
Present 25.6 23.5 
 
27.2 21.8 
 
Perineural invasion 
      
Absent 81.2 87.4 0.23 81.6 85.2 0.5 
Present 18.8 12.6 
 
18.4 14.8 
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4.5.4 Association between combined expression levels with pathological 
variables and prognosis 
 
Next, we examined the possible association of clinicohistopathological characteristics and 
survival outcomes with the ATM/MRE11 two-protein combined panel. Figure 4.3A shows 
representative immunohistochemical staining of high and low/absent ATM and MRE11 
expression levels in rectal cancer tissues. Results from the combined marker analysis differed 
from our initial single biomarker studies of ATM and MRE11 alone, in that a high combined 
expression of ATM and MRE11 was significantly associated with a number of 
clinicohistopathological variables. These included neoadjuvant status (P=0.001 for TC), 
TRG (P=0.03 for TC, P=0.011 for TP), age (P=0.02 for TP), and nodal stage (P=0.042 for 
TP) (Table 4.7), demonstrating the informative power of this approach. 
 
Table 4-7 Associations between the combined expression of ATM and MRE11 in the TC and TP and 
clinicohistopathological data 
 
Combined TC Combined TP 
Lo
w 
(%) 
Hig 
(%) 
P 
valu
e 
Lo
w 
(%) 
Hig
h 
(%) 
P 
valu
e 
Sex 
Male 62.5 
67.
3 
0.562 65.3 66.8 0.381 
Female 37.5 
32.
7 
 34.7 33.2  
Age 
<70 43.8 
46.
3 
0.747 42.9 46.0 0.020 
>70 56.2 
53.
7 
 57.1 54.0  
Tumour 
stage 
T1–2 50.0 
29.
5 
0.496 38.3 31.9 0.877 
T3–4 50.0 
70.
5 
 61.7 68.1  
Node stage 
Negativ
e 
60.0 
52.
4 
0.840 44.7 55.8 0.042 
Positive 40.0 
47.
6 
 55.3 44.2  
Metastasis 
stage 
M0 97.8 
91.
6 
0.282 100 91.1 0.252 
M1 2.2 8.4  0 8.9  
Grade 
1–2 93.8 
92.
1 
0.508 89.8 92.9 0.131 
3 6.2 7.9  10.2 7.1  
Vascular 
invasion 
Absent 82.6 
74.
6 
0.231 77.1 75.6 0.380 
Present 17.4 
25.
4 
 22.9 24.4  
Perineural 
invasion 
Absent 84.8 
83.
6 
0.928 85.4 83.3 0.500 
Present 15.2 
16.
4 
 14.6 16.7  
Adjuvant No 70.0 
69.
5 
0.483 65.0 70.9 0.55 
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therapy 
Yes 30.0 
30.
5 
 35.0 29.1  
Neoadjuvan
t therapy 
No 65.2 
81.
1 
0.001 71.7 79.9 0.64 
Yes 34.8 
18.
9 
 28.3 20.1  
Tumour 
regression 
grade 
0–2 31.6 8.0 0.030 33.3 6.0 0.011 
3 68.4 
92.
0 
 66.7 94.0  
 
 
 
By Kaplan Meier survival analysis, a high score for the two-protein combined expression 
panel in the TC was significantly associated with worse OS (P=0.003) and DFS (P=0.035) 
(Figure. 4.3 B and C). However, no significant survival difference was seen amongst high 
or low groups for expression in the TP (OS, P=0.208 and DFS, P=0.748; Figure.4.3 D and 
E, respectively). 
 
By univariate Cox regression analysis, a high two-protein combined status in the TC was 
significantly associated with reduced DFS (combined TC high versus low: HR=1.944, 
95%CI 0.037–3.645, P=0.038) (Table 4.8). Finally, by multivariate Cox analysis (adjusted 
for combined expression of ATM and MRE11, and perineural invasion), the two-protein 
combination panel (HR = 2.178, 95%CI 1.115–4.256, P=0.023) as well as perineural 
invasion (HR=2.183, 95%CI 1.222– 3.899, P=0.008) remained significantly associated 
with DFS (Table 4.8). 
 
 
 148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
Figure 4-3 Association between combined protein expression levels of ATM and MRE11 in rectal cancer tissues 
and survival 
(A) Representative immunohistochemical staining of ATM and MRE11 in rectal cancer tissues. Scale 
bar=200μm. Staining for each protein was scored as high or low, as described in Chapter 2.  
(B) Overall survival according to combined protein expression levels of ATM and MRE11 was determined 
by Kaplan−Meier survival analyses and compared using the log-rank test. Patients with high combined 
protein expression levels of ATM and MRE11 in the TC (greenline) showed significantly worse OS 
than those with low expression (blueline; P=0.003). 
(C) Similarly, patients with high expression levels in the TC (greenline) exhibited worse disease-free 
survival than those with low expression (blueline; P=0.035). 
(D) (E)When measured in the TP, no significant survival difference was seen between the high- and low- 
expression groups for overall survival (P=0.208) or disease-free survival (P=0.748). 
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Table 4-8 Cox regression analyses of combined TC expression level with clinicohistopathological variables and 
DFS. From: Ho et al (2016) 
 
 
 
4.5.5 Prognostic implications of two-protein combined panel in LN-  
positive and neoadjuvant radiotherapy subgroups 
 
 
As noted above, the DFS interval of rectal cancer patients overexpressing of the two-
protein combined panel was significantly worse than that of patients showing lower 
expression. When patients were grouped according to LN involvement, high expression 
of the two-protein combined panel was again associated with decreased DFS in patients 
with LN-positive tumours (P = 0.029; Figure 4.4B), but not in those with LN-negative 
tumours (P = 0.480; Figure 4.4A). By multivariate Cox analysis, expression of the two-
protein combined panel in the TC in the LN positive subgroup significantly correlated with 
DFS (HR = 3.474, 95% CI 1.054–11.451, P = 0.041) (Table 4.8). 
 
We next sought to determine any associations with neo-adjuvant radiotherapy in our 
cohort. The OS estimates in the subgroup that received neo-adjuvant radiotherapy are 
shown in Figure 4.4 C, demonstrating that a higher combined expression level is 
significantly associated with worse OS (P=0.024).Similarly, the DFS of patients that 
underwent radiotherapy and overexpressed the two-protein combined panel was also 
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significantly worse than that of patients with lower expression levels (Figure 4.4D, 
P=0.028).These results demonstrate that the MRE11/ATM two-protein panel has specific 
potential as a predictive marker of the tumour response to radiotherapy.  
 
 
 
Figure 4-4 Kaplan-Meier survival analysis of ATM/MRE11  
(A) and (B) respectively show survival curves of high (greenline) and low (blueline) ATM/MRE11 two-protein 
expression groups in lymph node (LN) negative and LN positive rectal cancers. These show the effect of LN 
status on the association between expression levels and disease-free survival (DFS).  
(C) and (D) respectively show overall survival (OS) and DFS survival curves of 54 patients who received 
preoperative radiotherapy in terms of high (greenline) and low (blueline) two protein expression groups. Worse 
OS (P=0.024) and DFS (P=0.028) were seen with high expression. 
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4.5.6 ATM and MRE11 expression in relation to TRG 
 
Finally, to investigate the relationship between TRG and tissue levels of ATM and MRE11 
(and the two- protein combined panel), univariate analysis was carried out using the 
Mann−Whitney U test. A significant association was found between increasing TRG, and 
the TC expression levels of MRE11 (P=0.015, Figure 4.5B) and that of the combined two-
protein panel (P=0.011, Figure 4.5C). 
 
The discriminatory power of each protein biomarker, and that of the combinatorial panel, 
were further characterised using an ROC-AUC analysis of good response (TRG 0-2) 
versus poor response (TRG3) groups. The average ROC-AUC was found to be 0.745 for 
the combined panel, compared with 0.618 for ATM, and 0.711 for MRE11 proteins 
(Figure 4.5 D). These results suggest that the combinatorial biomarker provides excellent 
discrimination between good and poor tumour responses after radiotherapy.  
 
 153 
 
 
Figure 4-5 ROC-AUC analysis of ATM, MRE11, and combined protein panel expressions with tumour 
regression grade (TRG) 
(A−C) Box plots show levels of ATM, MRE11, and their combined expression in the TC categorized by TRG as 
0–2 (good response) or 3 (poor response). The association between protein expression with TRG was examined 
by Mann−Whitney U test (ATM, P = 0.27; MRE11, P = 0.015; and combined proteins, P = 0.011).  
(D) Receiver operating characteristic (ROC) curve analysis comparing the performance of ATM and MRE11 
alone with the combined 2-protein panel. It should be noted that cc is actually referring to TC and cp is referring 
to TP 
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4.6 Concluding remarks 
 
In contrast to what we discovered with regards to ATM expression in the previous chapter, 
MRE11 expression alone was not found to affect the survival outcomes of patients with rectal 
cancer.  
 
The level of MRE11 protein in the TC or TP, however, was found to influence patient outcomes 
when participants were positive for perineural invasion, metastasis, or high-grade disease. 
Accordingly, knowledge of MRE11 gene/protein expression status may affect clinical 
decision-making, and improve patient welfare. 
 
The ATM/MRE11 combinatorial panel developed as part of this study merits further 
investigation as a clinical predictive marker of the tumour response to neoadjuvant 
radiotherapy.We accept the limitation of a small sample size of pretreatment biopsies in our 
study rendering any interpretation of pretreatment data meaningless. Future studies however 
would evaluate the results of pretreatment biopsies in a predictive model to determine cases 
responding optimally to radiotherapy.  
 
In conclusion, our data suggest that optimal rectal cancer management may benefit from 
tailored treatment based on biomarker expression.  
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5.1 Introduction 
 
This chapter concerns the DNA DSB repair protein, NBS1, another critical member of the 
MRN complex discussed previously (Kobayashi et al., 2004); emphasising specifically the role 
of chromosomal integrity mechanisms in rectal oncogenesis.  
 
Taking a similar approach to what has been described in previous Chapters, NBS1 protein 
expression will be interrogated by immunohistology in tumour samples obtained from rectal 
cancer patients. By so doing – and remembering that results relating to RAD50 will be covered 
in Chapter Six – a more complete picture of how this complex/pathway contributes to rectal 
cancer pathogenesis will be clarified, as discussion of which will follow in Chapter Seven. 
Furthermore, the information here presented is relevant to the results of a combinatorial panel 
(composed of MRE11, NBS1 and RAD50) in the same clinical context, which is presented in 
Chapter Six.  
 
In this chapter, different members of the same complex are studied in tandem, although the 
statistical benefits and increased biological information associated with the use of 
combinatorial biomarker panels has furthered methods to determine panels de novo (Milward 
et al., 2014), from hypothesis-free networks built from genome-wide datasets (Tanić and Beck, 
2017).  
 
5.1.1 NBS1: biochemistry and mechanisms of action  
 
At present, NBS1 is also commonly referred to as Nibrin, and has also previously been known 
as cell cycle regulatory protein p95, as well as Nijmegen breakage syndrome protein 1 (from 
where it got its now-common abbreviated name). The varied nomenclature history is 
demonstrative of the long-held interest in this gene/protein, and its notable association with 
human clinical diseases (Zhou and Elledge, 2000). Indeed, defects in the NBN gene (located 
on human chromosome 8q21) encoding the NBS1 protein, lead to aberrant DNA repair and 
chromosomal instability (Wu, 2016), which has effects across the entire organism. 
 
As with the other members of the MRN complex, NBS1 is highly conserved (Zdobnov et al., 
2017). NBN can trace its origins beyond the beginning of eukaryotic life (Speir et al., 2016). 
Important studies have shown the role of this protein in organising and maintaining DNA 
integrity and function in the plant, Arabidopsis thaliana, where NBS1 was found to participate 
in DNA recombination during the very early stages of meiosis; which it achieves in tandem 
with ATM (Waterworth et al., 2007).  
 
In-keeping with its best-known role across taxa, the majority of NBS1 at any one time is found 
in the cell’s nucleus, notably in nuclear dots (or PML bodies) interspersed between chromatin 
folds (Naka et al., 2002). Thus, it is located in close proximity to potential lesions that arise 
during DNA replication, and in association with many of the co-factors involved in its function 
(Misteli and Soutoglou, 2009).  
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A primary component of nuclear dots has been shown to be the protein, sp100, which in 
response to interferons (such as those released during viral infection), drive transcription 
(Misteli and Soutoglou, 2009), and presumably additional mechanisms exist to regulate PML 
body utility. Sp100 has also been shown to recruit NBS1 to nuclear dots (Naka et al., 2002). 
Interestingly, the Human Herpes Virus protein, ICP0, has been found to disrupt nuclear dot 
formation (Hutchinson et al., 2002). As will be discuss below, ICP0 is also a key regulator of 
the MRN complex, and NBS1. Several common human variants in NBS1 also lead to nuclear 
foci formation disruption (Tauchi et al., 2001). 
 
NBS1 is also associated with telomeres and is known to move into the cytoplasm when 
required, such as during heat shock (Seno and Dynlacht, 2004). Again, and in common with 
other members of the MRN complex, NBS1 has been shown to have crucial roles in 
maintaining telomere integrity, cell-cycle progression, and the regulation of meiosis, aside 
from its role in DSB repair (Zhang et al., 2006). In the context of DSBs, ATM first 
phosphorylates members of the MRN complex (Lee and Paull, 2007), including NBS1, as well 
as H2AX. These phospho-residues on H2AX are detected by the BRCT and FHA domains of 
NBS1 (Kobayashi et al., 2002). Activated NBS1 is also known to further regulate DNA damage 
signalling through effects on ATM, ATR and PRKDC, and is also involved in bringing MRE11 
and RAD50 into the proximity of DSBs in a H2AX-dependent manner (Enriquez-Rios et al., 
2017). Furthermore, NBS1 is also a potent cell cycle regulator, and has been shown to regulate 
both the G1 and G2 checkpoints (Komatsu, 2016).   
 
In mammals, complete abrogation of the gene encoding NBS1 leads to embryonic lethality 
(Zhu et al., 2001), as shown here in mice, and in agreement with the hypothesis that in 
individuals with NBN mutations, some level of gene and protein function remains (i.e. the 
mutants are still compatible with maintaining cell viability up to a point). Genes displaying 
embryonic lethality illustrate the absolute requirement of said element for life; being 
irreplaceable in certain circumstances; which may be genetically or developmentally 
determined, or driven by the environment. Furthermore, disruption of different segments of the 
gene have been associated with female infertility due to oogenesis failure, again highlighting 
its important role in germ-cell development (Kang et al., 2002).  
 
According to the respected IntAct database of the EBI EMBL, which is routinely updated 
(Orchard et al., 2014), and which quantifies protein-protein binary interactions at the sub-
cellular level, the proteins most associated with changes in NBS1 expression are H2AX, TCOF, 
MDC1 and VRK1. We know about some of the mechanisms of H2AX already; TCOF may be 
involved in the maturation of rRNA (something that needs to be curtailed when halting cell 
growth, as occurs during infection (Zhang and Kuspa, 2009)); MDC1 recruits and anchors 
proteins to DSB lesions (Stucki and Jackson, 2006); and VRK1 has been shown to promote the 
stability of p53 (Vega et al., 2004); to name but a few functions of these associated co-factors, 
all of which are central to safeguarding cellular genomic DNA and the cell cycle.  
 
These interactions and the functions of NBS1 are mediated by its structure. The primary 
isoform of the human protein is 754 amino acids in length, and has a mass of approximately 
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85 kDa(The UniProt Consortium, 2015). The N-terminal region of the protein is characterised, 
first by a forkhead-associated domain (FHA) and secondly by a BRCT domain. The FHA 
domain recognises phosphor-peptides (which widely regulate cellular physiology, and this 
domain has been reported to be essential for T cell development (Weng et al., 2015)), as does 
the BRCT domain, which is known to be important in proteins responsible for cell cycle 
control, and is widely known to participate in cancer development through studies of breast 
cancer, where it was named (Yu, 2003). 
 
Part of the BRCT domain also confers the capacity for NBS1 to interact with SP100 (the major 
component of nuclear dots), whilst the middle section of the protein is involved in mediating 
interactions with the central metabolic regulators mTOR, MAPKAP1 and RICTOR. Indeed, 
residues 221-402 of NBS1 mediate the interaction of the protein with the 
mTOR/RICTOR/SIN1 complex (Wang et al., 2013), which drives AKT activity – a key 
regulator of cell growth and proliferation, as well as glucose utilisation and apoptosis.  
 
At the C-terminal end of the protein lie the nuclear localisation signal sequence, and the 
EEXXXDDL motif, which mediates the interaction of NBS1 with ATM (Passananti and 
Fanciulli, 2007). NBS1 has been shown to activate ATM under various conditions 
(Difilippantonio et al., 2005), and provides a critical link between the phosphatase and the 
MRN complex. Antibody-binding epitopes have also been discovered at the C-terminal end, 
which may regulate the function of NBS1. Indeed, the increasing understanding of intracellular 
antibody responses has opened a number of interesting avenues, and antibody-coated 
pathogens, for example, in the intracellular space, may be detected by NBS1 (McEwan et al., 
2013).  
 
As mentioned earlier, and like the proteins ATM and MRE11, NBS1 has also been associated 
with viral infectivity in humans and primates. In an interesting study from 2016 study by Lou 
and colleagues, an intrinsically disordered region of NBS1 was found to represent a species-
specific barrier to Herpes Simplex Virus 1 in primates; i.e. some primates carried a variant 
allowing for HSV infection (Lou et al., 2016). Further analysis of the variants that promoted 
infection revealed that primate NBS1 interacted with viral ICP0 via a region of structural 
disorder in NBS1. Thus, at least two outcomes are possible. The human protein senses the virus 
to halt infectivity (and some variants may be better at this than others), or the virus hijacks the 
protein via such a disordered region. Both are likely to occur, given the pathogenic arms race 
and the reported associations of other MRN complex members with anti-viral responses, both 
discussed previously.  
 
The authors of this study extend their analyses to a further 1,237 mammalian proteins known 
to bind to viruses, and found an enrichment for similar disordered domains in these proteins, 
compared to non-interacting factors (Lou et al., 2016). It is tempting to speculate that what we 
here refer to as disorder, actually represents fine variability in the structural methods required 
to identify pathogens (as has been described for the T-cell receptor that can selectively responsd 
to peptide antigens of 8 amino acids) by such putative pattern recognition receptors.  
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Related studies have explored this area further, and it has been shown that the interaction 
between Herpes viruses and the MRN complex is profound and also includes the viral protein 
ICP8, which is known to also modulate the function of RAD50, MRE11, and PRKDC 
(Balasubramanian et al., 2010). Many authors have suggested that the MRN complex is 
required for Herpes virus infectivity, presumably by means distinct from the mechanisms in 
primates, discussed above. Further high-resolution structures of these components, and 
genome-wide CRISPR screens (Puschnik et al., 2017), are likely to provide additional 
information in this respect. Given the ubiquitous nature of viruses, bacteriophages and other 
micro-organisms over evolutionary time, it is likely that we are only beginning to understand 
the means by which our cells sense foreign material and relay that information to other cellular 
components; maybe sometimes we need to do as the virus tells us, and the protective effects of 
viral infections against a range of ailments are well established (Furman et al., 2015; Staras et 
al., 2006). Further functional analysis of the NBS1 protein showed that it has important 
transcription factor binding domains, allowing it to regulate gene expression (Ashburner et al., 
2000). Indeed, positive and negative regulation of gene expression is essential to maintain cell 
cycle control.  
 
Hence, NBS1 has diverse, important roles in all eukaryotic cells. Before moving on to the role 
of NBS1 in cancer, and rectal cancer in particular, it is useful to consider the clinical 
manifestations of Nijmegen breakage syndrome (NBS), from where the protein gets its name, 
as it is well described, systemic and insightful into the protein we here study. Thankfully, 
genetic testing has for decades been helping heterozygous parents (carrying NBN mutations) 
inform their future parenthood choices, as well as helping diagnose new cases (Varon et al., 
2000). 
 
In the autosomal recessive, congenital disorder, NBS (also known as ataxia telangiectasia 
variant 1), patients who all carry mutations in NBN, display several significant clinical features 
(Varon et al., 2002). For example, patients are typically characterised by a short stature, 
microcephaly, immunosuppression (and an increased infectious disease burden), cognitive 
dysfunction, vitiligo, and a common skeletal morphology leading to distinctive facial features 
(large forehead, large ears, small mandible and prominent nose) and many other conditions - 
including an increased risk to cancer (Berardinelli et al., 2013).  
 
The inheritance pattern further demonstrates the redundancy in the DSB repair pathway and 
the potent tumour suppressor effect of NBS1, although it should be noted that heterozygous 
patients display heightened radiation sensitivity, and have been found to have fertility defects, 
but in the absence of the typical facial deformity of homozygous patients (Warcoin et al., 2009).  
 
At present, estimates suggest that patients carrying some of the most penetrant lesions in NBS1 
are 50 times more likely to develop cancer than non-affected individuals (Kondratenko et al., 
2007). Strikingly, more than 40% of patients with a common deletion in the gene (described 
below) develop cancer before the age of 21 (Kondratenko et al., 2007). The life expectancy is 
estimated to lie between 30-40 years with routine medical monitoring and access to the latest 
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treatment, although estimates vary widely and many patients do not reach adulthood (The 
International Nijmegen Breakage Syndrome Study Group, 2000).   
 
Historically, it appears that a large proportion of patients with Nijmegen breakage syndrome 
are of Slavonic origin, with many carrying a typical 5 nucleotide deletion (657-661 
delACAAA) in the gene. Additional truncating mutations have been found in other patients 
with distinct haplotypes (International Nijmegen Breakage Syndrome Study Group, 2000). 
These truncated variants are less able to efficiently repair DNA DSB and participate in other 
essential cellular processes, and thus dysregulation arises. In a recent study looking at the 
Czech population, the frequency of heterozygotes for this mutation was found to be 1: 158-170 
people (Seeman et al., 2004; Tauchi et al., 2002); with slightly lower rates being reported in 
other affected populations. Why this variant was maintained within this and other populations 
is unknown, but it may have served a selective advantage epistatically or in respect to the 
environment.  
 
In Nijmegen breakage syndrome patients, microcephaly and decreased body growth is apparent 
from parturition in the majority of affected individuals, and normally becomes a progressive 
microcephaly where the brain remains further stunted in proportion to the rest of the body 
(Digweed and Sperling, 2004; Varon et al., 2000). By the age of 3, the majority of patients 
show the characteristic facial morphology associated with the condition. Notably, however, 
intellectual development does not appear to be aberrant before the age of 2, perhaps as during 
this time the body is investing energy into rapid tissue growth and environmental adaptation 
(i.e. in immunity; see Dopico et al., 2015), and not into the formation of social contacts, upon 
which many diagnoses of intellectual disability are made. Furthermore, given that the majority 
of infants do not begin to show preference for phonemes in their native language until 
approximately 6-7 months of age, defects in speech are also likely to be missed by parents and 
professional healthcare practitioners (Purves et al., 2001). Thus, it is likely that many of the 
defects and mechanisms leading to later observable phenotypes in these patients begin in utero 
as mutations progressively accumulate. Patients with NBN mutations are highly predisposed to 
the development of non-Hodgkin lymphoma, with many patients acquiring the disease during 
their teenage years (Seemanová et al., 2007). 
 
Notably, affected individuals also show profound defects in immunity, presumably because 
many haematopoietic lineages undergo rapid, extensive clonal expansion and turnover in 
response to homeostasis and pathogens, and also due to genomic recombination in adaptive 
immunity. Given the high amount of DSBs generated during V(D)J recombination during 
thymocyte development and early B lymphocyte development (Murphy et al., 2008), NBS1 
defects are likely to impact the process. Indeed, NBS1 and H2AX (introduced previously) have 
been shown to form nuclear foci that co-localise with the T cell receptor alpha locus in response 
to RAG-mediated cleavage at designated VDJ junctions (Chen, 2000). Furthermore, given that 
many specialised immunological lineages (such as those that show memory to pathogens) 
depend upon tissue-resident stem cells to replenish the surveying lymphocyte pool (Gattinoni 
et al., 2011), a similar clinical picture may emerge in these patients, as has been found to occur 
in multiple myeloma patients; where seamlessly endless putative cancer cells are generated, 
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with many clones showing hallmark cancer features (such as dysregulated proliferation), but 
with protracted periods of sub-clinical disease (Guedez and Stetler-Stevenson, 2010). 
Furthermore, in NBS patients, decreased IgG and IgA levels – which require high-fidelity DNA 
recombination in co-operation with RAG genes and plasma cell population expansion to arise 
– contribute to an increased risk of respiratory infections such as pneumonia, bronchitis and 
sinusitis; further demonstrating the link between the processes. Increased infection will lead to 
increased host cell death, mutation accumulation, and cancer predisposition.  
 
Aside from Nijmegen Breakage Syndrome, NBS1 mutations have been associated with the 
development of aplastic anaemia, in which the bone marrow fails to produce adequate numbers 
of erythrocytes and haematopoietic cells. Consequently, patients exhibit pancytopenia and 
marrow hypoplasia (Shimada et al., 2004).  
 
5.1.2 Associations between NBS1 and cancer 
 
As discussed above the case of Nijmegen breakage syndrome patients, mutations within NBN 
are known to be associated with diverse types of cancer. In addition to non-Hodgkin 
lymphoma, and rectal cancer (which will be discussed in detail below), NBN mutations or 
defective function, have been associated with several different types of brain tumour, such as 
glioma and medulloblastoma (Ciara et al., 2010; Piekutowska-Abramczuk et al., 2010). 
Mutations in this locus have also been associated with the development of tumours in skeletal 
muscle, such as rhabdomyosarcomas (Seemanová et al., 2007).  
 
NBN mutations also represent an important contribution to breast cancer, and expression of 
NBS1 has been shown to be a negative prognostic marker in lung and pancreatic cancer (Uhlen 
et al., 2017).  
 
Polymorphisms in the NBS1 locus have been associated with colorectal cancer development, 
with a SNP in the 3’-untranslated region (rs2735383C/G) being the most associated with 
disease development (Li et al., 2015). Perhaps variation in this region underpins differences in 
NBS1 expression, impinging upon the ability of the protein to efficiently repair DNA damage. 
Indeed, follow-up work from the association revealed the rs2735383 C allele to have reduced 
binding affinity to the transcriptional regulator has-miR-509-5p, reducing expression (Li et al., 
2015). This fits in with the studies we have previously discussed, in which decreased DSB 
repair proteins are associated with increased cancer risk.   
 
A 2013 meta-analysis attempted to combine the available genetic association data concerning 
NBS1 and cancer to date. The work, based on more than 60 peer-reviewed publications and 
nearly 40,000 patients, showed rs275383 to be the most associated markers with cancer 
susceptibility, with an OR of 1.12 (Gao et al., 2013). The variants, I171V, 657del5 and R215W 
were also associated with cancer risk, albeit with each of them having low penetrance. 
Furthermore, studies from Uhrhammer and colleagues in France, found human 8q21.3 to 
harbour a gene with abundant allelic imbalance and with a tumour suppressive effect in 
colorectal cancer, namely NBS1 (Uhrhammer et al., 2000), although this is disputed (Varon et 
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al., 2002). This allelic imbalance has since been confirmed in other studies (Varon et al., 2002), 
suggesting that deleterious alleles contribute to cancer development; remembering that 
heterozygosity is rarely sufficient to cause disease.  
 
In a Polish population (Slav populations being predisposed to lesions in this region), the 
R215W variant was found to be the most associated with colorectal cancer development, with 
the aforementioned 657del5 mutation being most associated with melanoma and non-Hodgkin 
lymphoma (Steffen et al., 2004). Furthermore, in this study, those with the 657del5 mutation 
were more likely to develop secondary tumours.  The 657del5 mutation has also been found in 
colorectal and stomach cancer patients (di Masi and Antoccia, 2008), and deep-sequencing of 
additional patients is likely to reveal additional germ-line and somatic variants associated with 
cancer development.  
 
Given the robust and reproducible associations reported between NBS1 and cancer, genetic 
testing of this locus has long been in the clinic, helping people avoid cancer risk factor and 
develop the psychological mechanisms which may be required to cope with such a condition. 
Indeed, the 657del5 mutation is routinely screened for in people with a history of breast cancer 
(Heikkinen et al., 2006). In the future, it is hoped that high-resolution, individual genetic data 
will allow for prophylactic consultation and disease prevention.  
 
As part of the MRN complex, expression of NBS1 has also been described as an important 
prognostic marker. In a cohort of gastric cancer patients, Altan and colleagues report that high 
expression levels of the complex are associated with poor prognosis and chemoresistance 
(Altan et al., 2016). Similarly, work by Lee, Park and Lee show that NBS1 expression in 
epithelial ovarian cancer tissue was associated with advanced stage, high grade disease, and 
patients with high expression survived on average 48 months less than those with low/negative 
expression, demonstrating the applicability of NBS1 to inform upon the disease course (Lee et 
al., 2015). Furthermore, NBS1 expression levels also predicted the recurrence of epithelial 
ovarian cancers after treatment, further illustrating how NBS1 is associated with detrimental 
clinicohistopathological features.  
 
Additional work by Wokolorczyk and colleagues has also shown worse survival in prostate 
cancer patients carrying the 657del5 mutation in NBS1 (Wokolorczyk et al., 2012). Ehlers and 
Harbour has shown NBS1 expression to also be a useful prognostic marker in uveal melanoma, 
with high expression again being associated with worse survival (Ehlers and Harbour, 2005). 
As we have seen in other examples, the combinatorial panels of MRN complex proteins have 
been associated with the response to radiotherapy (Söderlund et al., 2007), although published 
studies exploiting NBS1 alone as a marker are lacking.   
 
Several studies have also reported that different NBN mutations can influence chemotherapy 
success, as has been shown in non-small cell lung cancer, where platinum-based therapeutics 
were affected by rs1805794 and rs13312840, both of which lie within NBS1 (Xu et al., 2012), 
although why this occurs remains unknown.  
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5.2 Hypothesis and study overview 
 
Given the role of the MRN complex in cancer, as discussed, and the evidence suggesting NBS1 
could have a pathological role in rectal cancer, we here investigated whether expression of this 
protein in rectal cancer tissue was associated with patient survival outcomes and the response 
to radiotherapy. 
 
To achieve our aims, we used immunohistochemical techniques and validated reagents to 
survey NBS1 expression in primary pathological samples, as described previously.  
 
5.3 Results   
 
Whilst convincing associations have been demonstrated by our studies with regards to ATM, 
MRE11 (and will be shown for RAD50 in the following Chapter), NBS1 proved to be the least 
informative marker in our studies; where expression levels in rectal tumours had weaker 
predictive value with respect to our known clinicohistopathological variables.  
 
Nevertheless, demonstrating null associations is as important as demonstrating positive ones, 
especially when studying associations between different members of the same 
pathway/process; provided, of course, that the study is sufficiently powered statistically to 
detect the differences hypothesised to exist. With this in mind, and as a limited number of 
robust associations with respect to NBS1 were discovered in our relatively small study, large, 
independent rectal cancer cohorts should be studied to further delineate the mechanistic and 
clinical associations for NBS1.   
 
5.3.1 Patient populations 
 
A total of 266 patients were included in this study, similarly to what has been described in 
previous Chapters. In total, 176 (66.2%) patients were male, whilst 90 (33.8%) were female. 
The median age of participants whose samples were used in the study was 72 years (range: 35–
100 years) (Table 5.1).  
 
Of the 246 patients involved, 77 (31.3%) were treated with radiotherapy, and from these, 55 
(71.4%) received preoperative therapy. During the time of sample collection, patients were 
followed for a median period of 3.16 years (range: 0−12.6 years), and the median time to death 
in the cohort was found to be 2.5 years after surgery (ranging between 0−11.1 years). 
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Table 5-1 Patient cohort characteristics for the NBS1 study  
 
All Patients (%) 
Total, n 266 
Age median 72 
Sex 
 
Male 176/266 (66.2) 
Female 90/266 (33.8) 
Tumour stage 
 
T1–2 88/260 (33.8) 
T3–4 172/260 (66.2) 
Node stage 
 
N0 140/259 (54.1) 
N1–2 119/259 (45.9) 
Metastasis stage 
 
M0 223/240 (92.9) 
M1 17/240 (7.1) 
Histological Grade 
 
1–2 246/266 (92.5) 
3 20/266 (7.5) 
Vascular invasion 
 
Absent 201/263 (76.4) 
Present 62/263 (23.6) 
Perineural invasion 
 
Absent 220/263 (83.7) 
Present 43/263 (16.3) 
Radiotherapy 
 
Total 77/246 (31.3) 
Neoadjuvant 55/77 (71.4) 
Adjuvant 22/77 (28.6) 
 
 
 
5.3.2 NBS1 expression in tumour sections  
 
In this part of our investigation, NBS1 protein was detected using immunohistochemistry in a 
total of 260 samples. Following the staining scoring guidelines described in Chapter Two, 
analysed samples were taken from the tumour centre and periphery.  
 
In samples taken from the tumour centre, 239/260 (92%) showed positive staining for NBS1, 
whilst twenty-one samples (8%) did not show evidence of NBS1 expression. When samples 
taken from the periphery of the tumour were considered, again 239 samples stained positive 
for NBS1, whilst 21 were negative. Staining intensity was also found to be similar between 
both the tumour centre and periphery (Figure 5.1). 
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As the majority of samples stained positive for NBS1, this is predicted to reduce our ability to 
spot differences between sub-groups of patients in the study. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Representative examples of NBS1 staining (in rectal cancers) are shown.  
The left two images show negative NBS1 staining, whilst the right-hand panels show positive NBS1. Examples 
of positive and negative staining as shown for comparable anatomical sections of tumours on each row. 
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5.3.3 Association between NBS1 expression and clinicohistopathological 
features and prognosis 
Although fewer and less statistically robust associations were reported for NBS1, by Kaplan-
Meier survival analysis we did discover that positive expression in the tumour centre was 
associated with decreased OS (P = 0.02). Furthermore, we report a marginal association 
between NBS1 expression at this location with DFS (P = 0.059); as shown in Figure 5.2. In 
contrast, we did not observe any similar significant associations with NBS1 protein expression 
in the tumour periphery (Figure 5.3).  
Furthermore, univariate cox regression analyses demonstrated that positive expression of 
NBS1 in the cancer centre, was significantly associated with reduced OS (p = 0.025), but not 
with worse DFS (p = 0.066). These analyses also allowed us to interrogate the interacting 
effects of clinicohistopathological variables, and revealed that advanced tumour stage (P = 
0.009), vascular invasion (P = 0.001), perineural invasion (P < 0.001) and adjuvant 
radiotherapy (P = 0.01) were also associated with worse overall patient survival (Table 5.2).  
Furthermore, multivariate Cox regression analyses demonstrated that NBS1 expression in the 
tumour centre, vascular invasion, perineural invasion, and adjuvant therapy, remained 
associated with overall survival in our cohort, when interacting variables were taken into 
account. Please see Table 5.3.  
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Figure 5-2 Associations between NBS1 expression in the tumour centre and patient survival are shown. 
Results are from Kaplan-Meier Survival Analysis, as previously described.  
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Figure 5-3 Associations between NBS1 expression in the tumour periphery and patient survival are shown. 
A Kaplan-Meier Survival Analysis was again used.  
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Table 5-2 Univariate analysis of Nbs1 with disease-free survival and overall survival 
 
DFS OS 
Variables HR 95% CI P Value HR 95% CI P Value 
Nbs1 TC 
      
positive 2.370 0.944-5.950 .066 2.586 1.127-5.936 .025 
negative 
      
Nbs1 TP 
      
positive 1.199 0.518-2.778 .671 1.244 0.604-2.562 .554 
negative 
      
Age 
      
≤72 1.279 0.785-2.086 0.323 1.334 0.897-1.984 .155 
>72 
      
Sex 
      
Male 1.074 0.657-1.754 0.776 1.092 0.734-1.625 .664 
Female 
      
Tumour stage 
      
T1–2 1.643 0.983-2.747 .058 1.796 0.897-1.984 .009 
T3–4 
      
Node stage 
      
Negative 1.138 0.709-1.827 .593 1.454 0.987-2.140 .058 
Positive 
      
Grade 
      
1–2 1.646 0.712-3.804 0.244 1.561 0.836-2.916 .162 
3 
      
Vascular 
invasion 
      
Absent 1.188 0.650-2.171 .575 2.030 1.340-3.075 .001 
Present 
      
Perineural 
invasion 
      
Absent 2.534 1.310-4.157 0.001 2.48 1.594-3.859 <0.001 
Present 
      
Adjuvant 
therapy 
      
No 0.65 0.373-1.134 0.129 0.506 0.301-0.850 0.01 
Yes 
      
Neoadjuvant 
therapy 
      
No 1.147 0.672-1.957 0.616 0.63 0.556-1.427 0.63 
Yes 
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Table 5-3 Multivariate analysis of NBS1 with overall survival 
 
Multivariate 
Variables HR 95% P Value 
Nbs1 TC 2.396 1.016-5.650 0.046 
Vascular invasion 1.805 1.057-3.083 0.031 
Perineural invasion 2.537 1.408-4.573 0.002 
Adjuvant therapy 0.290 0.165-0.507 <0.001 
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5.4 Summary 
 
Although limited associations were discovered with respect to NBS1 expression in our 
samples, we do report that rectal cancers express significant levels of NBS1 protein. In-keeping 
with a role for the DDR pathway in maintaining genome integrity in the face of oncogenesis, 
and that the cancer has a high mutation burden.  
 
In addition, we are able to report marginal associations between NBS1 expression in the tumour 
centre and patient overall survival (as well as the expected clinicohistopathological 
associations reported; i.e. perineural invasion (PNI)-positivity), although additional samples 
need to be studied to confirm this observation; given the marginal statistical association.  
 
Patients in whom NBS1 staining was absent, perhaps due to disease or treatment stage, appear 
to drive the statistical association between high expression and overall survival. Sub-sets of 
rectal cancer patients with mutations in individual components of the DDR/MMR protein 
machinery would be informative for learning about disease development and pathway 
redundancy; such samples are likely to become increasingly available as more genomes get 
sequenced. Furthermore, the relative redundancy of different DDR proteins remains a 
controversial issue.  
 
These results suggest that NBS1 is a less informative marker than ATM, MRE11 and RAD50 
with respect to rectal cancer prognosis and disease pathophysiology, although, as noted, 
additional patient samples are required to convincingly demonstrate this.  
 
Further exploration NBS1 expression utility in this context will be explored in Chapter Six, 
where the protein is described as forming part of a three-component biomarker panel with other 
MRN complex members.  
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6.1 Introduction  
 
This chapter presents the results on the study of the expression of RAD50, the MRN complex 
ATPaseand a major activator and modulator of the complex’s activity in relation to rectal 
cancer radiotherapy response and survival.  
 
This Chapter will also cover our experiments concerned with the development and application 
of a combinatorial three-marker panel, composed of MRE11, RAD50 and NBS1 staining, to 
our rectal cancer samples.  
 
By using this combined approach, an increased amount of information can be captured 
concerning the status of the DSB repair machinery in every cancer sample. Given the marked 
cancer-associated variation in many of these genes, being able to monitor how the entire 
pathway is working is important. For example, using the three-marker panel, patients with 
reduced ATM expression but normal MRN complex expression could be distinguished, 
allowing different therapeutics to be used when genetics in considered concomitantly.  
 
6.1.1 RAD50: biochemistry and mechanism of action 
 
In humans, the DNA repair protein RAD50 (RAD50) is encoded by a gene of the same name 
that is found on chromosome 5 (5q31.1) (Figure 6.1). RAD50 is a member of the structural 
maintenance of chromosome (SMC) family (Ball and Yokomori, 2001), and being an ATPase, 
is thought to be the primary means by which the MRN complex exploits energy stored in ATP 
to facilitate strand repair (Hopfner et al., 2000a); although the precise mechanistic details of 
this function remain to be determined (Kinoshita et al., 2009). SMC proteins are also well 
known to participate in chromatin condensation, and high-order organisation of genomic DNA 
(Strunnikov, 1998).  
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Figure 6-1 The genomic context of RAD50 is shown via graphical output from the UCSC Genome Browser 
(Speir et al., 2016). As can be seen by the blue tracks (position marked on the right-hand side of the image), the 
RAD50 gene is located in a region rich in cytokine genes, such as IL-4,IL-5 and IL-13, as well as the immune 
activator, interferon response factor 1 (IRF1), and the microtubule motor involved in nucleic acid and protein 
transport, KIF3A. This genomic organisation may allow for concomitant regulation of the DDR and 
inflammation, especially in cells like neutrophils, eosinophils and basophils, who produce such cytokines and 
proliferate rapidly in response to inflammatory triggers. Exonic regions in the blue tracks are represented by 
vertical dissecting lines/rectangles; depending on exon size. Furthermore, the start of the RAD50 gene is marked 
by a H3K27AC modification in 7 cell lines analysed as part of the ENCODE dataset (Ecker et al., 2012), 
allowing for the gene’s frequent transcriptional regulation. Conservation of the exonic RAD50 sequence 
between species is illustrated in the black tracks towards the bottom of the image, noting that very high levels of 
intronic conservation is present between Rhesus macaques and Homo sapiens.   
 
 
 
RAD50 shows marked homology to proteins in highly diverse species (Hopfner et al., 2000b). 
In yeast, for example, RAD50 poses numerous catalytic activities which are essential for DSB 
repair to take place (Anderson et al., 2001). In-keeping with the well described roles of other 
members of the MRN complex and fertility, disruption of RAD50 in Arabidopsis leads to plant 
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sterility, and experiments exploiting the DSB-inducing agent, methyl methane sulphonate, 
demonstrated the protein to be involved in DSB repair in plants (Gallego et al., 2001). 
Furthermore, homologues of RAD50 have been found in prokaryotic archaea, where it again 
helps mediate the response to gamma radiation and homologous recombination repair (De 
Jager et al., 2004). Abrogation of the gene in mice can lead to embryonic lethality/deformity 
and a high sensitivity to ionising radiation (Luo et al., 1999), where defects predispose to 
premature ageing, cancer and other systemic abnormalities.  
 
The major isoform of the protein is 1,312 amino acids in length (approximately 154 kDa 
weight), and in contrast to the other members of the MRN complex (which is formed by two 
heterodimers of RAD50/MRE11 and a single NBS1), RAD50 shows a long, repeating, internal 
coiled-coil domain composed of five alpha helices between 29-291 amino acids long, that 
allows the N- and C-termini of the protein to form a globular structure (The UniProt 
Consortium, 2015). Indeed, a protein with a coiled-coil domain is required for MRN complex 
function (Hohl et al., 2010). Crucially, this folding is dependent on the acquisition of a zinc ion 
by RAD50 (which is achieved via the Zinc-hook located between residues 635-734 – 
separating the large internal coiled regions), forming a metal-bound homodimer with a newly-
formed ABC ATPase head region (Hopfner et al., 2002); mutations at both the extreme C- and 
N-terminal ends of the protein can interfere with ATP hydrolysing ability. This region of the 
protein is essential for mediating the MRE11 interaction, whilst the zinc-hook contains two 
cysteine residues which bind the zinc ion, with each residue contributing one bond across the 
homodimer, which forms a V-shaped rod composition as a whole (Park et al., 2017).  
 
Present consensus states that RAD50’s ability to change conformation from open to closed in 
the presence of free DNA ends, is essential for tethering DNA strands together for repair to 
take place – zinc-mediated tethering of DNA ends is thought to depend upon RAD50 (Bhaskara 
et al., 2007; Connelly and Leach, 2002). Thus, RAD50 is thought to be essential for allowing 
for sequence homology searches and ligation to take place.  
 
RAD50 is also responsible for curtailing the nuclease activity of MRE11 and for activating 
DNA ligase (Trujillo and Sung, 2001) – co-ordinating and fine-tuning the repair. Additional 
reports suggest that RAD50 is involved in stimulating ATM (Deshpande et al., 2017), as other 
members of the MRN complex have been reported to do. Thus, RAD50 is central to DNA 
repair and starting cell cycle arrest processes. Aside from its functions in DSB repair, RAD50 
– like the other members of the MRN complex – is involved in telomere maintenance, and 
meiosis (Vannier et al., 2006). For plants PSH1 was found to be essential for transport of 
RAD50 from the cytoplasm to execute meiotic recombination (Ronceret et al., 2009). Although 
the mechanisms in humans are probably different, RAD50 is still thought to be essential so 
similar meiotic processes, and has been associated with infertility (Handel and Schimenti, 
2010). One of few studies in mammalian cells in respect to meiosis has shown that the MRN 
complex co-opts Ctp1 to carry out meiotic DNA DSB repair (Ma et al., 2015). Mutations in 
the nuclease Ctp1 is also associated with inherited disorders such as Seckel syndrome, which 
is characterised by dwarfism, microcephaly and abnormal skeletal morphology, similar to what 
has been discussed for NBS1 mutations (Qvist et al., 2011). This study also found the PI3K 
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kinase, ATR (involved in activating the DNA damage checkpoint), to be a risk locus for Seckel 
syndrome. 
 
Unsurprisingly, RAD50 displays a predominantly nuclear localisation, although it can be re-
targeted as required by different cellular states, such as infection or temperature stress. For 
example, when a cell becomes infected and foreign dsDNA is present in the cytoplasm, RAD50 
forms a complex with the innate immune system adaptor protein, CARD9) (Roth et al., 2014). 
Together, they activate NF-kappa-B, which drives IL-1-beta production – a central molecule 
across innate and adaptive immunity and the hypothalamic pyretic axis.  
 
RAD50 has also been documented by several reports to be a member of the BRCA1-associated 
genome surveillance complex (BASC), which consists of a group of proteins involved in DNA 
damage repair and cell cycle control (Wang et al., 2000). Amongst the proteins found in the 
BASC complex are the TSGs and DNA damage response proteins, such as MSH2, MSH6, 
MLH1, ATM and BLM, as well as MRE11 and NBS1. Similar to the amounts of MRN 
complex that has been described in nuclear dots, this spatial organisation likely allows for DNA 
damage sensing and repair to take place more quickly; being compartmentalised in close 
proximity to lesions and having the inherent ability to modify chromatin structure to execute 
repair.  
 
Bioinformatic approaches that rely on vast databases and chemical and biophysical predictions 
are useful first steps when considering protein function, as many features may have been seen 
before. Indeed, the multiple associated Gene Ontology functions attributed to RAD50 included: 
ATPase activity; adenylate kinase activity; DNA binding, G-quadruplex binding; protein 
binding; metal ion binding; and single- and double-stranded telomeric DNA binding, 
demonstrating the range of activities and capabilities of the protein, and agreeing with what 
has been reported in the literature (Ashburner et al., 2000). The same functional analysis of the 
protein suggests that it is involved with telomere capping, nucleic acid phosphodiester bond 
hydrolysis, and mediating Pi3K-dependent signal transduction.  
 
Given its wide range of functions, it is also not surprising to learn that lesions in this gene are 
associated with debilitating clinical diseases. Mutations in RAD50 are known to cause 
Nijmegen breakage syndrome-like conditions. For example, Waltes and colleagues describe in 
detail a patient previously diagnosed as having NBS (mental retardation, facial malformation, 
microcephaly) (Waltes et al., 2009). Unlike true NBS patients, this patient did not harbour 
lesions in the NBN gene, but rather was compound heterozygous for mutations in RAD50 that 
led to the generation of an unstable protein. Cells from the patient displayed increased radiation 
sensitivity, abnormal MRN complex foci formation, chromosomal instability, defective ATM 
activity, and defects in G1/S cell cycle regulation; all of which could be rescued by wild-type 
RAD50 in vitro. The fact that very few of such cases have been reported in the medical 
literature is likely due to the highly penetrant and deleterious nature of mutations within or 
around RAD50; remembering that its deletion leads to mouse embryo death.  
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Common polymorphisms in RAD50 are also associated with a range of human traits as can be 
seen by data from genome-wide associatgion studies in the NHGRI-EBI GWAS Catalogue 
(MacArthur et al., 2017). RAD50 variants are strongly associated with the levels of circulating 
eosinophils and basophils; the strongest being rs2706345, an intronic variant in RAD50. 
Additional intronic variants in the RAD50-IL13 region have been associated with atopic 
dermatitis, asthma and inflammatory skin disease (MacArthur et al., 2017), although the 
various cytokines present in the RAD50 region would appear to be the most likely genetic 
cause of that biology (Figure 6.1). Indeed, other SNPs in the region (such as rs2040704) have 
been reported to increase IgE titres more than 13%, again suggesting inflammatory pathology 
linked to IL-13, an important mediator of allergic inflammation (Weidinger et al., 2008). 
Various cis- and trans-regulatory processes and regulatory roles have been widely reported at 
other loci (Davison et al., 2012).  
 
Another SNP in the region (within a RAD50 intron), rs13164856, marks a haplotype 
encompassing RAD50, C5ORF56 and IRF1, that is associated with polycystic ovary syndrome 
(Day et al., 2015), perhaps suggesting defects in germ cell maintenance and reproductive tract 
function.  
 
 
 
6.1.2 Associations between RAD50 and cancer  
 
Thus, compared to the other members of the DNA DSB repair pathway discussed thus far, it 
seems that less is known concerning RAD50 and cancer development.  
 
Perhaps the relative scarcity of information concerning RAD50 and cancer is due to increased 
redundancy in the MRN complex’s zinc-dependent ATP-hydrolysing component, compared to 
the ATM (a protein)-binder NBS1, or the nucleic acid-editing MRE11. Along these lines, Kish 
and DiRuggiero (2008) have reported that Rad50 is not essential for Mre11-dependent repair 
of DNA DSBs in Halobacteria. After exposing bacteria deficient in either Mre11 or Rad50 (or 
both) to gamma radiation, the alkylating agent N-methyl-N’-nitro-N-nitroguanidine, and UV-
C, it was discovered that cells lacking Mre11 showed a reduced rate of DNA repair, whereas 
those lacking Rad50 were not different to controls (Kish and DiRuggiero, 2008). The same is 
not thought to occur in eukaryotes, but the problem has not been fully explored, and many 
homologous proteins to RAD50 are encoded in the human genome; such as the nuclear-located 
A8K3I2 (or cDNA FLJ75532), which a quick bioinformatics search reveals it also harbours 
internal coil-coil domains and ATPase activity (The UniProt Consortium, 2015).    
 
The links between RAD50 and cancer predisposition (Gasch et al., 2016; Hood and Rowen, 
2013) were established from a study of Nordic populations.  A truncation mutation in RAD50, 
687delT (originating in Finland), has been found to predispose to breast cancer (Heikkinen et 
al., 2006). Additional predisposing variation in this clinical context has also been described in 
other patients, including the IVS3-I G>A mutation that interferes with RAD50 splicing.  
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It has been reported that a lack of RAD50 (and NBS1 and MRE11) typified epithelial ovarian 
carcinoma, where the authors relied on histology to describe their findings (Brandt et al., 2017), 
adding to similar findings in cystadenomas (Ali-Fehmi et al., 2010). Perhaps in this instance, 
RAD50 function was impaired by the cancer, and post-translational mechanisms must also be 
considered when describing the mechanisms of oncogenesis (Dwek et al., 2001). Furthermore, 
neither cancer heterogeneity, sample or disease collection variables (Baker, 2016), or the 
current genomic resolution based on limited numbers of patients (Devine and Smith, 1998; 
Spencer et al., 2009), can be overlooked as limitations in such kinds of studies.  
 
The case of RAD50 (a gene that one would assume would have deleterious cancer-predisposing 
mutations associated with it) demonstrates the importance of individual germ-line and tumour 
DNA/RNA analysis to determine how individual cancers develop and progress (Auslander et 
al., 2016). The same way that the majority of cases suffering from an outbreak of infectious 
disease might have sub-clinical presentations, only determining the precise base pair sequence 
of the host and tumour will allow for the determination of cancer causality conclusively. The 
human genetics field has long been troubled by the problem of missing heritability (Manolio 
et al., 2009), and the search for low-frequency deleterious variants that predispose to complex 
polygenic diseases is on-going – with mixed success thus far (Chubb et al., 2016; Hunt et al., 
2013; Nejentsev et al., 2009).  
 
6.2 Hypothesis and study overview 
 
The aim of the experiment described in this chapter is to determine the relationship between 
RAD50 expression in rectal tumour tissue and clinicopathological features including survival 
in a cohort of Australian patients. Although relatively fewer deleterious germ-line or somatic 
variants in RAD50 have been associated with cancer (compared to ATM, MRE and NBS1), 
the critical role of this protein in powering DSB repair makes it possible that its expression 
levels and activity could be indicative of disease state and treatment response.  
 
The primary interest is to determine whether RAD50 expression in tumours can be used as a 
corollary marker for radiation sensitivity in rectal cancer patients.  
 
Furthermore, expression of all three MRN complex proteins – MRE11, RAD50 and NBS1 – 
as a combinatorial biomarker panel is investigated for the same purposes; hypothesising that 
additional metrics of the DNA DSB response will increase the predictive power of any marker 
alone, especially when different genomic lesions in different patients can influence a single 
component of the pathway.  
 
* The results presented in this chapter have recentlybeen published. Citation: Ho, V., Chung, 
L., Singh, A., Lea, V., Revoltar, M., Lim, SH., Tut, TG., Ng, W., Lee, M., de Souza, P., Shin, 
J and Lee, CS. (2017). Early postoperative low expression of RAD50 in rectal cancer patients 
associates with disease-free survival. Cancers 9, 16.  
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6.3 Results                                                                                                                                                                          
6.3.1 Patient Populations 
A total of 266 patients were included in this study, similarly to what has been described in 
previous Chapters. In total, 176 (66.2%) patients were male, whilst 90 (33.8%) were female. 
The median age of participants whose samples were used in the study was 72 years (range: 35–
100 years) (Table 6.1).  
 
Of the 246 patients involved, 77 (31.3%) were treated with radiotherapy, and from these, 55 
(71.4%) received preoperative therapy. During the time of sample collection, patients were 
followed for a median period of 3.16 years (range: 0−12.6 years), and the median time to death 
in the cohort was found to be 2.5 years after surgery (ranging between 0−11.1 years). 
 
Table 6-1 Patient characteristics for the RAD50 study 
 
All Patients (%) 
Total, n 266 
Age median 72 
Sex 
 
Male 176/266 (66.2) 
Female 90/266 (33.8) 
Tumour stage 
 
T1–2 88/260 (33.8) 
T3–4 172/260 (66.2) 
Node stage 
 
N0 140/259 (54.1) 
N1–2 119/259 (45.9) 
Metastasis stage 
 
M0 223/240 (92.9) 
M1 17/240 (7.1) 
Histological Grade 
 
1–2 246/266 (92.5) 
3 20/266 (7.5) 
Vascular invasion 
 
Absent 201/263 (76.4) 
Present 62/263 (23.6) 
Perineural invasion 
 
Absent 220/263 (83.7) 
Present 43/263 (16.3) 
Radiotherapy 
 
Total 77/246 (31.3) 
Neoadjuvant 55/77 (71.4) 
Adjuvant 22/77 (28.6) 
 
 188 
6.3.2 Association between RAD50 expression and clinicohistopathological 
features and prognosis 
The associations between postoperative RAD50 expression and the clinicohistopathological 
characteristics available to use for this study are presented in Table 6.2. 
 
Table 6-2 Associations between RAD50 protein expression in the tumour centre and tumour periphery and 
clinicohistopathological data 
  
Tumour center Tumour periphery   
Low (%) High (%) P value Low (%) High (%) P value 
Sex Male 26.3 73.7 0.98 29.6 70.4 0.42  
Female 26.1 73.9 
 
34.4 65.6 
 
Age ≤72 28.8 71.2 0.39 30.6 69.4 0.82  
>72 24.1 75.9 
 
31.9 68.1 
 
Tumour stage T1–2 23.5 76.5 0.65 32.1 67.9 0.68  
T3–4 26.2 73.8 
 
29.6 70.4 
 
Node stage Negative 26.5 73.5 0.67 31.1 68.9 0.95  
Positive 24.1 75.9 
 
30.8 69.2 
 
Metastasis 
stage 
M0 25.5 74.5 0.72 31.5 68.5 0.09 
 
M1 29.4 70.6 
 
11.8 88.2 
 
Histological 
Grade 
1–2 26.1 73.9 0.88 31.3 68.7 0.98 
 
3 27.8 72.2 
 
31.6 68.4 
 
Vascular 
invasion 
Absent 26.3 73.7 0.74 31.9 68.1 0.50 
 
Present 24.2 75.8 
 
27.4 72.6 
 
Perineural 
invasion 
Absent 24.7 75.3 0.40 32.2 67.8 0.28 
 
Present 31.1 68.9 
 
23.8 76.2 
 
Adjuvant 
therapy 
No 25.2 74.8 0.83 24.8 75.2 0.04 
 
Yes 26.6 73.4 
 
38.8 61.2 
 
Neoadjuvant 
therapy 
No 23.8 76.2 0.14 27.1 72.9 0.16 
 
Yes 34.1 65.9 
 
37.3 62.7 
 
Tumour 
regression 
grade 
0–1 50 50 0.14 50 50 0.22 
 
2-3 28.3 71.7 
 
32.8 67.2 
 
MSH6 Negative 50.0 50.00 0.43 0 100 0.35  
Positive 25.5 74.5 
 
30.8 69.2 
 
PMS2 Negative 55.6 44.4 0.04 44.4 55.6 0.36 
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Positive 25.5 74.5 
 
30.1 69.9 
 
 
 
Low RAD50 protein expression levels are found in the tumour periphery (TP) to be 
significantly associated with adjuvant therapy treatment in the cohort (P = 0.04). No significant 
differences were observed for age, sex, histological tumour stage, lymph node involvement, 
metastasis, vascular invasion, or perineural invasion, between patients with low or high RAD50 
expression.  
 
Kaplan–Meier survival analysis demonstrated that low RAD50 expression levels in the tumour 
centre (TC) were significantly associated with worse DFS (P = 0.016; Figure 6.2), whereas the 
association between RAD50 expression and OS was of borderline significance (P = 0.056; 
Figure 6.2B). No significant difference in survival was seen between patients with high or low 
RAD50 expression in the TP (DFS, P = 0.295; OS, P = 0.695) (Figures 6.2C and 6.2D). These 
results suggest that RAD50 expression serves to limit the progression of cancer, as reduced 
levels are associated with worse patient outcomes, although the effect was not observed in the 
tumour periphery. Representative immunohistochemical staining of high and low RAD50 
expression in rectal cancer tissues is shown in Figures 6.3 A and 6.3 B. 
 
 
Figure 6-2 Association between postoperative RAD50 expression in the TC and TP and survival  
(A-D) Kaplan–Meier survival analysis illustrating DFS (A, C) and OS (B, D) of patients with RAD50 
expression in the TC (A, B) and TP (C, D). Blue lines represent patients with low RAD50 expression and green 
lines represent patients with high RAD50 expression. 
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The status of the MMR pathway in patient samples was investigated by evaluating the 
association of MMR proteins with RAD50 expression. All cases were found to be positive for 
MLH1 and MSH2 expression, and therefore, none of the cases were classified as MSI-high 
(MMR-negative). Furthermore, expression of MSH6 and PMS2 was found to be negative in 
2/253 (0.8%) and 9/253 (3.6%) cases, respectively. Additionally, no significant associations 
between RAD50 and MSH6 expression, in either the TC or TP, were found. Finally, low post-
operative RAD50 expression was significantly associated with PMS2 expression in the TC (P 
= 0.04), but not in the TP (P = 0.36) (Table 6.2). The MRE11-RAD50-NBS1 (MRN) complex 
is known to interact with the mismatch repair system and indeed is dependent on mismatch 
repair activity for its formation (Mirzoeva et al, 2006). This lends support to an intriguing 
interaction between RAD50 and PMS2 that warrants further investigation.  
 
 
Low expression levels of RAD50 were found in the TC (HR = 0.552, 95% CI 0.339–0.899, P 
= 0.017; by univariate Cox regression) was significantly associated with reduced DFS in 
patients (Table 6.3). Additionally, using multivariate Cox analysis, we found that RAD50 
expression (HR = 0.567, 95% CI 0.345–0.931, P = 0.025) and perineural invasion (HR = 2.364, 
95% CI 1.343–4.162, P = 0.003) remained significantly associated with DFS (Table 6.3). 
However, in multivariate Cox analysis relating to OS, perineural invasion (HR = 1.701, 95% 
CI 1.036–2.792, P = 0.036) remained significantly associated with OS, but not with tumour 
RAD50 expression (HR = 0.712, 95% CI 0.462–1.095, P = 0.122) (Table 6.3). 
 
Finally, by means of a Kaplan–Meier analysis of DFS to compare RAD50 low and high 
expression groups with tumours classified according to their perineural invasion status, low 
levels of RAD50 expression in rectal cancer tissues were significantly associated with 
perineural invasion (Figure 6.3C and 6.3D). These results indicate that low RAD50 in the 
context of PNI is a marker of poor prognosis, as shown above for DFS and OS. 
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Figure 6-3 Correlation between RAD50 expression and perineural invasion and survival in early stage rectal 
cancers  
(Panels A, B) Images showing representative immunohistochemical staining of RAD50 in rectal cancer samples 
(high versus low expression shown).  
(Panels C, D) Kaplan–Meier survival analysis of DFS in the low RAD50 expression group (C) and the high 
RAD50 expression (D) group, with (green line) or without (blue line) perineural invasion.  
(Panels E, F) Kaplan–Meier survival analysis illustrating the relationship of RAD50 expression with DFS (E) and 
OS (F) in low-grade (G1–2) with the early tumour stage (T1-2) subgroup. The analyses were divided into four 
subgroups including the low-grade with early stage tumours (G1-2, T1-2, n = 64), high-grade with early stage 
tumours (G3, T1-2, n = 4), low-grade with late stage tumours (G1-2, T3-4, n = 113) and high-grade with late stage 
tumours (G3, T3-4, n = 8). 
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Table 6-3 Cox regression analyses of postoperative RAD50 with overall survival. 
Variables 
Univariate Multivariate 
HR  95% CI p Value  HR  95% p Value  
RAD50             
Low 0.674 0.448–1.012 0.047 0.712 0.462–1.095 0.122 
High       
Age        
≤72 1.334 0.897–1.984 0.155    
>72       
Sex        
Male 1.092 0.734–1.625 0.664    
Female       
Tumor stage             
T1–2 1.796 1.158–2.786 0.001 1.382 0.858–2.226 0.183 
T3–4       
Node stage             
Negative 1.454 0.987–2.140 0.058    
Positive       
Grade              
1–2 1.561 0.836–2.916 0.162    
3       
Vascular invasion             
Absent 2.03 1.340–3.015 0.001 1.365 0.848–2.196 0.200 
Present       
Perineural invasion             
Absent 2.48 1.594–3.859 0.000 1.701 1.036–2.792 0.036 
Present       
Adjuvant therapy              
No 0.506 0.301–0.850 0.09    
Yes       
Neoadjuvant therapy             
No 0.891 0.550–0.427 0.63    
Yes             
HR, hazard ratio; CI, confidence interval; RAD50: DNA repair protein RAD50 homolog. 
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Table 6-4 Cox regression analyses of post-operative RAD50 with disease-free survival 
 
Univariate Multivariate  
HR 95% CI P-value HR 95% P-
value 
RAD50 
      
Low 
High 
0.552 0.339–0.899 0.017 0.567 0.345–0.931 0.025 
Age 
≤72 
>72 
 
1.279 
  
 
0.785-2.086 
 
  
 
0.323 
 
  
   
Sex 
Male 
Female 
 
1.074 
 
 
 
0.657-1.754 
 
 
0.776 
 
   
Tumour stage 
      
T1–2 1.643 0.983–2.747 0.058 
   
T3–4 
      
Node stage 
      
Negative 1.198 0.709–1.827 0.593 
   
Positive 
      
Histological Grade 
      
1–2 1.646 0.712–3.804 0.244 
   
3 
      
Vascular invasion 
      
Absent 1.888 0.650–
0.2171 
0.575 
   
Present 
      
Perineural invasion 
      
Absent 2.534 0.373–1.134 0.001 2.364 1.343–4.162 0.003 
Present 
      
Adjuvant therapy 
      
No 0.65 0.373–1.134 0.129 
   
Yes 
      
Neoadjuvant 
therapy 
      
No 1.147 0.672–0.957 0.616 
   
Yes 
      
T1–2, G1–2,† 
RAD50 
   
0.218 0.084-0.570 0.002 
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T3–4, G3, † RAD50 
   
0.401 0.065-2.471 0.324 
HR, hazard ratio; CI, confidence interval; TC, tumour centre, †denotes 
interaction 
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6.3.3 RAD50 Expression as a Putative Prognostic Factor for Early Stage 
Rectal Cancer 
 
The DFS of rectal cancer patients showing a low level of RAD50 expression was found to be 
significantly worse than for patients exhibiting high levels of RAD50 expression.  
When patients were grouped into early tumour stage (T1–2) and low-grade (G1–2) subgroups, 
a low expression of RAD50 was found to be associated with decreased DFS (P = 0.001) (Figure 
6.3E), indicating that RAD50 expression may be a useful prognostic biomarker for the early 
tumour stage and low-grade subgroups.  
 
Similarly, low RAD50 expression in early tumour stage and low-grade tumour subgroups was 
significantly associated with worse OS (P < 0.001) (Figure 6.3F). Additional Cox regression 
analyses confirmed that expression of RAD50 in early tumour stage and low-grade subgroups 
significantly correlated with DFS (HR = 0.218, 95% CI 0.084–0.570, P = 0.002) (Table 6.4). 
 
 
6.3.4 Results of the combinatorial MRE11-NSB1-RAD50 biomarker panel 
 
6.3.4.1 Patient populations  
 
A total of 265 patients were included for this part of the study, with patient characteristics being 
listed in Table 6.5. In total, one hundred and seventy-six (66.4%) volunteers were male, whilst 
89 (33.6%) were female. The median age of the cohort was 71 years (ranging between 35–100 
years). 77 out of 246 patients (31.3%) were treated with radiotherapy, and 55 of these (71.4%) 
also received preoperative therapy. Patients were followed for a median period of 3.16 years 
(ranging between 0−12.6 years), and the median time to death was 2.5 years after surgery 
(ranging between 0−11.1 years). 
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Table 6-5 MRN combinatorial panel patient characteristics 
 
All Patients (%) Preoperative Radiotherapy 
Group 
Total, n 265 55 
Age median 71 66 
Gender 
  
Male 176 (66.4) 37 (67.3) 
Female 89 ( (33.6) 18 (32.7) 
Tumour stage 
  
T1-2 87/260 (33.4) 17/55 (30.9) 
T3-4 173/260 (66.6) 38/55 (69.1) 
Node stage 
  
N0 140/259 (54.1) 29/55 (52.7) 
N1-2 119/259 (45.9) 26/55 (47.3) 
Metastasis stage 
  
M0 223/240 (92.9) 53/54 (98.1) 
M1 17/240 (7.1) 1/54 (1.9) 
Grade 
  
1-2 245/265 (92.5) 51/55 (92.7) 
3 20/265 (7.5) 4/55 (7.3) 
Vascular invasion 
  
Absent 201/263 (76.4) 47/55 (85.5) 
Present 62/263 (23.6) 8/55 (14.5) 
Perineural invasion 
  
Absent 220/263 (83.7) 41/55 (74.5) 
Present 43/263 (16.3) 14/55 (25.5) 
Radiotherapy 
  
Total 77/246 (31.3) - 
Neoadjuvant 55/77 (71.4) - 
Adjuvant 22/77 (28.6) 0/55 (0) 
Recurrence 
  
Absent 131/213 (61.5) 25/46 (54.3) 
Present 82/213 (28.5) 21/46 (45.7) 
Tumour regression grade 
  
0-2 (good response) - 9/55 (16.4) 
3 (poor response) - 46/55 (83.6) 
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6.3.4.2 Establishment of a putative biomarker panel of the MRN 
complex 
 
In order to determine the utility of this combinatorial MRN biomarker in rectal cancer, MRE11, 
RAD50 and NBS1 protein expression levels in the TC were tested in a forward and reverse 
binary logistic regression analysis; using a dataset of immunohistochemical scoring derived 
from 262 tumour samples and 258 normal tissue samples.  
 
The final biomarker model gave an average receiver operator characteristic area under the 
curve (ROC-AUC) value of 0.870 when the three proteins of the MRN complex were 
combined. Similarly, MRE11, RAD50 and NBS1 protein expression levels in the TP (tumour, 
n = 261; normal, n = 258) were also evaluated, with the model giving an average ROC-AUC 
value of 0.862.  
 
The sensitivity and specificity values for the MRN combinatorial panel were 89.0% and 77.2% 
for TC, and 78.2% and 77.6% for TP, respectively (see Table 6.5).  
 
Table 6-6 Performance of the MRN three proteins combined classification models 
Model Tumour Normal Sensitivity 
(%) 
Specificity 
(%) 
Overall 
(%) 
ROC-
AUC 
Combined TC* 262 258 89.0 77.2 83.1 0.870 
Combined TP† 261 258 78.2 77.6 77.9 0.862 
*Tumour centre; †Tumour periphery 
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6.3.4.3 Association between the MRN combined expression and 
clinicohistopathological features  
 
The association between the three-protein combined expression levels and the 
clinicohistopathological characteristics is summarised in Table 6.7. 
 
Table 6-7 Associations between the MRN combined expression in the tumour center and tumour periphery and 
clinicohistopathological data 
  
Tumour Center Tumour Periphery   
Low 
(%) 
High 
(%) 
P value Low 
(%) 
High 
(%) 
P value 
Sex Male 62.5 66.8 0.567 80.0 64.6 0.121  
Female 37.5 33.2 
 
20.0 35.4 
 
Age ≤70 43.8 46.5 0.751 36.0 47.1 0.290  
>70 56.2 53.5 
 
64.0 52.9 
 
Tumour stage T1–2 50.0 30.0 0.009 44.0 32.5 0.246  
T3–4 50.0 70.0 
 
56.0 67.5 
 
Node stage Negative 60.0 53.1 0.395 52.0 54.5 0.811  
Positive 40.0 46.9 
 
48.0 45.5 
 
Metastasis stage M0 97.8 91.7 0.147 100 92.1 0.153  
M1 2.2 8.3 
 
0 7.9 
 
Grade 1–2 93.8 92.2 0.707 88.0 92.9 0.376  
3 6.2 7.8 
 
12.0 7.1 
 
Vascular invasion Absent 82.6 75 0.27 84 75.5 0.343  
Present 17.4 25 
 
16 24.5 
 
Perineural invasion Absent 84.8 83.8 0.869 92 83.1 0.250  
Present 15.2 16.2 
 
8 16.9 
 
Adjuvant therapy No 70.0 69.4 0.945 52.4 71.4 0.072  
Yes 30.0 30.6 
 
47.6 28.6 
 
Neoadjuvant therapy No 65.2 80.9 0.021 68 78 0.205 
 
Yes 34.8 19.1 
 
32 22 
 
Tumour regression 
grade 
0–2 31.6 11.3 0.042 30 14.5 0.223 
 
3 68.4 88.7 
 
70 85.5 
 
MSH6 Negative 0 100 0.518 0 100 0.663  
Positive 17.3 82.7 
 
8.7 91.3 
 
PMS2 Negative 11.1 88.9 0.669 0 100 0.345  
Positive 16.5 83.5 
 
9.1 90.9 
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High expression levels of the MRN combinatorial panel were found in the TC and were 
significantly associated with the histological tumour stage (P = 0.009), and with a TRG of 0 to 
2 (responders) (P = 0.042), indicating that MRN-mediated DNA damage repair may mediate 
an important DNA damage response. No significant differences were associated with patient 
age, sex, lymph node involvement, metastasis, vascular invasion, or perineural invasion and 
low and high MRN complex protein expression.  
 
Subsequent Kaplan–Meier survival analyses demonstrated that a high score for the 
combinatorial MRN complex expression in the TC was significantly associated with a worse 
DFS in patients (P = 0.021; Figure 6.4A), and OS (P = 0.002; Figure 6.4B). No significant 
differences in survival were seen between patients with high or low MRN complex protein 
expression levels in the TP (DFS, P = 0.646; OS, P = 0.251; Figures 6.4C and 6.4D, 
respectively).  
 
 
Figure 6-4 Association between MRN complex proteins expression in the TC and TP and survival  
(A-D) Kaplan–Meier survival analysis illustrating DFS (A, C) and OS (B, D) of patients with the MRN combined 
expression levels in the TC (A, B) and TP (C, D). Blue lines represent patients with low MRN combined 
expression and green lines represent patients with high MRN combined expression. 
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Using univariate Cox regression analysis, we found that high expression of the combined three 
protein panel in the TC (HR = 2.069, 95% CI 1.102–3.882, P = 0.024) was significantly 
associated with reduced DFS (Table 6.8). Additionally, multivariate Cox analysis (adjusted for 
the combined three-protein expression of MRN complex and perineural invasion) 
demonstrated that MRN complex expression (HR = 2.114, 95% CI 1.096–4.078, P = 0.026) 
and perineural invasion (HR = 2.16, 95% CI 1.209–3.859, P = 0.009) remained significantly 
associated with DFS (Table 6.8), implying that those markers together are strongly prognostic 
for disease-free survival in rectal cancer patients. 
 
Table 6-8 Cox regression analyses of MRN combined TC expression with clinicohistopathological variables 
  
Univariate Multivariate  
n (%) HR 95% CI P Value HR 95% P Value 
MRN 
combined TC* 
       
High 81.9 2.069 1.102-
3.882 
0.024 2.114 1.096-4.078 0.026 
Low 18.1 
      
Tumour stage 
       
T1–2 33.6 1.501 0.897-
2.512 
0.122 
   
T3–4 66.4 
      
Node stage 
       
Negative 54.3 1.44 0.976-
2.126 
0.066 
   
Positive 45.7 
      
Grade 
       
1–2 92.5 1.537 0.823-
2.872 
0.178 
   
3 7.5 
      
Vascular 
invasion 
       
Absent 76.3 1.167 0.638-
2.134 
0.617 
   
Present 23.7 
      
Perineural 
invasion 
       
Absent 84.0 2.334 1.310-
4.157 
0.004 2.16 1.209-3.859 0.009 
Present 16.0 
      
Adjuvant 
therapy 
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No 69.5 0.602 0.341-
1.063 
0.08 
   
Yes 30.5 
      
Neoadjuvant 
therapy 
       
No 78.0 0.855 0.529-
1.381 
0.521 
   
Yes 22.0 
      
LN-negative† 
combined TC 
54.3 
   
1.339 0.589-3.042 0.486 
LN-positive† 
combined TC 
45.7 
   
3.472 1.051-
11.454 
0.047 
*Three marker combined expression in the tumour center; † denotes interaction 
 
HR, hazard ratio; CI, confidence interval; TC, tumour center; LN, lymph node 
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6.3.4.4 Association between MRN combinatorial panel and MMR 
protein expression 
 
All cases were positive for MLH1 and MSH2 expression in this cohort, and therefore, none of 
the cases were classified as MSI-high (MMR-negative).  
 
The expression of MSH6 and PMS2 was negative in 2/256 (0.8%) and 9/252 (3.6%) cases, 
respectively, and no significant associations between combined MRN protein expression and 
MSH6 or PMS2 expression, in either TC or TP samples, were found (Table 6.7).  
 
6.3.4.5 Correlation of the MRN combined expression with 
neoadjuvant radiotherapy 
 
 
Disease-free and overall survival outcomes were analysed in the 55 patients that had previously 
received pre=operative radiotherapy. Of these 55 patients, thirty-seven (67.3%) of them were 
male, and 18 (33.6%) were female (Table 6.5). The DFS estimates in the subgroup receiving 
neo-adjuvant radiotherapy are shown in Figure 6.6A, demonstrating that a higher combined 
expression level of the MRN complex is significantly associated with worse DFS in this cohort 
(P = 0.024).  
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Figure 6-5 Relationship between preoperative MRN in rectal cancer tissues and survival and MRN combined 
expression in relation to TRG 
(A, B) Kaplan–Meier survival analysis illustrating DFS (A) and OS (B) in preoperative radiotherapy patient 
groups with low (blue line) and high (green line) MRN complex panel expression.  
(C) Box plot shows levels of MRE11 (green), RAD50 (yellow), NBS1 (purple), and their combined expression 
(blue) in the TC categorized by TRG as 0-2 (good response) or 3 (poor response). The association of between 
protein expression with TRG was examined by Mann-Whitney U test.  
(D) Receiver operating characteristics (ROC) curve analysis comparing the performance of MRE11, RAD50 and 
NBS1 alone with the MRN combined three-protein panel. 
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Similarly, when considering the overall survival of patients receiving radiotherapy, 
overexpression of MRN complex proteins was also associated with significantly worse OS than 
that of patients with lower expression (Figure 6.4B, P = 0.028). These results suggest that the 
MRN three-protein combined panel has potential as a predictive marker of the tumour response 
to radiotherapy. 
 
As expected, multivariate analyses in patients that had received preoperative radiotherapy (see 
Table 6.9) revealed that a higher histological grade was strongly correlated with decreased 
overall survival (HR = 7.275, 95% CI 1.842−28.730, P = 0.005). High expression of the three 
MRN complex proteins was also significantly associated with worse OS (HR = 4.196, 95% CI 
0.968−18.191, P = 0.045).  
 
Table 6-9 Multivariate analysis of MRN combined expression with overall survival in patients who received 
preoperative radiotherapy 
 
Multivariate  
HR 95% P Value 
MRN combined TC 
expression 
4.196 0.968-18.191 0.045 
Grade 7.275 1.842-28.730 0.005 
Sex 3.017 1.199-7.592 0.019 
 
 
6.3.4.6 MRN complex proteins expression in relation to TRG 
 
TRG provides a valuable tool to assist in clinical oncology decision making. In the TRG 
subgroup study, we used a univariate analysis by the Mann−Whitney U test to explore the 
relationship between TRG and expression of MRN complex proteins.  
 
A significant association was found between increasing TRG and the expression level of the 
combinatorial MRN panel in the TC (P = 0.005, Figure 6.5C), and MRE11 and RAD50 
proteins (P = 0.046 and P = 0.01, respectively), but we did not find there to be a significant 
association between TRG scores and NBS1 expression.  
 
Using a ROC-AUC analysis of good versus poor histological tumour response among patients 
treated preoperatively with radiotherapy, the average ROC-AUC was 0.725 for the combined 
panel, 0.711 for MRE11, 0.677 for RAD50 and 0.602 for NBS1 alone, respectively (Figure 
6.5D). 
 
Together, these results strongly suggest that the combined three-protein biomarker panel may 
provide better levels of discrimination between good and poor tumour responses after 
radiotherapy, than either marker alone.  
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6.3.4.7 Prognostic implications of MRN complex proteins in LN- 
positive subgroup 
 
The DFS of rectal cancer patients showing overexpression of the combinatorial MRN panel 
was significantly worse than that of patients found to have lower expression.  
 
When patients were grouped according to the status of LN involvement, high expression of the 
MRN complex proteins was associated with decreased DFS, and worse OS in patients with 
LN-positive tumours (P = 0.029 for DFS, Figure 6.6B; P = 0.020 for OS; Figure 6.6D), but not 
in those with LN-negative tumours (P = 0.485 for DFS, Figure 6.6A; P = 0.073 for OS; Figure 
6.6C).  
 
By multivariate Cox regression analysis, expression of the MRN combined panel in TC in the 
LN positive subgroup was significantly correlated with DFS (HR = 3.474, 95% CI 1.054–
11.451, P = 0.041) (Table 6.8). 
 
These results suggest that the three-protein combined expression of the MRN complex may be 
associated with lymph node involvement in relation to patient survival. 
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Figure 6-6 Kaplan-Meier survival analysis of MRN combined expression according to lymph node involvement 
(A-D) respectively show survival curves of high (green line) and low (blue line) MRN combined expression 
groups in lymph node (LN) negative and LN positive rectal cancers. These show the effect of LN status on the 
association between expression levels and DFS (A, B) or OS (C, D). 
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7.1 Introduction 
 
To date, long-term clinical trials (Choudhury et al., 2010) and several meta-analyses (Camma 
et al., 2000; Colorectal Cancer Collaborative Group, 2001) have confirmed that neoadjuvant 
radiotherapy plus surgery, reduces the rate of local recurrence, and increases the survival rate 
of rectal cancer patients, where benefits far outweigh the associated side effects.  
 
However, patients with rectal cancer can have variable responses to radiotherapy (Aschele et 
al., 2011), therefore, the identification of rectal cancer-specific radio-sensitivity and prognostic 
markers would enable targeted therapeutic decisions, improve treatment results, and survival 
rates (Compton et al., 2000). Preliminary laboratory work in finding potential biomarkers can 
help pave the way for randomised controlled trials which are the gold standard approach to 
validate predictive markers (Forker et al, 2015).  
 
In the following sections major implications and considerations arising from the findings in 
this thesis will be outlined, covering each protein of interest individually, prior to reviewing 
the results arising from the two combinatorial panels.  
 
  
7.2 Results Discussion 
 
7.2.1 ATM  
 
ATM is a pleiotropic kinase that mediates several pathways to apoptosis, and facilitates cell 
cycle checkpoint regulation; as well as activating p53, BRCA1 and other TSGs (please see 
Chapter Three; (Lee and Paull, 2007)). High ATM expression would, therefore, be expected to 
correlate with increased DNA damage burden and repair, hallmarks of cancer. Indeed, high 
expression of ATM, the cell cycle protein Ki67, and PRKDC, have been reported in diverse 
types of malignant tumours, and have been described as prognostic markers. For example, work 
by Abdel-Fatah and colleagues showed high ATM expression to be predictive of serous 
cystadenocarcinoma and resistance to platinum-based chemotherapy (Abdel-Fatah et al., 
2014).  Additionally, in a study of early stage hormone receptor positive breast cancer, high 
ATM expression predicted a favourable prognosis, suggesting cells are able to repair DNA 
damage (Feng et al., 2016). These studies add weight to the notion that ATM expression is an 
important and informative feature of diverse cancers; necessitating its deeper understanding 
across different clinical contexts.  
 
A significantly higher ATM expression is found in cancer tissues compared with normal 
healthy mucosa. These observations suggest that, at the point of sample collection, the kinase 
has a more prominent role in cancer tissue compared to healthy tissue,  the malignant DNA 
tissue has a higher mutation burden than healthy tissue, and that DNA repair is occurring to a 
greater degree at this site. Theoretically, a loss of ATM expression could facilitate cell division 
in the face of DNA damage, and may be more important during the early stages of disease, or 
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in different sections of the tumour. 
 
This result (high ATM expression in tumours) does not agree with other studies that report a 
loss of ATM expression in colorectal carcinomas (Bai et al., 2004; Grabsch et al., 2006); 
although this could be due to tissue-specific (rectal versus colonic tumours show different 
mechanisms, as discussed) and patient cohort differences; including genetic variation (i.e. loss 
of ATM variants), age and sex distributions, disease stage, and concurrent chemotherapy. As 
discussed, differential scoring of the TRG could also impact variability between studies. 
Furthermore, as ATM has a number of diverse roles in the cell, different studies may be 
detecting the protein in relation to different functions, confusing the clinical picture. Indeed, 
ATM is predicted to have hundreds of protein targets in the cell (Shiloh and Ziv, 2013), and 
may contribute to, or restrain cancer, in a number of ways. Unfortunately, the only way to 
resolve such differences is through additional, more informed studies.  
 
In contrast to the findings of this thesis, high levels of ATM expression in rectal tumours may 
represent activation of ATM in response to an array of insults, including ionising radiation, 
mutagenic chemicals, replicative errors, inherited variants, and metabolic by-products; 
especially reactive oxygen species (Jackson, 2002). Along these lines, it is important to note 
that although cancers acquire the genetic ability to elude regulatory control, many normal 
molecular mechanisms remain intact and will function to restrain cell growth under deleterious 
conditions. 
 
ATM expression was, remarkably, found to be lower in samples taken from the periphery of 
tumours, compared with samples taken from more central tumour locations. This important 
distinction emphasises the heterogeneity within the tumour microenvironment (Quail and 
Joyce, 2013), where different cells carry out different roles (Buccione et al., 2009; Han et al., 
2017), and nicely describe the protein’s expression patterns within a single rectal tumour. How 
cancers regulate and co-ordinate the symbiotic development and specialisation of clonal cells 
within a tumour remains to be fully determined, although hormonal mechanisms and hijacking 
of adjacent stroma are known to facilitate tumour microenvironment development; by 
facilitating T-cell exclusion using chemokines, for example (Feig et al., 2013; Flint et al., 2016; 
Kraman et al., 2010). Indeed, hormonal paraneoplastic syndromes are well appreciated 
mechanisms tumours use to grow at the expense of the rest of the organism (Pelosof and 
Gerber, 2010). 
 
It is evident from our ATM immunohistochemistry results that differences in protein 
expression levels, and their association with clinicohistopathological variables and 
survival outcomes, exist; especially when comparing staining from the centre versus the 
periphery of the tumour mass. Effects due to sampling site variation across tumours have 
been noted previously; with multi-site tumour sampling being effective at capturing a more 
representative picture of the cancer (Guarch et al., 2016). For example, in an evaluation of 
biomarkers in ovarian cancer, Permuth-Wey et al reported sampling variability in protein 
expression analysis using tissue microarrays (Permuth-Wey et al., 2009). The authors 
concluded that, for ovarian cancer at least, more reliable data could be obtained from the 
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tumour periphery than from the centre, perhaps due to the hypoxic nature of the tumour 
centre affecting ex vivo staining protocols. Alternatively, this could be attributed to optimal 
exposure to fixatives at the periphery of the processed tissues (Yamashita-Kashima et al., 
2014), although the effect of tumour heterogeneity on sampling variation should also be 
considered. Across our studies, every effort was made to select sample cores from 
representative areas of pathology or healthy tissue in a blinded manner, although future 
studies could select a greater number of cores for a large number of sites within the same 
tumour.  
 
Peripheral tumour cells are generally thought to facilitate invasiveness and metastasis (Quail 
and Joyce, 2013) – where we found ATM expression to be lowest within the tumour – 
potentially allowing for more cancerous growth in the absence of other repair mechanisms . 
Furthermore, rapid, un-restrained growth in peripheral tumour cells leads to vascular 
insufficiency and hypoxia in the central tumour microenvironment (Gatenby et al., 2007). This 
could drive the increase in ATM expression, which helps keep cancer cells quiescent in the 
centre of the tumour, and alive in low-oxygen conditions. Indeed, mTORC signalling under 
hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1-alpha (Cam et 
al., 2010). Thus, the centrally-elevated levels of ATM could represent hypoxia due to rapid 
peripheral cell growth, which may indicate invasiveness. Indeed, a loss of ATM has been found 
to further the progression of pancreatic and breast cancer (Feng et al., 2015; Russell et al., 
2015). It is unsurprising, therefore, that ATM has previously been described as an anti-cancer 
barrier in early tumorigenesis (Bartkova et al., 2005; Reddy et al., 2010), and higher expression 
in peripheral tumour cells would be predicted to curtail tumour growth (expansion and 
basement membrane penetration); whilst a dysfunctional DDR pathway would be predicted to 
allow the cell to evade the safeguards preventing un-restricted clonal expansion. Our results 
support this, namely that there is insufficient ATM function in the tumour periphery.  
 
Indeed, negative/low peripheral ATM expression was found to be associated with higher grade 
tumours, and older patient age in this thesis. In older patients, increased ATM may be 
contributed by a higher mutation burden in these patients, compared to younger patients; along 
the lines of the DNA damage theory of ageing (Freitas and De Magalhães, 2011), from which 
it follows that more ATM is needed to repair cumulatively more lesions over time. As the 
cohort investigated in this thesis consisted mainly of elderly patients (with a mean age between 
71 and 72), similar studies need to be carried out in samples taken from younger patients.  
 
The fact that low peripheral ATM expression was associated with a higher grade of tumour 
further supports that ATM restrains oncogenesis and is defective in these samples. No 
correlations were found to be present for ATM staining in the tumour centre, highlighting the 
importance in studying the tumour as a whole. Here, limited sample numbers and TRG score 
resolution may mask associations. In future, wider tissue and cancer micro-environments 
should be considered in tandem to better evaluate disease stage, and determine and monitor 
treatment, which will also help uncover biological associations. Still, these results are of 
immediate clinical interest, as no previous correlations between ATM expression and 
clinicohistopathological variables in CRC or rectal cancer had been reported at the time of 
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writing. 
 
As well as studying ATM expression in this part of our studies, MSI-associated protein 
expression was also explored in the same samples. Microsatellite instability is a well-
recognised mechanism leading to ATM dysfunction (as well as of the MRN complex proteins) 
(Cortes-Ciriano et al., 2017), and was investigated by evaluating the expression patterns of 
known mismatch repair proteins - MLH1, MSH2, MSH6, and PMS2.  
 
Although in many instances, MSI has been associated with the loss of ATM function (Ham et 
al., 2006), any meaningful statistical analysis in the cohort of this thesis was impeded by the 
extremely low prevalence of MMR deficiencies. Both MLH1 and MSH2 were expressed in 
100 percent of samples, and MSH6 and PMS2 to be expressed in more than 99 percent of 
samples. These results suggest an absence of MSI, and illustrate that mismatch error repair is 
on-going in these cells, in-keeping with their high mutation burden. It would have been 
interesting to further add to the literature concerning ATM expression in the context of MSI, 
something which will no doubt be pursued by future studies.  
 
ATM expression was also evaluated in the context of radiotherapy. The response to 
radiotherapy was assessed by TRG scoring by two blinded, independent pathologists; to help 
negate biases. Although it is recognised that classification according to TRG systems in rectal 
cancer generally show a low concordance rate among pathologists (Chetty et al, 2012), 
disagreements between our two pathologists were rare. On those rare occasions where there 
were differences between the pathologists on scoring, a TRG score was provided by a third 
senior pathologist. When considering the TRG score, a lower value is representative of 
heightened radio-sensitivity; i.e. no disease detectable – 0. This system remains the most 
appropriate method of evaluating short-term radiotherapy response in such (historical) 
histological samples (and guides clinical decision making in living patients), although issues 
arise due to high scorer subjectivity and poor reproducibility between scorers, as discussed 
previously (Santos et al., 2013).  
 
There are only few published recommendations for the handling of surgical resection 
specimens. Some authors consider standard processing protocols are appropriate if the tumour 
is clearly visible (Chetty et al, 2012). We have adopted the personal approach of Thies and 
Langer (2013) in embedding the entire tumour bed from the beginning. A graphical outline of 
their approach to standardising workup and reporting of TRG is presented in Figure 7.1.  
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Figure 7-1 Thies and Langer approach to standardised workup and reporting of TRG 
 
 
In our studies, tumours displaying low/absent ATM expression in peripheral cells were found 
to display a better response to radiotherapy; in-keeping with the hypothesis that a lack of ATM 
hampers DSB repair, and cues apoptosis after DSB induction by radiotherapy. Thus, the 
mechanisms we hypothesise to be allowing the cancer to grow and metastasise (a lack of cell 
cycle control in response to low DNA damage repair in the tumour periphery), also lead to its 
downfall after radiotherapy. 
 
Long-term outcomes of radio-sensitivity were measured by disease-free and overall survival 
in our cohort patients. Positive responders to radiotherapy are known to benefit from lower 
rates of local disease recurrence, and improved disease-free survival (Camma et al., 2000; 
Colorectal Cancer Collaborative Group, 2001); outlining the importance of the treatment 
modality to rectal cancer.  
 
Survival outcomes in the index cohort were analysed in patients who had received pre-
operative radiotherapy (and compared to those that did not), although the study was limited by 
its statistical power, since only 55 patients in the cohort underwent pre-operative radiotherapy. 
In spite of this limited sample size, low ATM expression in peripheral tumour cells after 
radiotherapy was found to be convincingly associated with improved disease-free survival, and 
the association maintained significance in more stringent multivariate analyses (HR = 34.636 
(2.160 − 555.293), P = 0.012). Furthermore, low ATM expression patterns in central tumour 
cells were also found to be significantly associated with improved disease-free survival after 
radiotherapy, after adjusting for known confounders, as covered previously (HR = 6.948 (1.192 
− 40.504), P = 0.031). In the context of radiotherapy, cells which retain their ability to repair 
DNA damage are more likely to repair lesions, regain genomic stability and continue to 
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proliferate; whereas, cells with an impaired DDR pathway are more prone to undergo apoptosis 
(Roos and Kaina, 2013).  
 
The findings of low ATM expression and increased DFS presented in this thesis is in direct 
opposition to the findings of Grabsch et al and Beggs et al, who identified an association 
between reduced ATM expression in CRC and worse disease-free survival (Beggs et al,  2012; 
Grabsch et al., 2006). However, their cohorts were not strictly limited to rectal cancer patients, 
nor stratified according to pre-operative radiotherapy treatment; in this study’s subgroup 
analysis of patients who received adjuvant treatment, a clear association was not described. 
Grabsch et al, did however, report that reduced ATM expression was a poor prognostic marker 
in patients who received radiotherapy and/or chemotherapy, but this analysis was limited by 
small sample size (n = 38). On the other hand, Beggs et al found a trend towards reduced ATM 
expression and shorter disease-free survival which did not reach statistical significance in either 
the radiotherapy (n = 68) or chemotherapy (n = 436) group. 
 
The studies by Grabsch et al and Beggs et al show some important differences to those in this 
thesis, including how patients were stratified, what treatments they received, and when they 
were analysed. Furthermore, ATM function is known to be affected by platinum-based 
chemotherapies (Kim et al, 2002). These points highlight how clinical heterogeneity can 
contribute to discordant results between cohorts and groups, and only additional studies in 
larger sample sizes will help better understand the role of ATM in these different situations. It 
suffices to say that, to date, ATM has proved to be an ambiguous prognostic marker in a variety 
of cancers; although the repeated associations do suggest the protein plays an important role in 
pathogenesis, even if the directions and mechanisms of action remain to be fully determined. 
 
Despite these previous reports, the findings in this thesis establishes ATM expression as a 
negative prognostic marker in rectal cancer. Similar results have been noted in cervical cancer 
and non-small cell lung cancer (Roossink et al., 2012; Xing et al., 2008), whereas, high ATM 
expression is associated with superior survival in gastric cancer and B-cell chronic lymphocytic 
leukaemia (Austen et al., 2005; Kang et al., 2008). As discussed, these inconsistencies may be 
due to differences in cancer pathogenesis, characteristics, treatments, quantification of ATM 
expression and experimental methodology. For example, Xing et al attributed their ability to 
correlate reduced ATM expression with improved prognosis in NSCLC, to their measurement 
of the tumour: normal tissue (T/N) expression ratio, rather than on tumour expression alone. 
Similarly, the delineation of expression patterns between peripheral and central tumour 
samples has allowed for more consistent comparison between clinicohistopathological and 
clinical outcome data, and for novel associations to be discovered. 
 
A major aim of this thesis was to determine whether ATM expression could be used in a 
predictive manner in rectal cancer. These analyses did not result in the discovery of any 
correlations between ATM expression and disease-free, or overall survival, in either subgroup; 
further reinforcing the interpretation that ATM expression predicts response to radiotherapy. 
Similarly, studies in human cell lines in vitro have been shown that the response to radiotherapy 
can be improved by inhibiting the action of ATM (Collis et al., 2003; Kim et al., 2002; Li et 
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al., 2006; Lin et al., 2012). Therefore, ATM may not only have a role as a predictive and 
prognostic marker, but may provide a therapeutic target for enhancing the effectiveness of 
radiotherapy, especially when its expression is regulated by hypoxia, which a major barrier to 
the effectiveness of radiotherapy. 
 
There are a few limitations in the index study. Due to the retrospective nature of the study, 
complete clinicohistopathological data was not available for all patients; the problem of 
missing data in clinical medicine has been discussed at length elsewhere, and has led to large-
scale efforts for developing statistical tools to account for it (Little et al., 2012). Additionally, 
potential patient and treatment selection biases in such retrospective studies could result in 
false positive, or false negative, findings; the patients were randomly selected based on 
chronological receipt of the operative specimens receive in the pathology department.  
However main limitations of this study for ATM (and for the other biomarkers) were the small 
sample sizes of patients undergoing radiation treatment and small numbers of pretreatment 
tissue obtained. This prohibited an effective comparison of biomarker expression between 
cases that received neoadjuvant radiotherapy to those that did not receive any radiotherapy. 
Additionally the disease grade and vascular invasion categories, included groups in which no 
patients had died or experienced local recurrence, leading to large and unstable hazard ratios. 
Future prospective studies, or randomised clinical trials enlisting a larger cohort of patients 
undergoing preoperative radiotherapy and obtaining pretreatment biopsies, would be useful for 
further defining the causal relationships between ATM expression, TRG, and survival.  
 
Despite these limitations, the study in this thesis demonstrates that ATM is a promising 
candidate as a clinical biomarker of radio-sensitivity and disease-free and overall survival in 
rectal cancer.  
 
7.2.2 MRE11 
 
Based on evidence linking MRE11 expression and cancer progression, as discussed (Gupta et 
al., 2013), w the expression of the MRN complex nucleic acid editor, MRE11, was studied in 
the context of rectal cancers.  
 
However, although MRE11 appears to be a good candidate for such cancer expression studies, 
and given the associations discovered for ATM and what has been reported for MRE11, the 
study in this thesis failed to find any correlation between overall survival and the level of 
MRE11 expression in the centre or periphery of the rectal tumour samples. Similarly, a study 
by Sheriden et al, did not find a correlation between MRE11 expression (by 
immunohistochemistry) and survival or radio-sensitivity after neoadjuvant radiotherapy, in 
patients with CRCs (Sheridan et al., 2013). As with many studies in the field, however, this 
one was hampered by a small patient sample size. 
 
However, although MRE11 expression alone was not found to significantly affect the survival 
outcomes of patients with rectal cancer in our cohort, we found that the level of MRE11 
expression in the tumour centre or periphery significantly influenced the survival outcomes of 
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patients with concurrent perineural invasion, metastasis, or high-grade disease; suggesting that 
the predictive power of this marker increases as disease progresses, and additional 
clinicohistopathological variables are available to stratify patients. Specifically, survival 
outcomes (DFS and OS) were found to be significantly worse amongst: patients with high 
MRE11 expression in the tumour periphery who also had perineural invasion or metastasis; 
those with high MRE11 expression in the tumour centre and metastasis; and those with low 
MRE11 in the tumour centre and high-grade disease. Thus, high MRE11 expression was 
associated with disease metastasis (more advanced disease, with a greater amount of DNA 
damage), although low levels in the tumour centre were associated with higher grade disease.  
 
Importantly, several previous studies have reported associations between MRE11 protein 
expression in tumours, and survival outcomes for patients suffering from different types of 
malignancies. For example, Choudhury et al demonstrated an independent association between 
tumour MRE11 expression and cause-specific survival in patients with muscle invasive bladder 
cancer after radical radiotherapy, but not after surgery - with low tumour MRE11 expression 
predictive of poor survival (Choudhury et al., 2010). Similarly, low tumour expression of the 
MRN complex (MRE11/RAD50/NBS1), was associated with a poor response to radiotherapy 
in patients with early breast cancer (Söderlund et al., 2007). Furthermore, a recently-published 
systematic review of biomarkers of tumour radio-sensitivity by Forker et al, identified MRE11 
as one of the most promising predictive biomarkers in radiotherapy, although much remains to 
be determined about the mechanisms involved (Forker et al., 2015).  
 
Mutations in proteins involved in DNA repair might also influence the clinical response to 
chemotherapeutic agents that damage DNA, such as the topoisomerase I poison camptothecin 
and its derivatives, irinotecan and topotecan(Vilar et al., 2008). In pre-clinical trials, Vilar and 
colleagues showed that colorectal cancer cell lines that were MRE11/RAD50-deficient, 
displayed enhanced sensitivity to irinotecan, or a combination treatment of thymidine and 
CPT/irinotecan (Rodriguez et al., 2008). Therefore, patients with MRE11-deficient tumours 
might be found to respond better to treatment with topoisomerase I poisons, compared to those 
with a fully-functional MRN complex; highlighting the importance of known MRE11 status in 
tumours with regards to treatment.  
 
The loss of MRE11 protein expression also sensitises MSI positive colorectal cancer cells to 
inhibitors of the DNA repair enzyme, poly(ADP-ribose) polymerase (PARP) (McPherson et 
al., 2014; Vilar et al., 2011). In this regard, it is interesting that in the study of this thesis, 
adjuvant radiotherapy showed a protective trend in univariate analysis; in particular, low 
MRE11 expression in patients who did not receive adjuvant therapy showed significantly 
shorter overall survival than those who did.  
 
Although further research is required to confirm any prognostic and predictive roles of MRE11 
tumour expression in rectal cancer, our findings have important implications for the treatment 
of rectal cancer patients with perineural invasion, metastasis, or high-grade disease; where 
MRE11 expression was found to be associated with survival outcomes. In such cases, 
knowledge of MRE11 status can provide a clearer prognostic picture, and may affect clinical 
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management decisions. 
7.2.3 NBS1 
 
Another critical member of the MRN complex, is Nibrin. Mutations in this gene have been 
studied for a long time, and much is known about the role of NBS1 in the immune system, 
fertility, radiation sensitivity, and DSB repair (Difilippantonio et al., 2005; Varon et al., 2000; 
Warcoin et al., 2009).  
 
NBS1, therefore, presents as an ideal candidate rectal cancer gene, with which it has previously 
been implicated (di Masi and Antoccia, 2008; Uhrhammer et al., 2000). However, that the 
study in this thesis showed only few associations in respect of NBS1 expression– although a 
marginal association between NBS1 expression in the tumour centre and patient overall 
survival was described. In comparison to the other genes here analysed, NBS1 expression 
appears to be a worse predictive marker of patient survival in rectal cancer, and was not found 
to greatly help delineate clinicohistopathological variables.  
 
This may be because NBS1 is simply less important to rectal cancer progression and DSB 
repair during oncogenesis, relative to the other proteins studied – and there are several plausible 
reasons to hypothesise that this could be the case. Firstly, NBS1 activity in this context may be 
compensated for by other proteins, such as ATMIN (Zhang et al., 2012); making NBS1 
expression alone less important to DNA repair, and therefore its expression less predictive of 
lesion repair.  It is also worth considering that the high expression of the protein in the majority 
of tumours also reduces the dynamic range of the assay (Cox, 2012); compounded by the fact 
that a significant sub-set of patients showed complete absence of expression. Furthermore, 
there is no somatic or germ-line sequence data from the patients in the study cohort, the genetic 
integrity of the loci under investigation cannot be determined, which may impart differences 
on gene function in the tumour or elsewhere. 
 
There are many reasons for why differences were not detected according to NBS1 expression. 
However, the results do not suggest that NBS1 expression is not important to rectal cancer. 
The investigation of this gene represents the major limitation of this thesis; due to the statistical 
statistical limitations (Ioannidis, 2005; Sprent, 2003). This is further impacted upon by patient 
cohort heterogeneity (i.e. sex and age), and treatment variation between patients, all of which 
will impact the cancer transcriptome and proteome (Uhlen et al., 2017).  
 
In an ideal scenario, the associations of these proteins with rectal cancer would be investigated 
in a large cohort of patients that can be strictly classified according to the nature of their clinical 
history, genetics, specific treatments (dose and time), and other relevant 
clinicohistopathological features (Süt, 2014). Which is not to say that retrospective studies such 
as this from patient biobanks and collections are not central for discovering such associations 
and furthering the case for future, wider-scope studies. Indeed, the results here presented as a 
whole demonstrate the utility of such approaches.  
 
NBS1 quantification in tumours was useful for building the predictive-three marker panel (Ho 
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et al, 2018) and further emphasises the utility of analysing different members of the same 
pathway/complex to glean more information about the disease state (Garcia-Campos et al., 
2015).  
 
7.2.4 RAD50  
 
As has been shown for other members of the MRN complex, RAD50 expression has been 
found to correlate with a good response to treatment (Brandt et al., 2017). Furthermore, an 
adenovirus targeting RAD50 also showed promise in sensitising nasopharyngeal carcinoma 
cells to radiotherapy (Chang et al., 2016), further supporting its exploration in this context, and 
suggesting that RAD50 is central to the repair of radiation-induced DSBs.  
 
To achieve the aims of the thesis, any correlations between the available 
clinicohistopathological features and treatment type were explored, with long-term (DFS and 
OS) radiotherapy responses after staining for RAD50. Low levels of RAD50 expression at 
early tumour stages, and in low-grade tumour sub-groups, was significantly associated with 
worse disease-free survival and overall survival, defining a relationship between post-operative 
tumour expression of RAD50 and prognosis. Specifically, the results from univariate and 
multivariate analyses showed that worse DFS outcomes were associated, not only with low 
RAD50 expression in the tumour centre, but also with perineural invasion. These data, 
therefore, indicate that post-operative RAD50 expression predicts long-term survival in rectal 
cancer, if evaluated alongside other tumour-related clinicohistopathological features, and 
supports the potential use of RAD50 as an early prognostic biomarker in rectal cancer 
 
The role of RAD50 has also been evaluated in CRC by other studies. Gao et al demonstrated 
that RAD50 expression is reduced/low in MSI-positive CRCs, and is not associated with 
clinicohistopathological patient characteristics (Gao et al., 2008a). Conversely, RAD50 
expression was increased in early stage primary MSS CRCs, and interestingly the oncogenic 
RAD50 frameshift mutation (A)9 occurred in MSI, but not in MSS CRCs; suggesting that 
RAD50 might play different roles in these CRC phenotypic subtypes. The findings from this 
study, which show high or low levels of RAD50 to define different disease stages, highlight 
the complex roles of the protein during disease, and outline the importance of large sample 
sizes and accurate clinical denominators to identify robust, reproducible conclusions.  
 
Importantly, RAD50 was also described as a prognostic biomarker for colorectal mucinous 
adenocarcinoma (delineating between 10%–15% of all cases) through an integrated analysis of 
genetic and epigenetic features (Wang et al., 2015). The authors of this study showed low 
RAD50 expression to be associated with poor prognosis in patients with MSS CRC, and 
postulated that increased RAD50 expression in MSS CRC could be a tumour suppressive 
cellular response to prevent further tumour progression (Wang et al., 2015). Based on these 
reports, further investigation of the molecular role of RAD50 in MSI and MSS CRCs could 
help inform patient responses to therapy.  
 
In common with the other proteins investigated as part of this thesis, a larger sample size would 
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have been of benefit towards defining associations, as we will discuss. Furthermore, as this 
study also only involved two centres, larger, multi-center prospective studies are needed to 
validate the observations here reported.  
 
 
7.2.5 Combinatorial panels – ATM/MRE11 
 
 
The studies in this thesis provide conclusive evidence to support the further exploration of 
ATM, MRE11, NBS1 and RAD50 as biomarkers in rectal cancer. Still, despite the promise, 
no such biomarkers have been validated in randomised clinical trials, and their clinical 
value remains unclear. 
 
Furthermore, the directions of the associations between DDR proteins and such outcome 
measures are highly variable (i.e. low or high expression of ATM has been associated with 
CRC survival outcomes; please see previous sections), and as discussed, this could be due to a 
number of reasons. Given this marked variation, and the clinical heterogeneity of cancer, 
combinatorial biomarker panels that aim to capture information about a greater number of 
disease-associated proteins in tandem, hold promise for helping to define the clinical picture in 
a greater proportion and number of patients; by analysing different members of the same 
pathway (i.e. the MRN complex) simultaneously, a more complete picture of the pathway’s 
function within the tumour can be obtained (Rakha et al., 2010).  
 
Based on the hypothesis that both ATM and MRE11 are integral to the detection of DNA 
damage and subsequent intracellular signalling following radiotherapy (and hence, that 
their deficiency would equate to increased radio-sensitivity), a two-marker panel of ATM 
and MRE11 expression was established by carrying out binary regression analysis of 
tumour samples and normal tissues.  
 
When both ATM and MRE11 were combined into a single panel, subsequent analyses 
showed greater levels of association between biomarker expression and general 
clinicohistopathological parameters in our cohort, compared to either marker alone. The 
combined panel yielded a ROC-AUC value of 0.745, with high expression of the panel 
predicting poor histological tumour regression (i.e. a TRG score of 3) following 
radiotherapy. This value was superior to using ATM (0.618) or MRE11 (0.711) alone; 
demonstrating the increased power of the combinatorial approach. Furthermore, in both 
the neoadjuvant radiotherapy sub-cohort and the overall cohort, the combined 
ATM/MRE11 expression levels correlated with clinical survival outcomes; with high 
levels being associated with worse outcomes.  
 
These results demonstrate that expression of these markers, when used together, are 
associated with both, early (histological tumour regression), and late (clinical survival) 
responses to neoadjuvant therapy in rectal cancers. Additionally, these findings support 
the hypothesis (that increased protein expression leads to increased cancer cell survival 
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after therapy), and are also consistent with the fact that inhibitors of ATM and the MRN 
complex have shown potential as radio-sensitising agents (Permuth-Wey et al., 2009). 
 
On a final note, the role of lymph node status in predicting survival outcomes with regards 
to the 2-marker panel is intriguing, and further hints at the complexity of using biomarkers 
to predict patient outcomes. Among patients with LN-negative tumours in our cohort, there 
was no significant difference in survival between patients with a high or low, two-protein 
combined panel score in the tumour centre. In contrast, in patients with LN-positive 
tumours, a high two-protein combined panel score in the tumour centre was found to be 
significantly associated with worse survival. This suggests that the combined expression 
of ATM and MRE11 may be associated with LN involvement in relation to patient 
survival, and may represent increased DDR protein involvement in advanced disease 
stages. 
 
 
 
7.2.6 Combinatorial Panels – MRN Complex, three-marker panel   
 
 
To further explore the utility of a MRN complex combinatorial biomarker, a panel comprising 
the three MRE11, RAD50, and NBS1 was established. Combined MRN protein expression 
was found to have a high sensitivity and specificity in samples taken from both the centre and 
periphery of rectal tumours. Importantly, the sensitivity, specificity, and overall accuracy for 
the MRN panel was found to be higher than for the combined MRE11/ATM panel, both in the 
tumour centre and periphery; again supporting the argument that increased data points in such 
a setting serve to capture more of the clinical picture and increase the power to detect 
associations (Creixell et al., 2015; Samyn et al., 2015).  
 
Notably, high expression levels of the three MRN complex proteins in the tumour centre was 
significantly associated with disease-free and overall survival. Interestingly, none of the other 
clinicohistopathological variables were significantly associated with combined MRN 
expression. Therefore, this panel appears to be specifically prognostic of DFS and OS.  
 
A lack of associations between the three-marker panel and the other disease features in the 
cohort may be due to a lack of statistical power, as discussed, or because by combining data 
from three markers, the power of each marker, individually, is reduced; which, in limited 
sample sizes, is what allows for associations to be drawn from each marker independently. 
Furthermore, when the expression of the three-marker panel in the subset of patients that 
received pre-operative radiotherapy was examined, the association between combined MRN 
expression and outcome remained significant. This suggests that the prognostic value of this 
panel may be related to tumour radio-sensitivity.  
 
Interestingly, high MRN protein levels have been found to be associated with better outcomes 
in some other cancer types. In early breast cancer, for example, patients with high MRN 
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complex expression experienced the greatest reduction in recurrence from radiotherapy 
(Söderlund et al., 2007). Furthermore, in two different studies of bladder cancer, high MRE11 
expression was associated with better cancer-specific survival times in patients who also 
underwent radiotherapy, rather than a cystectomy (Choudhury et al., 2010; Laurberg et al., 
2012). Therefore, the MRN complex may play a very different role in cancers arising from 
different tissues, or during the course of the same disease (Punt et al., 2017). In addition, it is 
also possible that the prognostic value of MRN complex expression is dependent on certain 
combinations of chemotherapeutics, radiotherapy regimens, and surgery, which vary between 
the treatment modalities preferred for different cancers and patients. 
 
High combined MRN complex protein expression levels with DFS and OS was observed in 
LN-positive patients, but not in LN-negative patients; again, suggesting that these proteins are 
expressed during more advanced disease, where the mutation burden is greatest. In a study of 
rectal cancer patients undergoing long-course neoadjuvant chemo-radiotherapy, combining LN 
involvement with tumour grade was found to be prognostic for patient survival after treatment 
(Lindebjerg et al., 2009). Given these results, and the considerations discussed, it is possible 
that some biomarkers may specifically predict outcomes in patients with LN involvement or 
those without; again highlighting the need for further work in the area. Similarly, Quintanal-
Villalonga and colleagues found that a mutated version of the FGFR4 gene was associated with 
overall survival only in LN-involved patients (Quintanal-Villalonga et al., 2017). Thus, the 
prognostic value of the MRN expression panel may be related to the lymph node involvement 
of the patient. 
 
One mechanism that could lead to altered expression of the MRN complex proteins is defective 
MMR, as we have discussed. Along these lines, Giannini and colleagues found that the MRE11 
gene was mutated in MMR-deficient tumours and cell lines, but not in those with normal MMR 
function (Giannini et al., 2002). However, all of the tumours tested in the studies of this thesis 
expressed the two MMR proteins most frequently mutated in MMR-deficient patients, MLH1 
and MSH2. Furthermore, the absence of MSH6 or PMS2 protein expression was not 
significantly associated with combined MRN expression, although this analysis was limited by 
the very small number of cases lacking expression of either of these proteins and requires 
validation in a larger cohort. Therefore, the mechanisms underlying the prognostic change in 
MRN expression identified here seems to be independent of the MMR pathway, and is a subject 
for further study.  
 
The primary limitation of this three-marker panel study was the inability to analyse the 
relationship of combined MRN expression with tumour regression response. Only 10.6% of 
patients were classified as responders to radiotherapy, represented by a TRG score of 0 to 2. 
As such a small portion of the patients had good responses to radiotherapy, it also raises the 
possibility that combined MRN expression predicts late responses (survival) to treatment 
(radiotherapy), only in patients with relatively poor early responses.  
 
Finally, since increased MRN protein expression is associated with worse outcomes in rectal 
cancer patients, reducing MRN protein expression and/or activity could improve response to 
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radiotherapy. Indeed, the MRN complex inhibitors, mirin and telomelysin, have great radio-
sensitising effects, as has been shown in several pre-clinical studies (Dupré et al., 2008; Garner 
et al., 2009; Kuroda et al., 2012). As testament to their potential utility, telomelysin is currently 
undergoing Phase I and II trials for use in patients with melanoma (https://clinicaltrials.gov; 
NCT03190824), oesophageal cancer (NCT03213054), and hepatocellular carcinoma 
(NCT02293850).  
 
Additionally, in patients with higher MRN expression (who are thus expected to have worse 
outcomes), additional radio-sensitising treatments could be used in combination with 
neoadjuvant radiotherapy to improve survival times. Heat treatment, for example, shows good 
radio-sensitising effects in cells in vitro, and is being explored in cancer patients (Dewey, 
2009). Dynlacht and colleagues (2011) also found that heat radio-sensitisation was dependent 
on a functioning MRE11 protein further suggesting the utility of this treatment.  
 
 
7.3 Study implications 
 
By analysing the expression of four highly-conserved DNA damage response proteins with 
important roles in nucleic acid lesion repair and cell-cycle regulation, the studies in this thesis 
are able to identify associations between their expression, and outcomes in rectal cancer. These 
studies, therefore, implicated the DDR in rectal cancer pathophysiology and progression.  
 
Importantly, many of these associations are novel, and many results arising from this work 
have already been published in peer-reviewed publications. Therefore, these studies provide 
important starting points for further refining the role of DDR proteins in rectal cancer.  
 
In the case of ATM, the protein was shown to be more highly expressed in cancer tissue. 
Furthermore, its expression was highest in the periphery of tumours with a high histological 
grade, especially in older patients. Rectal tumours displaying low/absent ATM expression in 
peripheral cells, were also found to display a better response to radiotherapy, which correlated 
with improved DFS and OS in multivariate analyses.  
 
In contrast, MRE11, was less informative, with its expression only having predictive value in 
patients with concurrent perineural invasion, metastasis, or high-grade disease. Given the 
reduced predictive power of MRE11 compared to ATM, it was reassuring to discover that the 
combined panel formed from both proteins showed improved predictive power to either marker 
alone, and allowed for DFS and OS to be analysed more accurately.  
 
Still less informative individually proved to be NBS1, although a possible association between 
high expression and overall survival was reported. 
 
Lastly, low levels of RAD50 were associated with worse disease-free and overall survival. 
Specifically, worse DFS outcomes were associated not only with low RAD50 expression in 
the tumour centre, but also with perineural invasion, highlighting the use of RAD50 expression 
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in combination with clinicohistopathological variables to discern novel disease features.  
 
Finally, combination of the different proteins into a two- or three-marker biomarker panel was 
found to increase sensitivity and specificity, with regards to outcome measures, and the 
combinatorial panels proved to be a more powerful tool for describing associations with 
survival times in the cohort. 
 
These results arising are particularly important and timely, as they define important predictive 
markers of radiotherapy success and disease progression, and because much work remains to 
be done to better delineate rectal cancers from colorectal tumours - aetiologically, 
mechanistically and prognostically; not to mention the fact that data on predictive markers of 
radiotherapy response are still lacking from the literature and clinic.  
 
As developed economies face increasing non-communicable disease burdens and ageing 
populations (Boutayeb and Boutayeb, 2005; Christensen et al., 2009), determining which 
patients are likely to benefit from certain treatments to common human pathologies, will lead 
to large-scale cost savings and dramatic improvements in patient welfare (United Nations, 
2015). 
 
Together, given the different directions of associations in different regions of the tumours (i.e. 
high/low expression in the tumour centre/periphery) of different types of patients (i.e. those 
presenting with PNI), large studies incorporating longitudinal measurements (i.e. measure in 
the same patient over time), will help refine the mechanistic basis for these associations and 
further understand rectal cancer progression.  
 
7.4 Study Limitations  
 
Although this thesis has been successful in uncovering several novel associations between 
DDR protein expression and rectal cancer, much work remains to be done to address the 
discordancy present within the available literature and determine the mechanisms leading to 
disease and affecting disease progression/outcome. Several examples of associations between 
DDR protein expression and cancer survival outcomes running in different directions between 
studies exist; as has been discussed and shown for ATM and MRE11.  
 
These differences are likely to be due to a number of different factors, which can include: the 
choice of antibody used to detect the protein of interest (Baker, 2015); variation in TRG scores 
between laboratories (as discussed); differences in patient cohort characteristics between 
studies (i.e. ethnicity, age, sex, and disease stage) (Payne et al., 2012); concurrent patient 
treatments (Glimelius et al., 1997); and small sample sizes (Sprent, 2003).  
 
In the last decade, the number of irreproducible and erroneous biological and clinical medicine 
papers in the peer-reviewed literature due to small sample sizes has reached unprecedented 
levels (Baker, 2016; Emanuel et al., 2000), leading to considerable concern in the academic 
science community. Over the course of time, many results cannot be repeated (Halsey et al., 
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2015), added confusion to researchers in the field and slowing scientific progress. This has 
helped the development of more transparent editorial/peer-review processes, such as those 
started by the eLife journal (https://elifesciences.org, funded by the major academic science 
funders, the Wellcome Trust, Howard Hughes Medical Institute and Max Planck Institutes), 
which adds the names of reviewers, and their comments, alongside the manuscript, as well as 
the development of peer comment sites (like https://pubpeer.com) and open access 
depositories, such as https://www.biorxiv.org and https://www.ebi.ac.uk/arrayexpress/, where 
data and results can be shared and validated by others in a more timely manner. While many 
journals do not accept submission that have been previously published, many prestigious 
journals such as Science and Nature do, with the journals standing to benefit from publishing 
science that has already been exposed to the tests of the community. In this respect, the tide is 
turning, and studies are being placed under increased scrutiny to ensure only the best work gets 
disseminated.  
 
Part of the reason for this irreproducibility, many scientists suggest, is a lack of appropriate 
statistical testing of data (i.e. not applying Bonferroni corrections to multiple t-tests on the same 
dataset), leading researchers to publish false-positive and false-negative associations, which in 
many instances match their hypotheses (Halsey et al., 2015; Sprent, 2003). The pressures of 
publish or perish, are also believed to contribute to the dissemination of incomplete, rushed or 
fraudulent studies (Neill, 2008). Given the clinical and genetic heterogeneity of cancer patients, 
small sample sizes, and inappropriate statistical testing, can lead to spurious associations (as 
only a few extreme data points are sufficient to delineate mathematical differences between 
groups), and more likely, false-negatives. Thus, having a larger sample size not only provides 
more statistical power to detect differences, but also helps avoid not finding them (Devine and 
Smith, 1998; Faraggi and Reiser, 2002; Faul et al., 2009).  
 
In this thesis, although all analyses were carried out in a blinded fashion and appropriate 
statistical frameworks were used to test for associations, the studies still suffered from a 
relatively small number of samples, especially when considering patients who underwent pre-
operative radiotherapy (n = 55). It is important to remember that outbred human volunteers, 
show more phenotypic variability (due to different genes and environmental exposures) that 
common laboratory animal strains (which are often inbred for many generations), leading to 
greater standard deviations within outcome readings in humans; not to mention the fact that 
the biological pathways underpinning disease are different between species (Davis, 2008; 
Editorial, 2013).  
 
Ideally, prior to commencing any such study, power calculations should be carried out to 
determine the number of samples required to statistically detect differences of a given 
magnitude (Suresh and Chandrashekara, 2012). Thus, if the experiment is powered (i.e. has 
sufficient samples) to detect 5% differences between two groups (at an alpha of 0.05), and none 
are detected, it is more likely that the associations do not exist; compared to when the 
experiment is underpowered, the result obscured, and the associations missed. However, 
although power calculations a priori are best in terms of experimental design, often the number 
of samples is limited by factors beyond the control of the researchers, not least in retrospective 
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studies, such as this one, where patient samples were collected historically, and a degree of 
missing data was present. 
 
Given the immense power of banked patient samples to inform upon disease pathogenesis and 
the problems associated with recruiting large numbers of patients at any one time, it is 
encouraging to see increasing numbers of biobanks (where diverse patient samples are stored) 
opening up in academic and private centres around the world (De Souza and Greenspan, 2013). 
Good examples of these include the Cambridge BioResource at the University of Cambridge 
(https://www.cambridgebioresource.group.cam.ac.uk), The Human Immune Monitoring 
Centre at Stanford University (http://iti.stanford.edu/himc.html), and the Biospecimen 
Repository at Yale University (https://medicine.yale.edu/obgyn/drs/facilities/index.aspx), all 
of which aim to collect fresh human tissue samples, alongside medical history and genetic 
information to facilitate research.  
 
Such resources will be essential for testing hypotheses and determining molecular mechanisms 
in future, as new knowledge comes to the fore. Furthermore, as public healthcare education 
continues to increase with the help of the internet and efforts aimed to place patients at the 
centre of care decisions and management (Barratt, 2008), more volunteers will be encouraged 
to donate the diseased and healthy tissue required for such research to take place. Of course, 
such a future, in which vast amounts of personal data are stored and accessible to different 
researchers, will require extremely secure data networks and robust ethical frameworks to 
safeguard volunteers (Shoenbill et al., 2014; Switula, 2000).  
 
Another and important limitation concerned with this thesis is the fact that the patient cohort 
is composed predominantly of elderly male patients, making it difficult to extend the 
observations to females or younger patients; who are known to show profound differences in 
the molecular aspects of their physiology (Dopico et al., 2015; Karastergiou et al., 2012; Short 
et al., 2013). As this thesis represents a retrospective study, the make-up of the cohort cannot 
be controlled. Whilst the absolute number of colorectal cancers has been reported to be similar 
between males and females, male mortality and incidence rates are increasing at a faster rate 
than females, and males are more likely to have rectal tumours compared to females; who are 
more likely to have colonic cancers (Gao et al., 2008b; Murphy et al., 2011; Purim et al., 2013). 
Given these considerations, analysing the expression of these DDR proteins in additional 
cohorts seems essential to firmly establish the associations we here report with rectal cancer. 
Nevertheless, age, sex and other clinicohistopathological variables were added as confounding 
variables to multivariate analyses, allowing the values to be taken into account as much as 
possible.  
 
Finally, it is worth considering the limitations associated with not knowing the tumour, germ-
line, or somatic cell sequence of the patients in question – cancer is a genetic disease, after all 
(Balmain et al., 2003; Hayes and Kim, 2015). Given the rapidly falling cost of DNA sequencing 
(Church, 2006), at minimal it would have been an advantage to know the base-pair sequence 
of the proteins of interest, which could have been determined by capillary sequencing and PCR. 
For example, knowing a patient carries a lesion within ATM that reduces expression, would 
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allow the results from that patient to be considered separately to those without a mutation, 
allowing us to further refine how the DDR pathway works in disease.  
 
Such genetic data would also allow determination of, for example, whether any patients were 
carrying lesions within genes of interest from birth, or whether any deleterious variants arose 
sporadically (both of which could influence their expression levels) in the cancer cell lineage 
– helping to define familial and non-familial cases (Chubb et al., 2016).  
 
Furthermore, knowing which other variants are present genome-wide, could also be used to 
help refine oncogenic mechanism (i.e. which other variants are found to segregate with this 
cub-type of patients, and not this one), much in the same way that GWAS illustrated the loci 
predisposing to common, complex human diseases and traits (Sniekers et al., 2017). Indeed, a 
recent study of 120,000 cancer patients identified more than 80 loci contributing an increased 
risk to breast cancer (Michailidou et al., 2015). Similar studies in rectal cancer, and NGS of 
the index samples, would again allow for genetic risk to be better accounted for in such 
experiments.  
 
Knowing the genetic background of the patients would also help stratify patients according to 
disease risk, and monitor outcomes with respect to the genetic code. Prognostic genetic 
signatures (including transcription from known common gene variants) have also been 
documented for a large number of diseases (Ferreira et al., 2014; McKinney et al., 2010), 
including cancer (van ’t Veer et al., 2002; Stratton et al., 2009), and could be combined with 
DDR protein expression with respect to outcomes.  
 
However, having too much genetic data from a patient, and too few patients, will lead to 
erroneous results; highlighting that studies need to be powered to detect differences with 
respect to the technology employed. This is not surprising given that identifying causal 
mutations from a 3.3 billion sequence of letters again requires large sample sizes (to define 
health and an absence of risk) and high-fidelity sequencing to be able to detect single nucleotide 
polymorphisms that could drive disease.  
 
7.5 Summary 
 
Several novel associations are found in this thesis between rectal tumour expression of key 
DNA damage repair proteins and patient outcomes; which also considered the response to 
radiotherapy.  
 
Highlights from the work in the thesis include the publication of two predictive combinatorial 
biomarkers for rectal cancer – where co-expression of these DNA damage response proteins 
were found associated with disease outcomes. These studies highlight the important role of 
these proteins in rectal cancer pathogenesis; adding to the numerous reports implicating them 
in more heterogeneous colorectal cancer cohorts. The fact that differences in their expression 
are predictive of disease outcomes emphasises their importance as key modulators of 
oncogenesis and drug- and gene-therapy targets, which may aim to boost complex activity or 
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repair genomic lesions using modern base-editing approaches. 
 
These studies pave the way for numerous further studies, not only in rectal cancer, but also in 
other tumours and pathophysiological and developmental processes. A particularly interesting 
avenue of research, would be the exploration of these markers in rectal cancer patients in a 
non-invasive manner – such as by sampling cell-free DNA in blood samples (Diaz and Bardelli, 
2014), which would also allow for longitudinal measures to be considered in the statistical 
models. Such approaches would allow for the parallel understanding of genetic sequence 
during the disease course, although how the peripheral circulation represents the nature of 
tumour in situ is a complex problem and remains an area of intensive investigation.  
 
Future approaches will be discussed in the following chapter, and it suffices here to say that it 
is an incredibly exciting time in clinical medicine, where the heritage literature, research 
laboratory, and advances in statistics and technology, are increasingly clarifying the 
pathological basis of disease – welcome to the genomic age.  
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8.1 Future directions 
 
The collection of accurate patient data in a timely manner represents a major hurdle to treating 
complex human diseases. The missing patient data is due to a number of reasons, including 
poor public understanding of disease risk, a lack of timely physician consultation, and a fear 
of death leading to half-truths (Vrinten et al., 2016), as well as poor professional healthcare 
protocols (for example, where notes are not detailed and useful to other professionals 
(Stefanacci and Riddle, 2016)), and poor patient follow-up after diagnosis (Dugdale et al., 
1999). In an increasingly global world, where patients regularly switch doctors and domiciles, 
maintaining an accurate and searchable medical history is of paramount importance for 
understanding disease and the effectiveness of treatments.  
 
An incomplete clinical patient picture leaves one guessing as to the factors associated with 
disease progression, and future computerised, online medical records, where patient history 
can be easily referenced and related to relevant entries (such as an individual’s genome 
sequence), will help stratify patients for post- and ad-hoc research analyses (Bowman, 2013; 
Walport and Brest, 2011). Furthermore, the patient is not out with his/her environment (take 
tobacco and lung cancer, for example), and as is seen with regards to how seasons (Dopico et 
al., 2015), shift-work (Wang et al., 2011), jet-lag (Filipski et al., 2004), the microbiome (Cho 
and Blaser, 2012), diet (Carrera-Bastos et al., 2011), and artificial light (Chepesiuk, 2009), 
influence human physiology and cancer risk, detailed metrics of patient exposures to different 
environmental parameters will become increasingly important for building the complete 
clinical picture. 
 
Aside from building a more complete clinical history for each patient, more patient samples 
are needed to understand disease. For example, colorectal cancer and rectal cancer should not 
be considered the same disease any longer, given the evidence discussed, and therefore, the 
need to continue collecting as many patient samples as possible to further refine disease 
aetiology, mechanism, treatment and outcome cannot be overlooked (Braun et al., 2014). Only 
thorough the collection of geographically- and ethnically-unique populations will diseases like 
cancer be better understood. It may seem counterintuitive to think that as we are increasingly 
able to profile individual health, that large, diverse cohorts are needed, but it is through such 
windows where commonality can be seen (many data points require many samples for robust 
associations to be discovered; multiple testing (Sprent, 2003)), human physiology better 
understood, and individuals be placed into a more-refined clinical context. This will be further 
helped by the collection of longitudinal samples from the same individual (perhaps using 
modern laparoscopic techniques), allowing disease development and progression to be 
monitored in human subjects (Trastulli et al., 2012), not only animal models; which display 
key differences to humans in cancer physiology (Shanks et al., 2009). 
 
Such collections of tumours and healthy tissues from different patient groups and healthy 
volunteers will serve as valuable resources for genetics and environment to be associated with 
biological, molecular features of the tumour. For example, expanding cancer transcriptome and 
genome sequencing, proteomics, and metabolomics will allow for the finer molecular details 
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of tumours to be revealed (Uhlen et al., 2017; Weinstein et al., 2013). Indeed, the recent 
combination of high-throughput proteomics and gene expression microarray profiling from 
colorectal cancers led to the identification of putative cancer biomarkers (S100 calcium-
binding protein A9, annexin A3, nicotinamide phosphoribosyltransferase, carboxylesterase 2 
and calcium activated chloride channel A1) detectable in situ and the serum (Yu et al., 2016).  
 
Such molecular interrogations will be helped by advances in ribosome profiling (where only 
mRNA transcripts being actively translated on the ribosome are sequence; reducing 
background noise considerably) (Ingolia et al., 2009), mass cytometry (which combines flow 
cytometry with mass spectrometry, will allow blood cell tumours, especially, to be analysed in 
a multi-parametric manner at the single-cell level, helping define cell-surface phenotypes, for 
example which can be used as prognostic markers, or sorted by FACS for detailed, downstream 
molecular analyses) (Bendall et al., 2011; Dempsey, 2017), and metabolomics based on the 
latest low-molecular weight mass spectrometry methods (which will allow small molecular 
metabolite signatures of tumours to be defined) (Beger, 2013).  
 
All of these advances do not consider the advancement of pharmaceutical science, which is 
increasingly entering an era exploiting biological reagents (such as humanised monoclonal 
antibodies and autologous engineered T lymphocytes to destroy cancer cells), as well as human 
genome editing approaches to cure disease (Cartron et al., 2002; Gill and June, 2015; Jarboe et 
al., 2014; Paquet et al., 2016). A future in which deleterious variants can be replaced in your 
genome by a normal, wild-type allele may not be so distant, and already human trials involving 
CRISPR to replace highly-penetrant lesions in human embryos and patient cells have begun 
(Su et al., 2016; Tang et al., 2017); which add to older genomic methods able to correct lesions 
in specific cell types, and grow engineered autologous cells in vitro for later transplant back to 
the host (Hirsch et al., 2017).  
 
The first job of a physician is to: identify those patients most at risk of disease; help such people 
mitigate those risks; identify those in need; medically treat patients as individuals; and 
prognostic for them in context of their disease. A future in which vast amounts of patient data 
and predictive algorithms facilitate our mission will be warmly welcomed.   
 
8.2 DDR proteins 
 
With regards to extending the MRN complex and ATM studies, future studies should involve 
a larger number of patients, and those with concurrent microsatellite instability. This may be 
sourced from additional collections of other Australian institutions.   
 
Future studies should also be performed in the context of the tumour genome sequence, to 
further refine the associations, and attempt to expand upon the predictive value of the 
biomarkers here presented in rectal cancer.  
 
As has been shown in this thesis, combinatorial marker panels can be highly informative to 
disease progression and treatment response, and of further interest will be detailing how 
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different members of the same pathway behave in relation to one another and in respect to their 
gene sequence, and this should be further explored. Along these lines, immune-fluorescence 
approaches, where multiple tumour molecules/antigens can be analysed simultaneously in the 
same sample (as recently shown when refining the phenotype of breast cancer stem cells (Balic 
et al., 2011)), represent an exciting possibility; allowing one to investigate the relative 
contribution of different MRN complex members to the on-going pathology in the lesion. For 
example, it the levels of ATM are decreased, how do the levels of RAD50 change, and so on.  
 
The use of statistical models to describe patient cohorts and associations will be central future 
biomarker studies in rectal cancer where advanced mathematics will be required to tease apart 
biological interactions.  
 
Thus, with these things in mind, future rectal cancer research will involve investigation into 
the mechanisms underpinning rectal cancer development and the definition of predictive 
markers of treatment and disease outcome.  
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